NZ621345B2 - Methods of treatment of retinal degeneration diseases - Google Patents
Methods of treatment of retinal degeneration diseases Download PDFInfo
- Publication number
- NZ621345B2 NZ621345B2 NZ621345A NZ62134512A NZ621345B2 NZ 621345 B2 NZ621345 B2 NZ 621345B2 NZ 621345 A NZ621345 A NZ 621345A NZ 62134512 A NZ62134512 A NZ 62134512A NZ 621345 B2 NZ621345 B2 NZ 621345B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- cell
- cells
- retinal
- wnt
- catenin
- Prior art date
Links
- 201000007737 retinal degeneration Diseases 0.000 title claims abstract description 127
- 230000004258 retinal degeneration Effects 0.000 title claims abstract description 127
- 210000004027 cells Anatomy 0.000 claims abstract description 701
- 230000019491 signal transduction Effects 0.000 claims abstract description 167
- 210000003958 Hematopoietic Stem Cells Anatomy 0.000 claims abstract description 156
- 210000000130 stem cell Anatomy 0.000 claims abstract description 126
- 210000002901 Mesenchymal Stem Cells Anatomy 0.000 claims abstract description 99
- 210000004271 bone marrow stromal cells Anatomy 0.000 claims abstract description 65
- 239000000203 mixture Substances 0.000 claims abstract description 63
- 238000004519 manufacturing process Methods 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 9
- 238000002513 implantation Methods 0.000 claims abstract description 7
- 102000013814 Wnt Human genes 0.000 claims description 202
- 108050003627 Wnt Proteins 0.000 claims description 199
- 230000002207 retinal Effects 0.000 claims description 191
- 229930002945 all-trans-retinaldehyde Natural products 0.000 claims description 157
- 239000011604 retinal Substances 0.000 claims description 157
- 235000020945 retinal Nutrition 0.000 claims description 144
- 239000012190 activator Substances 0.000 claims description 66
- 230000002401 inhibitory effect Effects 0.000 claims description 63
- 239000003112 inhibitor Substances 0.000 claims description 60
- 230000004913 activation Effects 0.000 claims description 57
- 230000001404 mediated Effects 0.000 claims description 57
- 230000004927 fusion Effects 0.000 claims description 54
- 230000037361 pathway Effects 0.000 claims description 46
- 239000008194 pharmaceutical composition Substances 0.000 claims description 44
- 239000007924 injection Substances 0.000 claims description 36
- 230000011664 signaling Effects 0.000 claims description 35
- 238000002347 injection Methods 0.000 claims description 34
- 230000001718 repressive Effects 0.000 claims description 31
- -1 2-(4-acetylphenylazo)(3,3-dimethyl-3,4-dihydro-2H- isoquinolinylidene)-acetamide Chemical compound 0.000 claims description 28
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 claims description 21
- 235000007575 Calluna vulgaris Nutrition 0.000 claims description 20
- 208000002780 Macular Degeneration Diseases 0.000 claims description 8
- 229940035295 Ting Drugs 0.000 claims description 8
- 201000004569 blindness Diseases 0.000 claims description 8
- 206010064930 Age-related macular degeneration Diseases 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 125000005842 heteroatoms Chemical group 0.000 claims description 7
- 206010012601 Diabetes mellitus Diseases 0.000 claims description 6
- 208000010412 Glaucoma Diseases 0.000 claims description 6
- 208000007014 Retinitis Pigmentosa Diseases 0.000 claims description 6
- 230000003412 degenerative Effects 0.000 claims description 6
- 208000002177 Cataract Diseases 0.000 claims description 5
- 102100011470 ABCA4 Human genes 0.000 claims description 4
- 206010008785 Choroidal dystrophy Diseases 0.000 claims description 4
- 208000003571 Choroideremia Diseases 0.000 claims description 4
- 206010025412 Macular dystrophy congenital Diseases 0.000 claims description 4
- 108010008148 Member 4 Subfamily A ATP Binding Cassette Transporter Proteins 0.000 claims description 4
- 208000001140 Night Blindness Diseases 0.000 claims description 4
- 206010062766 Stargardt's disease Diseases 0.000 claims description 4
- 201000007790 vitelliform macular dystrophy Diseases 0.000 claims description 4
- 208000007556 Cone-Rod Dystrophy Diseases 0.000 claims description 3
- 201000003533 Leber congenital amaurosis Diseases 0.000 claims description 3
- 201000006754 cone-rod dystrophy Diseases 0.000 claims description 3
- 150000003230 pyrimidines Chemical class 0.000 claims description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 2
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 2
- 229940112258 Acular Drugs 0.000 claims description 2
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 claims description 2
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 claims description 2
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 claims description 2
- 102000015735 beta Catenin Human genes 0.000 claims 17
- 108060000903 beta Catenin Proteins 0.000 claims 17
- KXGVEGMKQFWNSR-LLQZFEROSA-N Deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims 3
- 201000006051 Usher syndrome Diseases 0.000 claims 3
- 229960003964 deoxycholic acid Drugs 0.000 claims 3
- DYUQAZSOFZSPHD-UHFFFAOYSA-N 1-phenylpropan-1-ol Chemical compound CCC(O)C1=CC=CC=C1 DYUQAZSOFZSPHD-UHFFFAOYSA-N 0.000 claims 2
- 208000008319 Bietti Crystalline Dystrophy Diseases 0.000 claims 2
- 201000007795 Bietti crystalline corneoretinal dystrophy Diseases 0.000 claims 2
- 206010010356 Congenital anomaly Diseases 0.000 claims 2
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 claims 2
- 208000008760 Optic Nerve Disease Diseases 0.000 claims 2
- 206010061323 Optic neuropathy Diseases 0.000 claims 2
- 102100015716 SFRP1 Human genes 0.000 claims 2
- 101700028193 SFRP1 Proteins 0.000 claims 2
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 206010001902 Amaurosis Diseases 0.000 claims 1
- 241000353097 Molva molva Species 0.000 claims 1
- 208000006623 congenital stationary Night blindness Diseases 0.000 claims 1
- 229950009195 phenylpropanol Drugs 0.000 claims 1
- 210000001525 Retina Anatomy 0.000 description 109
- 210000001116 Retinal Neurons Anatomy 0.000 description 101
- 238000002054 transplantation Methods 0.000 description 79
- 230000005700 syncytium formation by plasma membrane fusion Effects 0.000 description 70
- HOKKHZGPKSLGJE-GSVOUGTGSA-N NMDA Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 69
- 230000014509 gene expression Effects 0.000 description 66
- 230000023298 conjugation with cellular fusion Effects 0.000 description 64
- 208000003098 Ganglion Cysts Diseases 0.000 description 51
- 208000005400 Synovial Cyst Diseases 0.000 description 51
- 210000002569 neurons Anatomy 0.000 description 49
- 102000004169 proteins and genes Human genes 0.000 description 47
- 108090000623 proteins and genes Proteins 0.000 description 47
- 235000018102 proteins Nutrition 0.000 description 46
- 241000282414 Homo sapiens Species 0.000 description 44
- 210000001519 tissues Anatomy 0.000 description 41
- 230000004069 differentiation Effects 0.000 description 36
- 210000004255 neuroglia Anatomy 0.000 description 36
- 210000001671 Embryonic Stem Cells Anatomy 0.000 description 32
- 210000004940 Nucleus Anatomy 0.000 description 30
- 210000001185 Bone Marrow Anatomy 0.000 description 29
- 201000010099 disease Diseases 0.000 description 29
- 230000008929 regeneration Effects 0.000 description 26
- 238000011069 regeneration method Methods 0.000 description 26
- 108010054624 red fluorescent protein Proteins 0.000 description 24
- 102000001267 GSK3 Human genes 0.000 description 23
- 238000004458 analytical method Methods 0.000 description 23
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 23
- 150000001875 compounds Chemical class 0.000 description 22
- 241000699666 Mus <mouse, genus> Species 0.000 description 21
- 210000001357 hemopoietic progenitor cell Anatomy 0.000 description 21
- 150000002500 ions Chemical class 0.000 description 21
- 238000000034 method Methods 0.000 description 21
- 210000000411 Amacrine Cells Anatomy 0.000 description 20
- 102000008730 Nestin Human genes 0.000 description 20
- 108010088225 Nestin Proteins 0.000 description 20
- 240000002804 Calluna vulgaris Species 0.000 description 19
- 210000004754 Hybrid Cells Anatomy 0.000 description 18
- 101710026246 POU5F1 Proteins 0.000 description 18
- 102100019163 POU5F1 Human genes 0.000 description 18
- 239000000499 gel Substances 0.000 description 18
- 101700071614 WNT3A Proteins 0.000 description 17
- 230000001537 neural Effects 0.000 description 17
- 238000010186 staining Methods 0.000 description 17
- 108060001251 CD34 Proteins 0.000 description 16
- 102100016492 CD34 Human genes 0.000 description 16
- 102000008872 noggin protein Human genes 0.000 description 16
- 108091005284 noggin protein Proteins 0.000 description 16
- 108091008017 photoreceptors Proteins 0.000 description 16
- 108060006962 recR Proteins 0.000 description 15
- FWBHETKCLVMNFS-UHFFFAOYSA-N DATI Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 14
- 102100011593 PSMA7 Human genes 0.000 description 14
- 101710033516 PSMA7 Proteins 0.000 description 14
- 102000004965 antibodies Human genes 0.000 description 14
- 108090001123 antibodies Proteins 0.000 description 14
- 239000003550 marker Substances 0.000 description 14
- 101700070147 OTX2 Proteins 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 13
- 210000001082 somatic cell Anatomy 0.000 description 13
- 206010059512 Apoptosis Diseases 0.000 description 12
- 230000006907 apoptotic process Effects 0.000 description 12
- 230000004438 eyesight Effects 0.000 description 12
- 210000000608 Photoreceptor Cells Anatomy 0.000 description 11
- 206010057430 Retinal injury Diseases 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 210000003311 CFU-EM Anatomy 0.000 description 10
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 10
- 230000001058 adult Effects 0.000 description 10
- 230000003287 optical Effects 0.000 description 10
- 102000004121 Annexin A5 Human genes 0.000 description 9
- 108090000672 Annexin A5 Proteins 0.000 description 9
- 210000003996 CFU-GM Anatomy 0.000 description 9
- RQFCJASXJCIDSX-UUOKFMHZSA-N Guanosine monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 9
- 210000004263 Induced Pluripotent Stem Cells Anatomy 0.000 description 9
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 9
- 235000013928 guanylic acid Nutrition 0.000 description 9
- 239000002609 media Substances 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 230000035755 proliferation Effects 0.000 description 9
- 102100003279 CD38 Human genes 0.000 description 8
- 101700044948 CD38 Proteins 0.000 description 8
- 210000003229 CMP Anatomy 0.000 description 8
- 241000282412 Homo Species 0.000 description 8
- 101700018163 PDE6B Proteins 0.000 description 8
- 102000004330 Rhodopsin Human genes 0.000 description 8
- 108090000820 Rhodopsin Proteins 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 230000030833 cell death Effects 0.000 description 8
- 230000002708 enhancing Effects 0.000 description 8
- 238000010172 mouse model Methods 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 102000010832 Axin Protein Human genes 0.000 description 7
- 108010062386 Axin Protein Proteins 0.000 description 7
- 210000003050 Axons Anatomy 0.000 description 7
- WOVKYSAHUYNSMH-RRKCRQDMSA-N Bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 7
- 102100016985 KIT Human genes 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 210000001328 Optic Nerve Anatomy 0.000 description 7
- 102000015799 Qa-SNARE Proteins Human genes 0.000 description 7
- 108010010469 Qa-SNARE Proteins Proteins 0.000 description 7
- 230000001640 apoptogenic Effects 0.000 description 7
- 239000002771 cell marker Substances 0.000 description 7
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 7
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 230000004380 optic nerve Effects 0.000 description 7
- 230000002062 proliferating Effects 0.000 description 7
- 238000003753 real-time PCR Methods 0.000 description 7
- 101710009074 FLT3 Proteins 0.000 description 6
- 206010022114 Injury Diseases 0.000 description 6
- 101710009391 KIT Proteins 0.000 description 6
- 210000000822 Killer Cells, Natural Anatomy 0.000 description 6
- 241000699660 Mus musculus Species 0.000 description 6
- 102100005499 PTPRC Human genes 0.000 description 6
- 101700059076 PTPRC Proteins 0.000 description 6
- 206010038910 Retinitis Diseases 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000005755 formation reaction Methods 0.000 description 6
- 239000003102 growth factor Substances 0.000 description 6
- 238000006366 phosphorylation reaction Methods 0.000 description 6
- 230000000865 phosphorylative Effects 0.000 description 6
- 238000001711 protein immunostaining Methods 0.000 description 6
- 230000001172 regenerating Effects 0.000 description 6
- 230000001105 regulatory Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000001052 transient Effects 0.000 description 6
- 230000004393 visual impairment Effects 0.000 description 6
- 210000003719 B-Lymphocytes Anatomy 0.000 description 5
- 210000002304 ESC Anatomy 0.000 description 5
- 210000002889 Endothelial Cells Anatomy 0.000 description 5
- 102100004573 FLT3 Human genes 0.000 description 5
- 210000004185 Liver Anatomy 0.000 description 5
- 210000002540 Macrophages Anatomy 0.000 description 5
- 210000001020 Neural Plate Anatomy 0.000 description 5
- 102100000433 PDE6B Human genes 0.000 description 5
- 210000002966 Serum Anatomy 0.000 description 5
- 108010062659 Wnt3 Protein Proteins 0.000 description 5
- 102000011105 Wnt3 Protein Human genes 0.000 description 5
- 238000004166 bioassay Methods 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 230000032459 dedifferentiation Effects 0.000 description 5
- 230000001419 dependent Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 229940079593 drugs Drugs 0.000 description 5
- 102000005396 glutamine synthetase family Human genes 0.000 description 5
- 108020002326 glutamine synthetase family Proteins 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 239000001963 growth media Substances 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 210000001164 retinal progenitor cell Anatomy 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 238000007619 statistical method Methods 0.000 description 5
- 230000004083 survival Effects 0.000 description 5
- 230000017423 tissue regeneration Effects 0.000 description 5
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 4
- 206010056981 Adenomatous polyposis coli Diseases 0.000 description 4
- ZAINTDRBUHCDPZ-UHFFFAOYSA-M Alexa Fluor 546 Chemical compound [H+].[Na+].CC1CC(C)(C)NC(C(=C2OC3=C(C4=NC(C)(C)CC(C)C4=CC3=3)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=C2C=3C(C(=C(Cl)C=1Cl)C(O)=O)=C(Cl)C=1SCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O ZAINTDRBUHCDPZ-UHFFFAOYSA-M 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 210000000612 Antigen-Presenting Cells Anatomy 0.000 description 4
- 210000004369 Blood Anatomy 0.000 description 4
- 210000000601 Blood Cells Anatomy 0.000 description 4
- 102100003268 CD14 Human genes 0.000 description 4
- 101700027514 CD14 Proteins 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 210000001900 Endoderm Anatomy 0.000 description 4
- 101700002184 GATA4 Proteins 0.000 description 4
- 108060006662 GSK3 Proteins 0.000 description 4
- 102100018760 IL3RA Human genes 0.000 description 4
- 101700029869 IL3RA Proteins 0.000 description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M Lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
- 210000001616 Monocytes Anatomy 0.000 description 4
- 101710039712 NT5E Proteins 0.000 description 4
- 102100017063 NT5E Human genes 0.000 description 4
- 206010053643 Neurodegenerative disease Diseases 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L Sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- 102100008904 TFRC Human genes 0.000 description 4
- 101710036041 TFRC Proteins 0.000 description 4
- 101700026084 THY1 Proteins 0.000 description 4
- 210000003462 Veins Anatomy 0.000 description 4
- 101700078899 WNT9B Proteins 0.000 description 4
- 108010065207 Wnt2 Protein Proteins 0.000 description 4
- 102000012997 Wnt2 Protein Human genes 0.000 description 4
- 230000003213 activating Effects 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007172 antigens Proteins 0.000 description 4
- 102000038129 antigens Human genes 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 108091006028 chimera Proteins 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 230000003394 haemopoietic Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 229920000023 polynucleotide Polymers 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 238000002203 pretreatment Methods 0.000 description 4
- 230000000750 progressive Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000002269 spontaneous Effects 0.000 description 4
- 230000001225 therapeutic Effects 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 108010017009 CD11b Antigen Proteins 0.000 description 3
- 102000004354 CD11b Antigen Human genes 0.000 description 3
- 102100000188 CD244 Human genes 0.000 description 3
- 101700000388 CD244 Proteins 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 229960002433 Cysteine Drugs 0.000 description 3
- 101700033006 EGF Proteins 0.000 description 3
- 102100010813 EGF Human genes 0.000 description 3
- 229940116977 Epidermal Growth Factor Drugs 0.000 description 3
- 210000000981 Epithelium Anatomy 0.000 description 3
- 102000003951 Erythropoietin Human genes 0.000 description 3
- 108090000394 Erythropoietin Proteins 0.000 description 3
- 229920000665 Exon Polymers 0.000 description 3
- 210000002744 Extracellular Matrix Anatomy 0.000 description 3
- 102100018758 IL3 Human genes 0.000 description 3
- 108010002386 Interleukin-3 Proteins 0.000 description 3
- 229940076264 Interleukin-3 Drugs 0.000 description 3
- 229940100601 Interleukin-6 Drugs 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 102100001056 KITLG Human genes 0.000 description 3
- 210000003716 Mesoderm Anatomy 0.000 description 3
- 229920000272 Oligonucleotide Polymers 0.000 description 3
- 102000001253 Protein Kinases Human genes 0.000 description 3
- 102000014961 Protein Precursors Human genes 0.000 description 3
- 108010078762 Protein Precursors Proteins 0.000 description 3
- 238000010240 RT-PCR analysis Methods 0.000 description 3
- 108010039445 Stem Cell Factor Proteins 0.000 description 3
- 108091008153 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 102100008333 THY1 Human genes 0.000 description 3
- 206010043276 Teratoma Diseases 0.000 description 3
- 102100019577 VCAM1 Human genes 0.000 description 3
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 3
- 101700033758 WNT2B Proteins 0.000 description 3
- 101700012054 WNT6 Proteins 0.000 description 3
- 101700022654 WNT9A Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 230000000111 anti-oxidant Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 210000002798 bone marrow cell Anatomy 0.000 description 3
- 238000002659 cell therapy Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000003247 decreasing Effects 0.000 description 3
- 230000003111 delayed Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229940105423 erythropoietin Drugs 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 230000002068 genetic Effects 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 238000003125 immunofluorescent labeling Methods 0.000 description 3
- 101700012245 lin-44 Proteins 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004962 mammalian cells Anatomy 0.000 description 3
- 102000006240 membrane receptors Human genes 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000006011 modification reaction Methods 0.000 description 3
- 230000000051 modifying Effects 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000001603 reducing Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 201000011056 retinal disease Diseases 0.000 description 3
- 239000000790 retinal pigment Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000000451 tissue damage Effects 0.000 description 3
- 231100000827 tissue damage Toxicity 0.000 description 3
- 230000004304 visual acuity Effects 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N 2-mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 229960004308 ACETYLCYSTEINE Drugs 0.000 description 2
- 239000012103 Alexa Fluor 488 Substances 0.000 description 2
- 239000012112 Alexa Fluor 633 Substances 0.000 description 2
- 210000001772 Blood Platelets Anatomy 0.000 description 2
- 210000000988 Bone and Bones Anatomy 0.000 description 2
- 210000004556 Brain Anatomy 0.000 description 2
- 101710040446 CD40 Proteins 0.000 description 2
- 102100013137 CD40 Human genes 0.000 description 2
- 101700078950 CD44 Proteins 0.000 description 2
- 102100003735 CD44 Human genes 0.000 description 2
- 102100019451 CD80 Human genes 0.000 description 2
- 101700080477 CD80 Proteins 0.000 description 2
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Calypsol Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- 210000003855 Cell Nucleus Anatomy 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 229920002676 Complementary DNA Polymers 0.000 description 2
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N Cyclic guanosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 2
- 102100015284 DKK1 Human genes 0.000 description 2
- 101700029587 DKK1 Proteins 0.000 description 2
- 210000004443 Dendritic Cells Anatomy 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- FGXWKSZFVQUSTL-UHFFFAOYSA-N Domperidone Chemical group C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 2
- 102100009705 ENG Human genes 0.000 description 2
- 210000001161 Embryo, Mammalian Anatomy 0.000 description 2
- 229940088598 Enzyme Drugs 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000018233 Fibroblast growth factor family Human genes 0.000 description 2
- 108050007372 Fibroblast growth factor family Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 210000002216 Heart Anatomy 0.000 description 2
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 2
- 101710006572 ITGAM Proteins 0.000 description 2
- 102100019441 ITGAM Human genes 0.000 description 2
- 101710006661 ITGB1 Proteins 0.000 description 2
- 102100001478 ITGB1 Human genes 0.000 description 2
- 102000018358 Immunoglobulins Human genes 0.000 description 2
- 108060003951 Immunoglobulins Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000229754 Iva xanthiifolia Species 0.000 description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 206010025421 Macule Diseases 0.000 description 2
- 210000004693 NK cell Anatomy 0.000 description 2
- 241001182492 Nes Species 0.000 description 2
- 210000000440 Neutrophils Anatomy 0.000 description 2
- 230000005913 Notch signaling pathway Effects 0.000 description 2
- 229920001850 Nucleic acid sequence Polymers 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N PUROMYCIN Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 240000005373 Panax quinquefolius Species 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 108060006633 Protein Kinases Proteins 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 102100003837 RSPO3 Human genes 0.000 description 2
- 101700028929 RSPO3 Proteins 0.000 description 2
- 102100003838 RSPO4 Human genes 0.000 description 2
- 101700030228 RSPO4 Proteins 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N Rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 210000002536 Stromal Cells Anatomy 0.000 description 2
- 210000001744 T-Lymphocytes Anatomy 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 229960001603 Tamoxifen Drugs 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N Taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 101700080705 WNT5B Proteins 0.000 description 2
- 101700056690 WNT7A Proteins 0.000 description 2
- 101700072053 WNT8A Proteins 0.000 description 2
- 101700083721 WNT8B Proteins 0.000 description 2
- 108010047118 Wnt Receptors Proteins 0.000 description 2
- 102000006757 Wnt Receptors Human genes 0.000 description 2
- 108010085439 Wnt4 Protein Proteins 0.000 description 2
- 102000007483 Wnt4 Protein Human genes 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 210000001284 amacrine neuron Anatomy 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000002424 anti-apoptotic Effects 0.000 description 2
- 230000003110 anti-inflammatory Effects 0.000 description 2
- 230000003115 biocidal Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000001413 cellular Effects 0.000 description 2
- 230000001886 ciliary Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 229960005188 collagen Drugs 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000000139 costimulatory Effects 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 230000001086 cytosolic Effects 0.000 description 2
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 210000002257 embryonic structures Anatomy 0.000 description 2
- 230000001973 epigenetic Effects 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000001976 improved Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000000644 isotonic solution Substances 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 230000002147 killing Effects 0.000 description 2
- 108010046018 leukocyte inhibitory factor Proteins 0.000 description 2
- 230000000670 limiting Effects 0.000 description 2
- 229910003002 lithium salt Inorganic materials 0.000 description 2
- 159000000002 lithium salts Chemical class 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- VPNGEIHDPSLNMU-UHFFFAOYSA-N medetomidine hydrochloride Chemical compound Cl.C=1C=CC(C)=C(C)C=1C(C)C1=CNC=N1 VPNGEIHDPSLNMU-UHFFFAOYSA-N 0.000 description 2
- 108020004084 membrane receptors Proteins 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 210000002894 multi-fate stem cell Anatomy 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 230000000737 periodic Effects 0.000 description 2
- 230000002093 peripheral Effects 0.000 description 2
- 229940021222 peritoneal dialysis Isotonic solutions Drugs 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002335 preservative Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 2
- 101710044770 sll1951 Proteins 0.000 description 2
- 229940001482 sodium sulfite Drugs 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 102000002938 thrombospondin family Human genes 0.000 description 2
- 108060008245 thrombospondin family Proteins 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 102000003995 transcription factors Human genes 0.000 description 2
- 108090000464 transcription factors Proteins 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- VQOXZBDYSJBXMA-NQTDYLQESA-N (1S,3R,4E,6E,8E,10E,14E,16E,18S,19R,20R,21S,25R,27R,29R,32R,33R,35S,37S,38R)-3-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,29,32,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10,14, Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 1
- NZHGWWWHIYHZNX-CSKARUKUSA-N 2-[[(E)-3-(3,4-dimethoxyphenyl)prop-2-enoyl]amino]benzoic acid Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 description 1
- 125000006288 3,5-difluorobenzyl group Chemical group [H]C1=C(F)C([H])=C(C([H])=C1F)C([H])([H])* 0.000 description 1
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N 3-aminopropanol Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 1
- 125000006482 3-iodobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(I)=C1[H])C([H])([H])* 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- JDSJDASOXWCHPN-UHFFFAOYSA-N 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione Chemical compound O=C1N(C)SC(=O)N1CC1=CC=CC=C1 JDSJDASOXWCHPN-UHFFFAOYSA-N 0.000 description 1
- ITBGJNVZJBVPLJ-UHFFFAOYSA-N 5-(benzenesulfonyl)-N-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide Chemical group FC(F)(F)C1=CC=C(S(=O)(=O)C=2C=CC=CC=2)C=C1S(=O)(=O)NC1CCNCC1 ITBGJNVZJBVPLJ-UHFFFAOYSA-N 0.000 description 1
- YICWDMKVBLRMMK-UHFFFAOYSA-N 5-(benzylamino)-1,2,4-thiadiazol-3-one Chemical compound S1NC(=O)N=C1NCC1=CC=CC=C1 YICWDMKVBLRMMK-UHFFFAOYSA-N 0.000 description 1
- MDZCSIDIPDZWKL-UHFFFAOYSA-N 6-N-[2-[[4-(2,4-dichlorophenyl)-5-imidazol-1-ylpyrimidin-2-yl]amino]ethyl]-3-nitropyridine-2,6-diamine Chemical compound C1=C([N+]([O-])=O)C(N)=NC(NCCNC=2N=C(C(=CN=2)N2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1 MDZCSIDIPDZWKL-UHFFFAOYSA-N 0.000 description 1
- 102100011550 ACTB Human genes 0.000 description 1
- 101700033661 ACTB Proteins 0.000 description 1
- 101710032514 ACTI Proteins 0.000 description 1
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 description 1
- 101700047552 AXIN2 Proteins 0.000 description 1
- 102100016838 AXIN2 Human genes 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- UIQMVEYFGZJHCZ-SSTWWWIQSA-N Antorphin Chemical compound C([C@@H](N(CC1)CC=C)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 UIQMVEYFGZJHCZ-SSTWWWIQSA-N 0.000 description 1
- 210000001367 Arteries Anatomy 0.000 description 1
- 241000066478 Aspidiotus cryptomeriae Species 0.000 description 1
- BHELIUBJHYAEDK-OAIUPTLZSA-N Aspoxicillin Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3[C@H](C(C)(C)S[C@@H]32)C(O)=O)=O)NC(=O)[C@H](N)CC(=O)NC)=CC=C(O)C=C1 BHELIUBJHYAEDK-OAIUPTLZSA-N 0.000 description 1
- 241000182988 Assa Species 0.000 description 1
- 210000001130 Astrocytes Anatomy 0.000 description 1
- 101710005848 At4g18930 Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N BRL-49594 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 210000003651 Basophils Anatomy 0.000 description 1
- 229960000686 Benzalkonium Chloride Drugs 0.000 description 1
- PRDFBSVERLRRMY-UHFFFAOYSA-N Bisbenzimide Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- 210000004204 Blood Vessels Anatomy 0.000 description 1
- 238000010599 BrdU assay Methods 0.000 description 1
- 102100005826 CD19 Human genes 0.000 description 1
- 101700087100 CD19 Proteins 0.000 description 1
- 101710026548 CLEC11A Proteins 0.000 description 1
- 102100003428 CLEC11A Human genes 0.000 description 1
- 108060001895 CRIPT Proteins 0.000 description 1
- 101710005805 CYCS Proteins 0.000 description 1
- 102100002914 CYCS Human genes 0.000 description 1
- 229940046731 Calcineurin inhibitors Drugs 0.000 description 1
- 210000001736 Capillaries Anatomy 0.000 description 1
- 206010007749 Cataract diabetic Diseases 0.000 description 1
- 210000000170 Cell Membrane Anatomy 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 241000819038 Chichester Species 0.000 description 1
- OSASVXMJTNOKOY-UHFFFAOYSA-N Chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 1
- 229960004926 Chlorobutanol Drugs 0.000 description 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 1
- 206010009887 Colitis Diseases 0.000 description 1
- 108010003730 Cone Opsins Proteins 0.000 description 1
- 108010051219 Cre recombinase Proteins 0.000 description 1
- BQOHYSXSASDCEA-KEOHHSTQSA-N Cyclic ADP-Ribose Chemical compound C([C@@H]1[C@H]([C@H]([C@@H](O1)N1C=2N=CN3C(C=2N=C1)=N)O)O)OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H]3O1 BQOHYSXSASDCEA-KEOHHSTQSA-N 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N Cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 230000026641 DNA hypermethylation Effects 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 101710028159 DNTT Proteins 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- 206010012667 Diabetic glaucoma Diseases 0.000 description 1
- 102000017944 Dishevelled Proteins Human genes 0.000 description 1
- 108050007016 Dishevelled Proteins Proteins 0.000 description 1
- 210000003981 Ectoderm Anatomy 0.000 description 1
- 108010036395 Endoglin Proteins 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 210000003979 Eosinophils Anatomy 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 210000003414 Extremities Anatomy 0.000 description 1
- 208000009745 Eye Disease Diseases 0.000 description 1
- 208000010167 Eye Injury Diseases 0.000 description 1
- 210000000744 Eyelids Anatomy 0.000 description 1
- 102100015541 FCGR3A Human genes 0.000 description 1
- 101710044656 FCGR3A Proteins 0.000 description 1
- 101710044657 FCGR3B Proteins 0.000 description 1
- 241000272184 Falconiformes Species 0.000 description 1
- 101710037135 GAPC2 Proteins 0.000 description 1
- 101710037116 GAPC3 Proteins 0.000 description 1
- 101710025049 GAPDG Proteins 0.000 description 1
- 101710008404 GAPDH Proteins 0.000 description 1
- 102100006425 GAPDH Human genes 0.000 description 1
- 102100012697 GATA4 Human genes 0.000 description 1
- 102000025570 GPCRs class F Human genes 0.000 description 1
- 108091008163 GPCRs class F Proteins 0.000 description 1
- 101710010461 Gapdh1 Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N Glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 229960003180 Glutathione Drugs 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 210000002397 Granulocyte Precursor Cells Anatomy 0.000 description 1
- 210000003714 Granulocytes Anatomy 0.000 description 1
- 210000003128 Head Anatomy 0.000 description 1
- 210000000777 Hematopoietic System Anatomy 0.000 description 1
- 241000735445 Hetrodes Species 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 101700066198 ICI2 Proteins 0.000 description 1
- 210000000987 Immune System Anatomy 0.000 description 1
- 102000012355 Integrin beta1 Human genes 0.000 description 1
- 108010022222 Integrin beta1 Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 210000001153 Interneurons Anatomy 0.000 description 1
- 101700048573 KLF4 Proteins 0.000 description 1
- 102100006525 KLF4 Human genes 0.000 description 1
- 101710031437 KREMEN1 Proteins 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 101700076414 LRP6 Proteins 0.000 description 1
- 102100009516 LRP6 Human genes 0.000 description 1
- 210000000265 Leukocytes Anatomy 0.000 description 1
- 229960005015 Local anesthetics Drugs 0.000 description 1
- 229940083877 Local anesthetics for treatment of hemorrhoids and anal fissures for topical use Drugs 0.000 description 1
- 208000010415 Low Vision Diseases 0.000 description 1
- 210000004698 Lymphocytes Anatomy 0.000 description 1
- 230000035779 M Phase Effects 0.000 description 1
- 230000027311 M phase Effects 0.000 description 1
- 101700067074 MAPK Proteins 0.000 description 1
- 102100000918 MAPK14 Human genes 0.000 description 1
- 101710041325 MAPKAPK2 Proteins 0.000 description 1
- 101710025050 MK0970 Proteins 0.000 description 1
- 102100000165 MS4A1 Human genes 0.000 description 1
- 101710010909 MS4A1 Proteins 0.000 description 1
- 108010030317 Macrophage-1 Antigen Proteins 0.000 description 1
- 229920001776 Mature messenger RNA Polymers 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 241001237731 Microtia elva Species 0.000 description 1
- 210000003003 Monocyte-Macrophage Precursor Cells Anatomy 0.000 description 1
- 241001602730 Monza Species 0.000 description 1
- 235000013382 Morus laevigata Nutrition 0.000 description 1
- 244000278455 Morus laevigata Species 0.000 description 1
- 210000004253 Multipotent Stem Cells Anatomy 0.000 description 1
- 210000002027 Muscle, Skeletal Anatomy 0.000 description 1
- 210000000066 Myeloid Cells Anatomy 0.000 description 1
- 210000003643 Myeloid Progenitor Cells Anatomy 0.000 description 1
- YAEMHJKFIIIULI-UHFFFAOYSA-N N-(4-Methoxybenzyl)-N'-(5-Nitro-1,3-Thiazol-2-Yl)Urea Chemical compound C1=CC(OC)=CC=C1CNC(=O)NC1=NC=C([N+]([O-])=O)S1 YAEMHJKFIIIULI-UHFFFAOYSA-N 0.000 description 1
- 101700055154 NANOG Proteins 0.000 description 1
- 102100007761 NANOG Human genes 0.000 description 1
- 102100007544 NCAM1 Human genes 0.000 description 1
- 101700077124 NCAM1 Proteins 0.000 description 1
- 102000006310 Nanog Homeobox Protein Human genes 0.000 description 1
- 108010083388 Nanog Homeobox Protein Proteins 0.000 description 1
- 102000010648 Natural Killer Cell Receptors Human genes 0.000 description 1
- 108010077854 Natural Killer Cell Receptors Proteins 0.000 description 1
- 108010008267 Nerve Growth Factors Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 210000001178 Neural Stem Cells Anatomy 0.000 description 1
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 description 1
- 101700083667 PAX6 Proteins 0.000 description 1
- 102000007354 PAX6 Transcription Factor Human genes 0.000 description 1
- 229950010131 PUROMYCIN Drugs 0.000 description 1
- 229940056360 Penicillin G Drugs 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- 229940096826 Phenylmercuric Acetate Drugs 0.000 description 1
- 229960002553 Phenylmercuric nitrate Drugs 0.000 description 1
- XEBWQGVWTUSTLN-UHFFFAOYSA-M Phenylmercury acetate Chemical compound CC(=O)O[Hg]C1=CC=CC=C1 XEBWQGVWTUSTLN-UHFFFAOYSA-M 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 108091000081 Phosphotransferases Proteins 0.000 description 1
- 210000004011 Plasma Cells Anatomy 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M Propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 210000000449 Purkinje Cells Anatomy 0.000 description 1
- 102100007885 RBFOX3 Human genes 0.000 description 1
- 101710012983 RBFOX3 Proteins 0.000 description 1
- 101700033491 RPE65 Proteins 0.000 description 1
- 239000007759 RPMI Media 1640 Substances 0.000 description 1
- 206010064714 Radiation retinopathy Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229940116176 Remicade Drugs 0.000 description 1
- 208000008521 Retinal Cone Dystrophy 1 Diseases 0.000 description 1
- 210000003994 Retinal Ganglion Cells Anatomy 0.000 description 1
- 210000003583 Retinal Pigment Epithelium Anatomy 0.000 description 1
- 210000001210 Retinal Vessels Anatomy 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 102100000376 SERPINE2 Human genes 0.000 description 1
- 101710024178 SERPINE2 Proteins 0.000 description 1
- 101710019780 SLC22A3 Proteins 0.000 description 1
- 241000490025 Schefflera digitata Species 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N Sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002385 Streptomycin Sulfate Drugs 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 210000000225 Synapses Anatomy 0.000 description 1
- 101700070567 TBX18 Proteins 0.000 description 1
- 102000025219 TCF/LEF family Human genes 0.000 description 1
- 108091020838 TCF/LEF family Proteins 0.000 description 1
- 229950009638 TEPOXALIN Drugs 0.000 description 1
- 108091005711 TGF-beta receptors Proteins 0.000 description 1
- 229960003080 Taurine Drugs 0.000 description 1
- 241000278713 Theora Species 0.000 description 1
- 229940033663 Thimerosal Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L Thiomersal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 102000036902 Thrombopoietin Human genes 0.000 description 1
- 108010041111 Thrombopoietin Proteins 0.000 description 1
- 210000002303 Tibia Anatomy 0.000 description 1
- YTGJWQPHMWSCST-UHFFFAOYSA-N Tiopronin Chemical compound CC(S)C(=O)NCC(O)=O YTGJWQPHMWSCST-UHFFFAOYSA-N 0.000 description 1
- 108010058907 Tiopronin Proteins 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N Tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000014257 Transferrin receptor protein 1 Human genes 0.000 description 1
- 108050003222 Transferrin receptor protein 1 Proteins 0.000 description 1
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010045178 Tunnel vision Diseases 0.000 description 1
- 241000397921 Turbellaria Species 0.000 description 1
- 108091005908 Type I transmembrane proteins Proteins 0.000 description 1
- 108091005945 Type II transmembrane proteins Proteins 0.000 description 1
- 210000003954 Umbilical Cord Anatomy 0.000 description 1
- 101700058634 VCAM1 Proteins 0.000 description 1
- 102100015249 VEGFA Human genes 0.000 description 1
- 101700003987 VSX2 Proteins 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108010041332 Very Late Antigen Receptors Proteins 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 229940045997 Vitamin A Drugs 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 101710026627 WNT10B Proteins 0.000 description 1
- 101700025356 WNT7B Proteins 0.000 description 1
- 108010021176 Wnt-5a Protein Proteins 0.000 description 1
- 102000008223 Wnt-5a Protein Human genes 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- ORWSYHWTBSHFIV-ICFOKQHNSA-N [[(2Z)-2-(6-bromo-2-oxo-1H-indol-3-ylidene)indol-3-yl]amino] acetate Chemical compound O=C\1NC2=CC(Br)=CC=C2C/1=C1/N=C2C=CC=CC2=C1NOC(=O)C ORWSYHWTBSHFIV-ICFOKQHNSA-N 0.000 description 1
- 230000001594 aberrant Effects 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 210000001056 activated astrocyte Anatomy 0.000 description 1
- 108010023082 activin A Proteins 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000000735 allogeneic Effects 0.000 description 1
- 150000005005 aminopyrimidines Chemical class 0.000 description 1
- 229960003942 amphotericin B Drugs 0.000 description 1
- 231100001075 aneuploidy Toxicity 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001028 anti-proliferant Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 230000000890 antigenic Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000003190 augmentative Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 230000028956 calcium-mediated signaling Effects 0.000 description 1
- 150000001717 carbocyclic compounds Chemical class 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 101710025091 cbbGC Proteins 0.000 description 1
- 102000008395 cell adhesion mediator activity proteins Human genes 0.000 description 1
- 108040002558 cell adhesion mediator activity proteins Proteins 0.000 description 1
- 239000006143 cell culture media Substances 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 238000007374 clinical diagnostic method Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000001332 colony forming Effects 0.000 description 1
- 230000004456 color vision Effects 0.000 description 1
- 230000000295 complement Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000003636 conditioned culture media Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 108040003506 cyclic ADP-ribose hydrolase Proteins 0.000 description 1
- 230000001461 cytolytic Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 201000007025 diabetic cataract Diseases 0.000 description 1
- 101700000175 din-1 Proteins 0.000 description 1
- WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000003511 endothelial Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000002919 epithelial cells Anatomy 0.000 description 1
- 230000000925 erythroid Effects 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000001605 fetal Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 101710025070 gapdh-2 Proteins 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000002443 helper T lymphocyte Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 210000002287 horizontal cell Anatomy 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000002519 immonomodulatory Effects 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 230000001506 immunosuppresive Effects 0.000 description 1
- 230000001771 impaired Effects 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- 230000000977 initiatory Effects 0.000 description 1
- 235000013902 inosinic acid Nutrition 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002427 irreversible Effects 0.000 description 1
- 231100001032 irritation of the eye Toxicity 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 210000001985 kidney epithelial cell Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000003902 lesions Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000004298 light response Effects 0.000 description 1
- 235000015250 liver sausages Nutrition 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229940064003 local anesthetic throat preparations Drugs 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 230000004777 loss-of-function mutation Effects 0.000 description 1
- 230000004303 low vision Effects 0.000 description 1
- 230000000527 lymphocytic Effects 0.000 description 1
- 101700063896 mac-1 Proteins 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000011177 media preparation Methods 0.000 description 1
- 230000003340 mental Effects 0.000 description 1
- 230000002503 metabolic Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000000813 microbial Effects 0.000 description 1
- 230000002025 microglial Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000003278 mimic Effects 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000000877 morphologic Effects 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 210000001167 myeloblast Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000019581 neuron apoptotic process Effects 0.000 description 1
- 230000000324 neuroprotective Effects 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 230000003018 neuroregenerative Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- PDTFCHSETJBPTR-UHFFFAOYSA-N nitrooxy(phenyl)mercury Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drugs Drugs 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000004942 nuclear accumulation Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000000790 osteoblast Effects 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 230000005043 peripheral vision Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 210000001850 polyploid cell Anatomy 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- KYQCOXFCLRTKLS-UHFFFAOYSA-N pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2(1H)-one Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 108091007921 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027656 receptor tyrosine kinases Human genes 0.000 description 1
- 239000001044 red dye Substances 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000000717 retained Effects 0.000 description 1
- 230000028396 retina morphogenesis in camera-type eye Effects 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 230000004243 retinal function Effects 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 230000001177 retroviral Effects 0.000 description 1
- 101710024887 rl Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000001743 silencing Effects 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 101700045897 spk-1 Proteins 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000007801 sublethal irradiation Methods 0.000 description 1
- 201000010874 syndrome Diseases 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- XYKWNRUXCOIMFZ-UHFFFAOYSA-N tepoxalin Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(CCC(=O)N(C)O)=N1 XYKWNRUXCOIMFZ-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N thiazole Chemical class C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 229960004402 tiopronin Drugs 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 229960005342 tranilast Drugs 0.000 description 1
- 230000002103 transcriptional Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 230000001960 triggered Effects 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 230000001228 trophic Effects 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000004450 types of analysis Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/415—Wnt; Frizzeled
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0623—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
Abstract
Discloses use of a mesenchymal stem cell (MSC) or a cell population comprising a hematopoietic stem cell (HSC) and a progenitor cell, wherein the Wnt/?-catenin signalling pathway of said cells is activated, in the manufacture of a medicament for the treatment of a retinal degeneration disease by direct implantation of said cells into the eye of a subject in need of treatment. Also discloses a cell composition, wherein at least 50% of the cells of said cell composition are hematopoietic stem cells (HSCs) and progenitor cells and wherein the Wnt/?-catenin signalling pathway of said cells is activated. ect implantation of said cells into the eye of a subject in need of treatment. Also discloses a cell composition, wherein at least 50% of the cells of said cell composition are hematopoietic stem cells (HSCs) and progenitor cells and wherein the Wnt/?-catenin signalling pathway of said cells is activated.
Description
METHODS OF TREATMENT OF RETINAL DEGENERATION DISEASES
FIELD OF THE INVENTION
This invention s to the field of cell-based or regenerative therapy for
ophthalmic diseases. In particular, the invention provides s of treatment of
retinal degeneration diseases by administering cells. said cells having properties of stem
cells or progenitor cells, to the retina and reprogramming of retinal cells, such as retinal
neurons or retinal glial cells, mediated by cell fusion of said. cells with said. retinal cells,
said reprogramming being mediated. by tion of the Wnt/B-catenin signalling
pathway.
BACKGROUND OF THE INVENTION
The retina is a specialized light-sensitive tissue at the back of the eye that
contains photoreceptor cells (rods and cones) and. s connected. to a neural
network for the processing of visual information. The rods function in conditions of low
illumination whereas cones are responsible for color vision and. all visual tasks that
require high tion (e.g., reading). The rods are mostly located. away from the center
of the eye in the retinal periphery. The highest concentration of cones is found at the
center of the retina, the macula, which is necessary for visual acuity. For support of its
metabolic ons, the retina is dependent on cells of the adjacent retinal pigment
lium (RPE).
Retinal degeneration is the deterioration of the retina caused by the progressive
and eventual death of the retinal or retinal pigment ephitelium (RPE) cells. There are
several reasons for retinal degeneration, ing artery or vein occlusion, diabetic
retinopathy, retrolental fib'roplasia/retinopathy of prematurity, or disease (usually
hereditary). These may present in many different ways such as impaired Vision. night
blindness, retinal detachment, light ivity, tunnel vision, and loss of peripheral
vision to total loss of vision. Retinal degeneration is found in many different forms of
retinal diseases including retinitis tosa, age-related r degeneration
(AMD), diabetic retinopathy, cataracts, and glaucoma.
tis pigmentosa (RP) is the most common retinal degeneration with a
prevalence of approximately I in 3,000 to l in 5,000 individuals, affecting
imately 1.5 million people worldwide. RP is a heterogeneous family of ted
retinal disorders characterized by progressive degeneration of the photoreceptors with
subsequent degeneration of RPE. It is the most common inherited retinal degeneration
and is characterized by t deposits predominantly in the peripheral retina and by a
relative sparing of the central . The typical manifestations are present between
adolescence and early adulthood and. lead to devastating visual loss with a high
probability. In most of the cases of RP, there is primary degeneration of photoreceptor
rods, with ary degeneration of cones. RP is a long-lasting disease that usually
evolves over several decades, initially presented as night blindness, and, later in life as
viSual impairment in l conditions. Currently, there is no therapy that stops the
evolution of retinal ration or restores Vision. There are few treatment options
such as light avoidance and/or the use of low-Vision aids to slow down the progression
of RP. Some practitioners also er vitamin A as a possible treatment option to slow
down the progression of RP.
Effective treatment for retinal degeneration has been widely investigated. The
field. of stem ased therapy holds great potential for the treatment of retinal
degenerative diseases as many s in animal models suggest that stem cells have the
capacity to regenerate lost photoreceptors and retinal neurons and e Vision. To
date, these cells include retinal progenitor cells, embryonic stem cells, bone marrow-
derived. stem cells, and induced pluripotent stem cells.
Retinal progenitor cells (RPCs) are derived from fetal or neonatal retinas, and
se an immature cell population that is responsible for generation of all retinal
cells during nic development. RPCs can proliferate and generate new neurons
and specialized retinal support cells in Vitro, and can also migrate into all retinal layers
and develop morphological characteristics of various retinal cell types in viva
(MacLaren et (1]., 2006, Nature 444:203-7). These results support the hypothesis that
RPCs lants are a potential treatment for retinal degenerative diseases.
Embryonic stem cells (ESCs) are derived from the inner cell mass of blastocyst-
stage embryos, with self-renewal lities as well as the ability to differentiate into
all adult cell types, including photoreceptor progenitors, photoreceptor, or RPE in mice
and humans (Lamba ct al., 2006, PNAS USA "103:12769-74; Osakada et (11., 2008, Nat
Bioteclmol 26215—224). Lamba er al. showed that transplantation of retinal cells
derived from human ESCs into the subretinal space of adult Crx("r') mice promoted the
differentiation of hESCs-derived retinal cells into functional photoreceptors, and the
ure improved light responses in these animals a 6t (11., 2009, Cell Stem
Cell 4:73-9). Although ESCs are promising in retinal replacement therapies, there
remain ethical and immune rejection issues to be considered, and ESCs have also been
associated. with teratoma ion.
The bone marrow harbors at least two distinct stem cell populations:
mesenchymal stem cells (MSCs) and hematopoietic stem cells (HSCs). MSCs can be
induced into cells expressing photoreceptor e-specific markers in vitro using
activin A, taurine, and. epidermal growth factor (Kicic et (11., 2003, J Neurosci 2317742-
9). In on, an in vivo animal model demonstrated that MSC injected into the
subretinal space can slow down retinal cell degeneration and integrate into the retina
and differentiate into photoreceptors in Royal College of Surgeons (RCS) rats (Kicic et
al._, 2003, J Neurosci 23 :7742-9; Inoue er al., 2007. Exp Eye Res 85:234-41).
Otani er a]. have ed that intravitreally ed, lineage-negative (Lin')
hematopoietic stem cells (HSCs) can rescue l degeneration in rdj and NIH) mice
(Otani et (11., 2004, J Clin Invest 1'142755-7; US 2008/03'1772'1; US 20'10/0303768).
However, the transplanted retinas were formed of nearly only cones, and the
electroretinogram responses were severely abnormal and. comparable to untreated.
animals. There was a limitation in that intravitreally injected. Lin" HSCs were effectively
incorporated into the retina only during an early, postnatal developmental stage but not
in adult mice, only targeting activated astrocytes that are observed in neonatal mice or
in an injury induced model in the adult (Otani er LIL, 2002, Nat Med 821004-10; Otani er
(1]., 2004, J Clin Invest 'I 14:755-7; Sasahara et (11., 2004, Am J Pathol I72:'1693-703).
Induced pluripotent stem cells (iPS) derived from adult tissues are pluripotent
ESC-like cells reprogrammed in vitro from terminally differentiated. somatic cell by
retroviral transduction of four transcription factors: Oct3/4, 80x2, Klf4 and e-Myc. It
has been reported that human iPS have a similar potential of ESCs to mimic normal
retinogenesis (Meyer er al._. 2009, PNAS USA 106216698-703). However, major issues
include reducing the risk l ations and oncogene sion for tion of
iPS. These limitation may be me using alternative methods to obtain iPS such as
activation of signalling pathways, including the Wnt/B—catenin, MAPK/ERK, TGF-D
and Pl3K/AKT ssignalling pathways (; Sanges & Cosma, 2010, Int J
Dev Biol 54:1575-87).
Therefore, there is the need to provide an ive method for treating retinal
degenerative diseases.
SUMMARY OF THE INVENTION
Inventors have now found that retinal regeneration can be achieved by
implanting cells, said. cells having properties of stem cells or progenitor cells, into the
retina of a t which fuse with retinal cells, such as retinal neurons, e,g., rods, etc.,
or l glial cells, e.g., Miiller cells, to form hybrid cells which reactivate neuronal
precursor markers, proliferate, dc-d'ifferentiate and finally differentiate into terminally
entiated retinal neurons of st, e.g., photoreceptor cells, ganglion cells, etc.,
which can regenerate the damaged retinal tissue. The tion of the Wnt/B-catenin
signalling pathway is essential to induce de-differentiation of said. hybrid cells and. final
re-differentiation in the retinal neurons of interest. In an embodiment, activation of the
Wnt/B-catenin signalling pathway is, at least lly, ed. by the ted. cells
(which have been treated with a Wnt/B-catenin signalling pathway tor, or with an
inhibitor of a Wnt/B-catenin signalling pathway rcpressor, and/or overexpress a Wnt/B-
catenin signalling pathway activator), whereas in another embodiment, activation of the
WntlB-c-atenin signalling pathway is only provided as a result of administering a Wnt/B-
catenin signalling pathway activator, or an inhibitor of a Wnt/B-catenin signalling
pathway repressor, to the subject to be treated or as a consequence of a retinal damage
or injury, as occurs in, for example, retinal degeneration diseases (e.g., Retinitis
Pi gmentosa). The newborn retinal neurons fully regenerate the retina in the transplanted
mammalian, with some rescue of functional vision. Histological analysis shows that
said rated retinas are indistinguishable from retinas of wild-type mammalians two
months after transplantation. These data show that cell fusion-mediated. regeneration is
a very efficient process in mammalian retina, and that it can be red by tion
of Wnt/B-catenin signalling pathway in the transplanted cells, and that in vivo
reprogramming of terminally differentiated retinal s is a possible mechanism of
tissue regeneration. Consequently, these teachings can be d to treat diseases
wherein retina is degenerated.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure l. Cell fusion controls. (a) Schematic representation of the experiment
plan. o cell fusion between HSPCsRHme with l s of LoxP-STOP-
LoxP-YFP mice (R26Y) leads to excision of a floxed stop codon in the retinal neurons,
and in turn, to expression of YFP. The ing hybrids express both RFP and. YFP. (b)
Representative fluorescence raphs of R26YW s 24 h after inal
transplantation of BIO-treated 'm'm’. YFP positive cells represent hybrids
d from cell fusion of HSPCs with R26Y’d1 retinal cells. (c) RT-PCR analysis of
the target gene Axi'n2 shows B-catenin signalling activation in BIO-treated HSPCs. (d-e)
Representative fluorescence micrographs of 1310 wild-type R26Y retinas 24 h after
subretinal transplantation of BIO-treated HSPCsCRERFP. No YEP-positive cells (green)
were detected. Nuclei were counterstained with DAPI in (e). Dotted. lines show the final
part of the retinal tissue. OS: outer segment; ONL: outer nuclear layer; INL: inner
nuclear layer.
Figure 2-. Transplanted HSPCs fuse and induce de-d'ifferentiation of rdl'mousc
retinal cells upon Wnt/B-catenin signalling pathway activation. (a-d.) Representative
fluorescence micrographs of R26Y'Wmouse retinas 24h afier subretinal transplantation
of HSPCscml‘lRF'). Double-positive RFPIYFP (red/green) hybrids following cell fusion of
HSPCs (red) with rd] retinal cells were detected in the ONL, and a few in the INL.
Thcse YFP-positive hybrids (YFP, green) are also positive for markers to rod
(rhodops'in; red in b) and Muller (glutamine synthetase; red in c) cells, but not to cones
(d). (e-g) Quantification of apoptotic photoreceptors (e) and apoptotic (f) and
proliferating (g) hybrids 24h after transplantation of O-treated. (No BIO) and
BIO-treated (BIO) HSPCSCRH in p10 R26Yrdl eyes. Numbers were calculated. as the
percentage of TUNEL positive photoreceptors with respect to total photoreceptor nuclei
(e) or as the tage of Annexin V (i) or Ki67 (g) positive cells with t to the
total numbers of YFP positive hybrid. cells. (h) Real-time PCR of genes (as indicated.)
expressed in the HSPCs and retinal and hybrid cells (as indicated). 0N L: outer nuclear
layer; IN L: inner nuclear layer.
Figure 3. Proliferation and cell-death analysis of de-differentiated hybrids.
Representative immunofluorescence staining of Annexin V (a, b) and Ki67 (c, d) on
retinal sections of R26Y’d’ mice analysed 24 h after lantation at p10 with BIO—
treated l’lSPCscp‘E (BIO; a, c) or non-treated HSPCSCRE (No BIO; _b, d). YFP
fluorescence (green) localises hybrids obtained after fusion. Nuclei were 'counterstained
with DAPI (blue). Yellow arrows indicate apoptotic (b) or proliferating hybrids (c-d).
Figure 4. Immunofluorescence analysis of expression of precursor markers in
de-difi‘erentiated hybrids. Representative immunofluorescence staining of Nestin (a, (1,
red), Noggin (b, e, red) and Otx2 (c, f, red) in retinal sections from R26Y’d’ mice 24 h
after transplantation at p10 of BIO-treated I-ISPCsCRE (BIO; a-c) or ted cells (No
BIO; d-t). YFP s ) obtained after fusion were positive for these markers
only following BIO-treatment (a-c, yellow arrows).
Figure 5. Histological analysis time course of retinal regeneration in rd! mice.
(a-h) Representative H&E staining (a, b, (3-11) and TUNEL staining (c, d; red) of l
sections of R26Ynil mice transplanted at p10 with untreated (a, c, e, g) or BIO-treated
(b, d, f, h) HSPCsm/CRE and analysed 5 (p15; ad), 10 (p20; e, f) and 15 days (p25; g,
h) after transplantation. (i—p) Representative H&E staining of wild-type (i, j) and rd!
mice (k-p) without transplantation (i, j, o, p) or transplanted at p10 (k-n) with ted
(m, n) or BIO-treated (k-l) HSPCS (m-n), all analysed at p60. Magnification: 20x a-h, j,
1, n, p; 5X i, k, m, o. ONL: outer nuclear layer.
Figure 6. Histological analysis time course of transplanted R26Y"”eyes. (a)
entative H&E staining and TUNEL staining of retinal sections of R26Yrdl mice
transplanted at p10 with untreated. or BIO-treated HSPCSRWCRE and analysed 5 (p15),
(p20) and 15 days (p25) after lantation.(b) Representative immuno staining of
retinas of R26Y'd' mice transplanted with no Bio-treated HSPCSRFP’CRE ' ONL: outer
nuclear layer; INL: inner nuclear layer.
Figure 7. Analysis of hybrid entiation at p60. (a-f) Representative
immunofluorescence staining of retinal sections of R26Y““ mice t
RECTIFIED SHEET (RULE 91)
' lSA/EP
transplantation (e) and transplanted at p10 with BIO-treated. HSPCs (a-d, f) and
analysed at p60. (a-d) YFP-positive hybrids (green) are positive for rhodopsin (a, red)
but not for cone opsin (b, red), glutamine synthetase (c, red), and CD31 (d, red). Bottom
images: merges of red and green, with nuclei also counterstained with DAPI (blue). (ef
) Rhodopsin (red), Pde6b (magenta) and counterstained nuclei with DAPI (blue). (g)
Western blotting of Pde6b protein expression in the retina of wild-type (wt) and
R26Yrdl mice either untreated ('rd'l NT) or transplanted with BIO-treated HSPCs ('rdl
BIO), all analysed at p60. Total protein lysatcs were normalized with an anti-B-actin
antibody. ON L: outer nuclear layer; IN L: inner nuclear layer; GCL: ganglion cell layer.
Figure 8. YFP positive hybrids express PDE6B. (a) Representative
fluoreseence staining ofrhodopsin (red) in retinal section from R26Y mice 2
months after transplantation at p10 of ted HSPCsCRF' cells. Neither YFP hybrids
(green) nor rhodopsin (red) positive photoreceptors were detected. Nuclei were
counterstained. with DAPI. (b) Representative retinal sections of RZOYF‘“ mice
lanted at p10 with BIO-treated RE and analysed at p60. YFP positive
hybrids (green) are positive to both rhodopsin (red) and Pde6b (magenta). Nuclei in
merged images were counterstained with DAPI . ONL: outer nuclear layer; IN L:
inner nuclear layer; GCL: ganglion cell layer.
Figure 9. Damage-dependent cell fusion iii-viva. (A) Schematic representation
of cell fusion experimental plan. ln-vivo cell fusion between red —labelled SPCscm with
retinal s of L-oxP-STOP-LoxP-YFP mice (R26Y) leads to excision of a floxed
stop codon in the l neurons, and in turn, to expression of YFP. The resulting
hybrids express YFP and are also labelled in red. (B, C) Confocal photomicrographs of
R26Y NMDA—damaged (B) or healthy s (C) of mice transplanted with
Fm‘l’e. The mice were ced 24 h after tissue damage. Deiible-positive RFP
(red) and YFP (green) hybrids derived from cell fusion are detected in the presence of
NMDA damage (B, NMDA), but not in the maged eye (C, No NMDA). Nuclei
were counterstained with DAPI (blue). onI: outer nuclear layer; in]: inner nuclear layer;
gcl: ganglion cell layer. Scale bar: 50 um. (D) Quantification of hybrids formed 24 h
after cell lantation, as percentages of YFP-positive cells on the total red
HSPCscruiRFP localised in the optical fields. Sections of NMDA-damaged and non-
damaged (No NMDA) eyes were analysed. Data are means is.e.'m.; n = 90 (three
different retinal fields of 10 different retinal serial sections, for each eye. Three different
eyes were analysed). ***P <0.00‘l. (E-G): I'mmunohistochemical analysis of the l
fusion cell partners. YFP hybrids also positive for ganglion (E, Thyl.l, red), ne
(F . sintaxin, red) or negative for Muller (G, GS, red) cell s are detected 12 h after
transplantation of HSPCsUe in NMDA-damaged eyes. Yellow arrows indicate cells
positive to both YFP and marker staining. Scale bar: 10 um.
Figure 10. Analysis of cell fusion events. (A) H&E staining (left) and, schematic
representation of the retinal tissue. (B) TUNEL staining (green) on sections of R26Y
mice eyes sacrificed 48h after NMDA injection. (C) NMDA treatment in R26Y mice
does not activate YFP expression (green) in retinal neurons. (D) Cell transplantation
was performed at least in 3 different eyes for each experiment. Then, a total of ten serial
sections from each of the eyes were examined in three different regions for each n.
The number ofirnmunoreactive marker positive. of YFP-positive or GFP- positive cells
within three areas (40X optical fields) of the retina was counted in dual sections.
The ratio between the latter numbers and the total number of red-labelled. (DiD) cells or
RFP positive cells in the same fields resulted. in the percentage of positive cells. The
40X fields (red rectangles) were chosen in areas including the gel and the inl of the
retinal . (E) Flow cytometry analysis of tetraploid. cells with a 4C content of DNA
was performed. on total cells isolated. from NMDA-damaged. RZnY retinas transplanted
with BIO-HSPCu'e. The presence of tetraploid. cells in a GZ/M phase of the cell cycle
was detected when gating on the RFP positive cells ds) (right graph) while were
not in control unfused RFP HSPCsCrc (left graph). (F) Statistical analysis of the retinal
fusion rs. Numbers ent the percentage of YFP hybrids also positive either
for a ganglion, amacrine or Mfiller retinal cell markers detected 12 h after
transplantation of HSPCscre in NMDA-damaged R26Y eyes.
Figure II. is of ESC and RSPC fusion events. (A) Representative
samples of Cscre and. DiD-RSPCsUe injected either into mice eyes pre-treated
for 24 h with NMDA to induce cellular damage, or in healthy eyes (No NMDA). In
R26Y eyes 24 h after cells injection (DiD cells, red), YFP sion (YFP, green) is
detected in the NMDA—damaged eyes (NMDA), but not in the non-damaged eye (No
NMDA). Nuclei were counterstained with DAPI (blue). Scale bar: 20 um. (B)
fication of YFP-positive cells as percentage relative to the total number of
transplanted DiD- ESCscm and DiD-RSPCsCr0 localized in the optical fields. Sections of
NMDA-damaged and non-damaged eyes were analysed in mice sacrificed 24h after
transplantation. Data are means :ts.e.m.; n=30 (three different areas of '10 different
retinal serial sections for each eye). P value <0.001 (***). (C) NMDA (intravitreal) and
BrdU peritoneal) were injected in R26Y mice; one day later, unlabelled ESCs
were ed vitreal) and. finally BrdU ng was performed. on eye sections of
mice sacrificed after further 24 h. Total BrdU positive cells (red. arrows) were counted.
in the gel in a 40X field. YFP positive hybrids were never positive to BrdU staining
(green arrows). Data are means is.e.m.; n=30.
Figure 12-. Analysis of reprogramming of retinal s after fusion. (A)
lmmunofluorescence staining using an anti B-catenin antibody (red) was med on
sections from eyes treated either with NMDA. with both NMDA and DKK'] or
untreated as control. The expression and nuclear accumulation of B-catenin in retinal
cells detected. in NMDA-damaged eyes (red. ) is reduced after treatment with
DKKl. Scale bar: 20_um. (B) Schematic representation of iii—viva reprogramming
experimental plan. Red—labelled SPCs either non-treated ol), or treated for 24 h
with BIO were injected in NMDA-damaged. or undamaged eyes of Nanog-GFP-Puro
recipient mice. The sion of GFP in reprogrammed hybrids was analysed one day
after injection. (C) NMDA treatment does not activate GFP expression (green) in
Nanog-GFP retinal neurons. (D-F) BIO treatment of HSPCs activates B-catenin
signalling as shown by RT-PCR of the target gene Axin2 (D) or by nuclear
location of B-cate'nin in untreated (E) or BIO-treated (F) cells. (G) Transplantation
of BIO-treated HSPCsRFP (red) in healthy Nanog-GFP eyes does not induce vation
ofthe Nanog-GFP transgene (green). Nuclei were counterstained. with DAPI.
Figure 13. Activation of the Wnt/B-catenin signalling pathway enhances neuron
reprogramming after cellfusion in-vivr). (A) Schematic representation of in-vivo
reprogramming experimental plan. Nestin-CRE mice received. intravitreal injection of
both NMDA and DKKl, NMDA alone, or PBS as l, one day before HSPCsR26Y
injection. Before transplantation, HSPCsR26Y were pre-treated or not with Wnt3a or BIO
and labelled with DiD red dye. Samples were analysed 24 h after cell transplantation.
Only as a consequence of cell fusion and reprogramming can the Cre. re-expressed in
adult mice due to the tion of the Nestin promoter. induce expression of YFP in
hybrids that retain the red membranes. (B) Only in the presence of NMDA Without
DKKl do transplanted red HSPCstoY start to express YFP (green arrows). Yellow
arrows indicate double-positive red. and green cells. Wnt3a pre-treatment of red
’Y before transplantation ses the amounts of -positive red-”green
s. Scale bar: 50 um (C—D) Statistic-a1 analysis of the s of double red/green
(DiD!YFP)—positive hybrids detected in Nestin-CRE (C) or Nanog GFP (D) retinas
treated. with NMDA, NMDA+DKK1, or untreated (No NMDA), 24 h after
transplantation of untreated HSPCs or of Wnt3a- or BIO-treated HSPCs. Percentages
were ated as the number of YFP-positive cells with respect to the total number of
red HSPCs detected in the optical fields. Data are means is.e.m._; n=90. ***P <0.00’l.
(E) Confocal photomicrographs 24h after transplantation of undamaged (No NMDA)
Nanog-GFP retinas and of NMDA Nanog-GFP retinas transplanted with HSPCs pre-
treated. with Wnt3a (NMDA + Wnt3 a).
Figure 14. Activation of the Wnt/B-catenin signalling pathway enhances neuron
reprogramming after cell fusion in vivo. (A) Representative samples where DiD-ESCs
were injected. 24h after PBS injection (No NMDA) or NMDA injection in Nanog-GFP-
puro mice. Twenty-four hours after ESC injection, Nanog-GFP expression (green) is
detected in ESC-neuron s (red and. green) in NMDA-damaged. (NMDA) but not
in non-treated eyes (No NMDA). P-re-treatment with DKK'] (NMDA+DKK'I) reduces
the number of GFP-positive hybrids. BIO and Wnt3a pre-treatment of ESCs augmented
the number of sitive reprogrammed neurons (red/green) with respect to the non-
treated ESCs (No BIO). Nuclei were counterstained with DAPI (blue). Scale bar: 20
um. (B) Hybrids isolated. from NMDA-damaged Nanog-GFP eyes transplanted with
BIO-treated (BIO) or untreated (No BIO) ESCs where cultured. in vitro under
puromyein selection. A mean of 23 sitive clones where detected after one
month of cell culturing. Clones are also positive to the alkaline phosphatase staining.
(C) Transplanted RSPCs (red) do not reprogram NMDA-damaged. retinal neurons in
presence or not of BIO ent. Nuclei were counterstained With DAPI (blue). (D)
Statistical analysis of the percentage of YFP- hybrids after injection of either untreated
or BIO-treated HSPCs‘I‘lI“ (white bars). ESCsC” (gray bars) or RSPCsCI“ (black bars), in
R26Y eyes eated (NMDA) or not (No NMDA) with NMDA.
Figure 15. Characterisation of the reprogrammed s. (A) RT-PCR analysis
of the expression of different genes in RFP positive hybrids sorted by FACS 24 h after
transplantation of BIO (black bars) or non-BlO-trcatcd (grey bars) MRFP in
R26Y NMDA—damaged eyes. (B) Confocal photomierographs of NMDA-damaged
R26Y retinas transplanted with BIO-treated HSPCsCIO and d 24 h later with anti-
Oct4, anti-Nanog, anti-Nestin, anti cKit or anti Tuj-l antibodies. YFP positive hybrids
(green) were also positive to Oct4, Nanog and Nestin (red, arrows) sion, however
they were not positive to c-Kit or Tuj-l , arrows). Scale bar: 50 p.111. (C-D)
Species-specific gene expression was evaluated. by RT-PCR using mouse (C) or human
(D) c oligos in hybrids FACS-sorted 24h after transplantation of BIO—treated and
DiD labelled human CD34+ HSPCs in NMDA—damaged eyes of Nanog-GFP mice. (E-
J) amaged R26‘i’ eyes were intravitreally injected with BIO treated (BIO) or
untreated (N0 BIO) HSPCsCfe and analyzed 24h later. To evaluate eration (E—G
and I) and cell death (F, H and J) of YFP positive hybrids (green), sections were stained
either with anti-Ki67 (G and. 1, red.) or anti-Annexin V (H and. J) antibodies. The amount
of positive hybrids was evaluated as the percentage of Ki67 (E) or Annexin V (F)
positive cells ve to the total number ofYFP hybrids. Data are means is.e.m.; n=30.
P value <0.001 (***). Yellow arrows in G and. J indicated Ki67 positive or Annexin V
positive hybrids respectively. Scale bar: 50 um. (K—L) The expression of markers for
ESCs (Oct4, Nanog), mesoderm (Gata4), e'ndoderm (Handl), neuroectoderm (Nestin,
Noggin and Otx2), HSPCs (c-Kit and Seal) or ally differentiated neurons (Tuj-l)
were evaluated in YFP hybrids formed after BIO-treated (K) or non-treated (L)
HSPCsCrc injected into NMDA-damaged eyes of R26Y mice and sacrificed 24 (white
bars), 48 (grey bars) and 72 h (black bars) after cell transplantation. Data are means
is.e.m.; n=30.
Figure 16. Proliferation and. gene expression in the hybrids. (A-B) RT-PCR
analysis of untransplanted NMDA-damaged. R26Y retinas (A) or of untreated, (No BIO,
grey bars) or BIO-treated (BIO, black bars) HSPCs cells. (C) Confocal
photomierographs of NMDA-damaged. Nanog-GFP retinas transplanted with DiD-
labelled and BIO-treated human CD34+ HSPCs (red). YFP positive s (green/red
cells, yellow ) were detected. (D-E) Ki67 (D) and Annexin V (E) staining were
med on YFP-positive reprogrammed hybrids obtained after injection of BIO-
treated or untreated ESCs in NMDA-damaged R26Y eyes. Positive hybrids were
evaluated as the percentage of positive cells ve to the total number of YF P hybrids.
Data are means is.e.n1.; n=30. P value <0.001 (***). (F) The expression of markers for
mesoderm (Gata4), endoderm (Handl). neuroectoderm (Nestin, Noggin and Otx2),
terminally differentiated neurons (Tuj-l) or ESCs (Oct4, Nanog) were evaluated in YFP
hybrids formed after BIO-treated HSPCsC”e injection into NMDA-damaged eyes of
R26Y mice sacrificed 24 (white bars), 48 (grey bars) and 72h (black bars) after cell
transplantation. Data are means ofn=30.
Figure [7. NMDA-damagcd retinas can be regenerated after fusion of
transplanted HSPCs. (A) H&E staining g increase 'in thickness of the inner
nuclear layer (inl, ts) and regeneration ofthe ganglion cell layer (gel, arrowheads)
in NMDA-damaged retina one month after BlO-HSPCscre transplantation. Arrows
indicated. ganglion cell loss in the NMDA—damaged retinas. Scale bars: 50 mm. (B-C)
Quantification of ganglion nuclei in the gcl (B) and nuclear rows in the inl (C) as
d in vertical retinal sections of damaged (NMDA) or undamaged retinas
transplanted with BIO-treated (BIO) or untreated. HSPCs. Data are means is.e.m. (n =
30). ***P < 0.001. (D) Neurons in the gel were counted along nasoremporal (left) and
dorsoventral (right) axes and. graphed cells per millimeter d. A total of 80
different images ing the whole retina were counted for each sample. Data are
means is.e.m. from 3 retinas. *P < 001. ON: optic nerve. (E) Total cells in the gel
excluding endothelial cells were counted along nasotcmporal (left) and dorsoventral
(right) axes and graphed as y maps. Dark red corresponds to a cell density of
,000 cellsfmmz, as indicated in the color bar.
Figure 18. Long-term differentiation potential of the hybrids obtained after cell
fusion-mediated reprogramming. (A) mental strategy to identify YFP- hybrids
one month afier BIO-treated or ted HSPCsCre in NMDA-damaged R26Y retinas.
(B) YFP+ neurons were detected in NMDA-injured R26Y retinal flat mounts one month
after BIO—HSPCsOre transplantation. Nuclei were counterstained with DAPI (blue).
Scale bars: 50 pm. A higher magnification of the YFP+ neurons is shown in the right
panel. (C) YFP+ differentiated hybrids ) expressed either the ganglion cell
marker SMI-32 (left, red) or the amacrine cell marker Chat (right, red). (D) YFP+ axons
(green) were detected in optic nerves from eyes transplanted with BlO-HSPCsC", but
not with untreated- HSPCsm. A higher ication of the YFP+ positive axons
(green) in the optic nerve is shown in the right panel.
Figure 19. Analysis of bone marrow replacement efficiency and analysis of
hybrid proliferation and. apoptosis after endogenous BM mobilization and cell
fusion.(A) entative chromocytometric analysis of mice one month after
bone marrow replacement. (B-C) Ki67 (B) and Annexin V (C) staining were med
on YEP-positive reprogrammed hybrids obtained 24h afier injection of B10 in NMDA-
REP-"Cm
damaged R26Y eyes from mice that received BM replacement.
Figure 20. Endogenous BM-derived cells ted in damaged eyes can fuse
with retinal neurons. (A) Experimental scheme. R26Y mice ed BMRFN3m
transplantation via tail vein injection after sub-lethal irradiation. After BM
reconstitution (1 month), right eyes received an intravitreal injection of NMDA, left
eyes were not injected; the mice were analyzed. 24 h later. Only in case of cell fusion of
ted-BM cells (red) and neurons, YFP/RFP double positive hybrids are detected.
(B-F) Double ve YFP/RFP hybrids were detected in NMDA-damaged (B-C.
NMDA) but not in healthy (D-E, No NMDA) eyes. (F) The percentage of YFPJRFP
double positive hybrids with respect to the total number of detected. RFP cells was
ated. (G—K) Immunohystochemical analysis of the retinal cell-fusion partners.
YFP hybrids ) are also positive for Seal (G) and c-Kit (H) HSPCs markers and
for ganglion (I, Thyl.ln red), amacrine (J, syntaxin, red) and Muller (K, GS, red) retinal
‘25 cell markers 24 h after NMDA damage. Yellow arrows indicate double positive cells.
Scale bar: 50 pm.
Figure 2|. Endogenous BM cell fusion-mediated reprogramming of retinal
neurons is induced by BIO. (A) Experimental scheme. Nestin-Cre mice received
BMR26Y transplantation via tail vein injection after thal irradiation. Afier BM
reconstitution (1 month), right eyes received an intravitreal injection of BIO+NMDA,
while the contralateral eyes were injected with NMDA alone. Only in case of cell
fusion-mediated reprogramming of hybrids between reeruited-BMCsRA“ and neurons,
-med'iated Cre expression leads to expression of the YFP. (B-C) Only after BIO
injection (C), YFP positive reprogrammed hybrids (green) after fusion of recruited BM-
cells and damaged neurons were detected. In contrast no YFP hybrids (B) were seen in
NMDA-damaged eyes without BIO. (D-E) Percentages of proliferating (Ki67 positive,
D) or dying (AnnexinV positive, E) hybrids were evaluated. as the number of YFP
double positive cells with the t to the total amount of YFP cells. Data are means
is.e.m.; n=30. (F-I) Confocal ic-rographs of IO treated. retinas show
expression of Oc-t4 (red in F—G) and Nanog (red in H-I) proteins in YFP-reprogrammed
s (green, see merge in G and. I). Percentages of Oct4 and Nanog positive hybrids
(E) were evaluated as the number of YFP double positive cells with the respect to the
total amount of YFP cells. Data are means is.e;m._; n=30.
Figure 2-2. Macrophage/monocyte analysis after HSPCs transplantation. (A)
Representative confocal image of flat-mounted NMDA-damaged retinas 1 month after
transplantation of untreated HSPCs. Only few YFP+ cells (green) were detected. Scale
bars: 50 um. (B) Optic nerve harvested. 24 h after transplantation of HSPCsUe in
NMDA-damaged R26Y eyes. Scale bars: 200 um (C-F) FACS analysis as percentages
of RFP+/YFP+ hybrids also positive for CD45 (C-E) and M acI (D-F) ng 24 h (C,
D) and 2 weeks (E, F) after lantation of HSPCsCWRFP in NMDA-damagcd R26Y
eyes.
ED DESCRIPTION OF THE INVENTION
Retinal ration can be achieved by implanting some types of cells into the
retina of a subject, said cells having properties of stem cells or progenitor cells such as
hematopoietic stem cells, progenitor cells and/or mesenchymal stem cells. These cells
fuse with retina] cells such as retinal neurons, e.g., rods, ganglion cells, amaerine cells,
and the like, or with retinal glial cells, e. g., Miiller cells, to form hybrid cells which in
turn de—differentiate and finally differentiate in retinal neurons of interest, e.g.,
photoreceptor cells and/or ganglion cells, etc., wherein tion of Wnt-‘B-eatenin
signalling pathway in the implanted. cells or in the hybrid cells is essential to induce de-
differentiation of said hybrid cells and. final re—differentiation in the retinal neurons of
interest. In an embodiment, activation of the Wnt/B-cateni-n signalling pathway is, at
least lly, provided by the ted cells (which have been treated with a Wnt/B-
n signalling pathway activator, or with an inhibitor of a Wnt/B-catenin ling
pathway sor, and/or press a Wnt/B-catcnin signalling y activator),
whereas in r embodiment, activation of the Wnt/B—catenin signalling y is
only provided as a result of administering a W'nt’B-catenin signalling pathway activator,
'J‘I or with an inhibitor of a W'nL’B-catenin signalling y repressor, to the subject to be
treated or as a consequence of a retinal damage or inj ury, as occurs in, for example,
retinal degeneration diseases.
Use of cells havinoI properties of stem cells or progenitor cells for treatment of
retinal degeneration diseases bv reproolramming= mediated by activation of the
Wnt/ -catenin athwa ~' of retinal cells fused to said cells
ent A
In an aspect, the invention relates to a cell, said cell having its Wnt/B-catenin
signalling pathway activated and being selected from the group consisting of a
hematopoietic stem cell, a progenitor cell, and a mesenchymal stem cell, for use in the
treatment of a retinal degeneration disease. In other words, according to this aspect, the
invention provides a cell selected from the group consisting of a hematopoietic stem cell
(HSC), a itor cell, and, a hymal stem cell (MSC), wherein the Wnt/B-
catenin signalling pathway of said cell is activated, for use in the treatment of a retinal
degeneration disease.
Thus, the invention provides a cell selected from the group consisting of a
poietic stem cell, a progenitor cell, and a mesenchymal stem cell, wherein said
cell is treated with a Wnt/B-catenin signalling pathway activator, or with an inhibitor of
a Wnt/B-catenin signalling pathway repressor, and/or it is a cell that overexpresses a
Wnt/B-catenin signalling pathway activator for use in the ent of a retinal
degeneration disease. As a result of said treatments, or cell manipulation to overexpress
a Wnt/B-catenin signalling pathway activator, the cell has its Wnt/B-catenin signalling
pathway activated and can be used in the treatment of a retinal degeneration disease. To
that end the cell so treated or manipulated is implanted in the eye of a subject in need of
treatment of a retinal degeneration disease.
In other words, this aspect of the ion relates to the use of a cell, said cell
having its Wnt/B-catenin signalling y activated and being selected From the
group consisting of a hematopoietic stem cell, a progenitor cell, and a mesenchymal
stem cell, in the cture of a pharmaceutical composition for the treatment of a
retinal degeneration disease; or, alternatively, this aspect of the invention relates to the
use of a cell selected from the group consisting of a hematopoietic stem cell, a
progenitor cell, and a mesenchymal stem cell, wherein said cell is treated with a Wnt/B-
catenin signalling y activator, or with an inhibitor of a Wnt’B-catenin signalling
pathway repressor, r overexpresses a Wnt’B-c-atenin signalling pathway activator,
in the manufacture of a pharmaceutical ition for the treatment of a retinal
degeneration disease.
According to Treatment A, activation of the Wnt/B-catenin signalling pathway
is, at least partially, ed by the implanted cells having their Wnt/B-catcnin
signalling pathway ted and being selected from the group consisting of a
hematopoietic stem cell, a itor cell, and a mesenchymal stem cell. . The subject
to be treated may also have activated. the Wnt-‘B—catenin signalling pathway after retinal
damage or injury.ln general, the Wnt/B-catenin signalling pathway is activated when the
target genes are transcribed; by illustrative, activation of the Wnt/B-catenin signalling
pathway may be confirmed. by tional techniques, for example, by analyzing the
expression of the target genes, e.g., AxinZ, by means known by the skilled person in the
art to analyze the expression of genes, such as, for example, RT-PCR (reverse
transcription-p0lymcrase chain reaction), or by detection of B-catenin translocation in
the nuclei of the cells by tional techniques, such as, for example, by
immunostaining, or by detecting the phosphorylation of Dishevelled or the
phosphorylation ofthe LRP tail, etc.
The manner in which the Wnt-‘B-eatenin signalling pathway is activated. can
vary. By illustrative, activation of the Wnt/B-catenin ling pathway in a cell
selected from the group consisting of a hematopoietic stem cell (HSC), a progenitor
cell, and a mesenchymal stem cell (MSC) can be achieved by treating said cell with a
Wnt/B-catenin signalling pathway activator, or with an inhibitor of a W’Iit’B-catcnin
signalling pathway repressor, in such a way that said pathway is activated, or by
manipulating the cell to overexpress a protein or peptide which is a Wnt/D-catenin
ling pathway activator, as it will be discussed below. Alternatively, activation of
the Wnt/B-catenin signalling pathway can be achieved as a consequence of a l
damage or injury. as occurs in, for example. l degeneration diseases or by
administering a Wnt/fi-catenin signalling pathway activator to the subject to be treated
or an inhibitor of a Wnt/B-catenin signalling pathway repressor, in such a way that said
y is activated, as it will be discussed. below.
The term “Hematopoietic stem cell” or “HSC”, in plural , as used herein
refers to a multipotent stem cell that gives rise to all the blood cell types from the
myeloid. (monoc-ytes and macrophages, neutrophils, basophils, eosinophils,
ocytes. ryocytesfplatelets, dendritic cells), and lymphoid lineages (T-c-ells,
B-cells, NK-cells). HSCs are a heterogeneous tion. Three classes of stem cells
exist, distinguished by their ratio of lymphoid to myeloid progeny (L/M) in blood.
Myeloid-biased (My-bi) HSCs have low L/M ratio (>0, <3), whereas id-biased
(Ly-bi) HSCs show a large ratio (>10). The third. category consists of the balanced.
(Bala) HSCs for which 3 S L/M : 10. As stem cells, HSCs are defined by their ability to
replenish all blood cell types (multipotency) and their y to self-renew. In reference
to phenotype, HSCs are identified by their small size, lack of lineage (lin) markers, low
staining (side population) with vital dyes such as rhodamine ”123 (rhodamine DU LL,
also called. mold) or Hoechst 33342, and presence of various antigenic markers on their
e. In humans, the majority of HSCs are CD34+CD38-CD90+CD45RA-.
However, not all HSCs are covered by said combination that, nonetheless. has become
popular. In fact. even in humans. there are HSCs that are D38-. In a preferred
embodiment the HSC is a mammalian cell, ably a human cell.
In a particular embodiment the HSC is a long-term HSC (LT-HSC), i.e._. a
hematopoietie stem cell which is capable of contributing to hematopoiesis for months or
even a lifetime and it is characterized by CD34-, C'D38-, SC‘A-l+, Thyl.1+,/low_, C-kit+,
lin-_. CD135-_. Slamfl/CD150+.
In another particular embodiment the HSC is a short—term HSC (ST—HSC), i.e., a
HSC which has a reconstitution ability that is limited to several weeks and it is CD34+_.
CD38+, SCA-H, Thy’l.l+/low, C-kit+, lin-, CD'135-_. Slamfl/CD'150+_. Mac-l
(CD1 lb)low.
The term “M” as used herein refers to a cluster of differentiation present on
certain cells within the human body. It is a cell surface rotein and Functions as a
cell-cell adhesion . It may also mediate the attachment of stem cells to bone
marrow extracellular matrix or directly to stromal cells. Cells expressing CD34 (CD34+
cell) are ly found in the umbilical cord and bone marrow as poietic cells,
a subset of mesenchymal stem cells, endothelial progenitor cells, endothelial cells of
blood vessels but not lymphatic-s. The complete protein sequence for human CD34 has
the UniProt accession number P28906 (July 26, 2012).
The term “CD38” as used herein refers to a cluster of differentiation 38, also
known as cyclic- ADP ribose hydrolase is a glycoprotein found on the surface of many
immune cells (white blood cells), including CD4+, CD8+, B and natural killer cells.
CD38 also functions in cell adhesion, signal transduction and calcium signalling. CD38
is a type II transmembrane protein that functions as a signalling molecule and mediates
the adhesion between lymphocytes and endothelial cells. It also ons enzymatic-ally
in the formation and hydrolyzation of the second messenger cyclic ADP ribose. In the
hematopoietic system, CD38 is most highly expressed. on plasma cells. The complete
n sequence for human CD38 has the t accession number P28907 (July 26,
2012).
The term “CD90” or Thy-l as used herein refers to Cluster of Differentiation 90,
a 25—37 kDa heavily N—glycosylated, g1ycophosphatidylinositol (GPI) anchored.
conserved cell surface protein with a single V-like immunoglobulin domain (The
immunoglobulin domain is a type of protein domain that consists of a 2-layer sandwich
of between 7 and 9 antiparallel B-strands arranged in two B-sheets with a Greek key
topology), originally discovered as a thymocyte antigen. The complete n sequence
for human CD90 has the UniProt ion number P04216 (July 26, 2012).
The term “m” as used. herein refers to family consisting of multiple members
that are all products of a single complex gene. This gene contains 34 exons and three
exons of the primary transcripts are alternatively d to generate up to eight different
mature mRNAs and after translation eight different n products. These three exons
generate the RA, RB and RC isoforms. Various isoforms of CD45 exist: CD4SRA,
CD45RB, CD45RC, CD45RAB, CD45RAC, CD4SRBC, CD45R0, (.‘D45R (ABC). The
complete proteinsequence for human CD45 has the UniProt accession number P08575
(July 26, 2012).
The term “SCA-l” refers to ataxin l which Function is unknown. The complete
protein sequence for human SCA-l has the UniProt accession number P54253 (July 26,
2012).
The term “c-kit” refers to a Mast/stem cell growth factor or (SCFR), also
known as proto-oncogene c-Kit or tyrosine-protein kinasc Kit or CD117, is a protein
that in humans is encoded. by the KIT gene. CD117 is a receptor tyrosine kinase type
III, which binds to stem cell factor, also known as "steel factor" or "c—kit ligand". The
complete protein sequence for human c-kit has the UniProt accession number P10721
(July 26, 2012).
The term “CD135”, as used herein refers to r of differentiation antigen
135 (CD135) also known as ke tyrosine kinasc 3 (FLT-3) or receptor-type
tyrosine-protein kinase.CD135 is a cytokine or expressed on the surface of
hematopoietic progenitor cells. The complete protein sequence for human CD135 has
the UniProt accession number P36888 (July 26, 2012).
The term I”, as used herein refers to signalling lymphocytic activation
molecule is a protein that in humans is encoded by the SLAMFl gene. SLAMFI has
also ly has been designated CD150 (cluster of differentiation 150). The te
n sequence for human SLAMFI has the UniProt accession number Q13291 (July
26,2012).
The term “Mac-1 tCDllb)”, as used. herein refers to a Integrin alpha M
(ITGAM) is one protein subunit that forms the heterod'imeric integrin alpha-M beta-2
(niMB2) molecule, also known as macrophage-'1 antigen ) or complement.
‘25 receptor 3 (CR3). ITGAM is also known as CR3A, and cluster of differentiation
molecule [18 (CDl'l B). The complete protein sequence for human Mac-l has the
UniProt accession number P11215 (July 26, 2012).
The term “li_n” refers to lineage s, a standard cocktail of antibodies
designed. to remove mature hematopoietic cells from a sample. Those antibodies are
targeted to CD2, CD3, CD4, CD5, CD8, NK1.1, B220, TER-119, and. Gr-l in mice and,
CD3 (T lymphocytes), CD14 (Monocytes), CD16 (NK cells, granulocytes), CD19 (B
lymphocytes), CD20 (B lymphocytes), and CD56 (NK cells) in humans.
A “progenitor cel ” refers to a cell that is derived from a stem cell by
differentiation and is capable of further differentiation to more mature cell types.
Progenitor cells typically have more restricted proliferation capacity as compared to
stem cells. In a particular embodiment, the itor cell is a hematopoietic progenitor
cell derived from a HSC by entiation during the progression from HSCs to
differentiated functional cells. The hematopoietic progenitor cell is characterized. by the
markers D38-CD90-CD45RA—. In a preferred embodiment the progenitor cell
is a ian cell, preferably a human cell.
In a particular ment the progenitor cell is an Early Multipotent Progenitor
(Early MPP) terized by CD34+, SCA-l+, Thyl.I-, C-kit+, lin-, ,
Slamfl/CD']50-, Mac-l (CD1 I b)l0W_. CD4low.
In another particular embodiment the progenitor cell is a Late Multipotent
Progenitor (Late MPP) defined by CD34+, SCA-I+, Thyl .l-, C-kit+_. lin-, CD135high,
Slamfl.-’CD150-, Mae-l (CD11b)low, .
In another particular embodiment the progenitor cell is a Lineage-restricted
Progenitor (LRP) cell characterized by CD150-CD48+CD244+.
In another particular embodiment the progenitor cell is a Common Myeloid
Progenitor (CM P), i.c., a colony forming unit that generates myeloid cells characterized
by CD34+CD38+1L3Ral°wCD4SRA3 In another particular embodiment the progenitor
cell is a Granu.locyte-.Vlaerophage Progenitor (0MP), the precursor for monoblasts and.
'myeloblasts characterized by CD34+CD38+I L3Ra-C D45Ra-.
In another ular embodiment, the progenitor cell is a Megakaryocyte-
E'ryth‘roid Progenitor (M EP) characterized by CD34+C D38+I L3 RA+ CD45 RA-.
The term ” as used herein refers to cluster of differentiation 4. It is a
glycoprotein found on the surface of immune cells such as T helper cells, monoeytes,
hages, and dendritic cells. CD4 is a eptor that assists the T cell receptor
(TCR) with an antigen—presenting cell. Using its portion that resides inside the T cell,
CD4 amplifies the signal generated by the TCR by recruiting an enzyme, known as the
tyrosine kinasc lck, which is essential for activating many molecules involved in the
signalling cascade of an activated T cell. CD4 also interacts directly with MHC class II
molecules on the surface of the antigen-presenting cell using its extracellular domain.
The complete protein sequence for human CD4 has the UniProt accession number
P01730 (July 26, 2012).
The term “M” as used herein refers to CD244 molecule, natural killer cell
receptor 234. This gene encodes a cell surface receptor sed on natural killer (NK)
cells (and some T cells) that mediate non-major histocompatibility complex (MHC)
restricted killing. The interaction between NK-cell and target cells via this receptor is
thought to modulate NK-cell cytolytic activity. The complete protein sequence for
human CD244 has the UniProt accession number Q9BZW8 (July 26, 2012).
The term “IL3RA” as used. herein refers to Interleukin 3 receptor, alpha (low
affinity) ), also known as CD123 (Cluster of Differentiation 123), is a type I
transmembrane protein of 41.3 Kda and IL-3RA has been shown to interact With
Interleukin 3. The te n sequence for human IL3RA has the UniProt
accession number P26951 (July 26, 2012).
The term “Mesenchymal stem cell” or “MSC”, in plural “MSCs”, as used. herein,
refers to a multipotent stromal cell that can differentiate into a variety of cell types,
including: osteoblasts (bone cells), ehondrocytes (cartilage cells), and. adipocytes (fat
cells). Markers expressed by mesenchymal stem cells include CD105 (8H2), CD73
(SH3/4), CD44, CD90 (Thy-l}, CD71 and Stro-l as well as the adhesion molecules
CD106, CD166, and. CD29. Among negative markers for MSCs (not expressed) are
poietic markers CD45, CD34, CD14, and the costimulatory molecules CD80,
CD86 and CD40 as well as the on molecule CD31 .
The term “m” as used herein refers to endoglin, a type I membrane
glycoprotein located on cell surfaces and is part of the TGF beta receptor complex. The
complete protein sequence for human CDIOS has the UniProt accession number Pl 7813
(July 26, 2012).
The term “CD73” as used herein refers to 5'-nu.cleotid.ase ), also known
as ecto-5'-nu.cleotidase or CD73 (Cluster of entiation 73), is an enzyme that in
humans is encoded by the NTSE gene. The complete protein sequence for human CD73
has the Uni Prot accession number P21589 (July 26, 2012).
The term “M” refers to antigen is a cell-surface glycoprotcin involved in
ell ctions, cell adhesion and ion. The complete protein sequence for
human CD44 has the UniProt accession number P16070 (July 26, 2012).
The term “CD71”, as used herein refers to Transferrin receptor protein 1 (Tle)
also known as (Cluster of Differentiation 71) (CD71) is a n that is required for
iron delivery from transferrin to cells. The complete protein sequence for human CD71
has the Uni Prot accession number P02786 (July 26, 2012).
The term “W” as used herein refers to a cell surface protein expressed by
bone marrow stromal cells and erythroid precursors.
The term “CD106” refers to a Vascular cell adhesion protein 1 also known as
vascular cell adhesion molecule 1 (VCAM-l) or cluster of differentiation 106 (CD106)
is a protein that in humans is encoded by the VCAM] gene and functions as a cell
adhesion molecule. The complete protein ce for human CD106 has the UniProt
accession number P19320 (July 26, 2012).
The term “CD166” as used herein, refers to a 100-105 kD typel transme‘mbrane
rotein that is a member of the i-mmunoglobulin superfamily of proteins. The
complete protein sequence for human CD166 has the UniProt accession number 0
(July 26, 2012).
The term “M” as used. herein refers to a integrin beta-1 is an integrin unit
associated. with very late antigen receptors. The complete n sequence for human
CD29 has the UniProt accession number P05556 (July 26, 2012).
The term “CD14”, as used. herein refers to cluster of differentiation 14 which is a
component of the innate immune system. The complete protein sequence for human
CD14 has the UniProt accession number P08571 (July 26, 2012).
The term “M” as used herein Cluster of Differentiation 80 (also CD80 and.
87-1) is a n found on ted B cells and 'monocytes that provides a
costi'mulatory signal necessary for T cell activation and survival. The complete protein
‘25 sequence for human (TDSO has the UniProt accession number P3368 '1 (July 26, 2012).
The term “CD86” as used herein refers to r of Differentiation 86 (also
known as CD86 and B7-2) is a protein sed on antigen—presenting cells that
provides costimulatory signals necessary for T cell activation and al. The
complete protein sequence for human CD86 has the UniProt accession number P42081
(July 26,2012).
The term “CD40” as used herein refers to a costi'mulatory protein found on
antigen presenting cells and is required for their activation. The te protein
sequence for human (.‘D40 has the UniProt accession number P25942 (July 26, 2012).
The term “w”, as used herein, refers to a Platelet endothelial cell on
molecule (PECAM-l) also known as cluster of differentiation 3'] (CD31) is a protein
that plays a key role in removing aged neutrophils from the body. The complete protein
sequence for human CD31 has the UniProt accession number P16284 (July 26, 2012).
The presence/absence of a marker in a cell can be determined, for e, by means of
flow cytometry using conventional methods and apparatuses. For instance, a BD LSR 11
Flow Cytometer (BD Biosciences Corp, Franklin Lakes, NJ, US) with commercially
available antibodies and following protocols known in the art may be employed. Thus,
cells emitting a signal for a specific cell surface marker more intense than the
background noise can be selected. The background signal is defined as the signal
intensity given by a non-specific antibody of the same isotype as the specific dy
used to detect each surface marker in the conventional FACS analysis. In order for a
marker to be ered positive, the observed c signal must be 20%, preferably,
%, 40%, 50%, 60%, 70%, 80%, 90%, 500%, [000%, 5000%, '10000% or above more
intense than the background signal using conventional methods and apparatuses (cg. by
using a FACSCalibur flow cytomctcr (BD Bioscicnccs Corp, Franklin Lakes, NJ , US')
and commercially ble antibodies). Otherwise the cell is considered negative for
said marker.
In a particular embodiment, the cell for use in the treatment of a retinal
degeneration disease according to Treatment A, said cell having its Wnt/B-catenin
signalling pathway ted, is a HSC. In another ular embodiment, said cell is a
LT-HSC or a ST-HSC.
In another particular ment, the cell for use in the treatment of a retinal
degeneration disease according to Treatment A, said. cell having its Wnt/B-catenin
signalling pathway activated, is a progenitor cell. In another particular embodiment,
said itor cell is an Early .VIPP, a Late MPP, a LRP, a (IMP, a GMP or a MEP.
In another particular embodiment, the cell for use in the ent of a retinal
degeneration disease according to Treatment A. said cell having its Wnt/B-catenin
signalling pathway activated, is a MSC.
The cells for use in the treatment of a retinal degeneration disease according to
the invention may be g part of a tion of said cells which use in the
treatment of a retinal degeneration disease tutes an additional aspect of the present
invention.
Thus. in other aspect. the invention further relates to a cell population
comprising a plurality of cells, said, cells having their Wnt/B-catenin signalling pathway
activated and. being ed from the group consisting of a hematopoietic stem cell
(HSC), a progenitor cell, a mesenchymal stem cell (MSC) and. any combination thereof,
for use in the treatment of a l degeneration e. Thus, according to this aspect,
the invention provides a cell population comprising a ity of cells, said cells being
selected from the group consisting of a hematopoietic stem cell (HSC), a progenitor
cell, a mcse'nchymal stem cell (MSC), and any combination thereof, wherein the W'nt/B-
cate'nin signalling pathway of said cells is activated, for use in the treatment of a retinal
degeneration disease.
In other words, the invention relates to a cell population comprising a ity
of cells, said cells being selected. from the group consisting of a HSC, a progenitor cell,
a MSC and any combination thereof, wherein said cell are treated with a Wnt/B-catenin
signalling pathway activator, or with an inhibitor of a W'nt/B-catenin signalling pathway
'reprcssor, and/or said cells ovcrcxpress a Wnt/B-catcnin signalling pathway activator,
for use in the treatment of a retinal degeneration disease. As a result of said treatments,
or cell lation to overexpress a protein or peptide which is a catenin
signalling pathway activator, the cells of the cell population have their Wnt/B-catenin
signalling pathway activated and can be used in the treatment of a retinal degeneration
e. To that end the cell population is implanted in the eye of a subject in need of
treatment of a retinal degeneration disease.
Alternatively drafted. this aspect of the invention relates to the use of a cell
tion comprising a plurality of cells, said. cells having their Wnt/B-catenin
signalling pathway activated and. being ed, from the group consisting of HSCs,
progenitor cells, MSCs and any ation thereof, in the manufacture of a
pharmaceutical composition for the treatment of a retinal degeneration disease; or.
alternatively, to the use of a cell population comprising a plurality of cells, said cells
being selected. from the group consisting of a HSC, a progenitor cell, a MSC and. any
combination thereof, wherein said cells are treated with a Wnt/B-catenin signalling
pathway activator, or with an inhibitor of a Wnt/B-catenin signalling pathway repressor,
and/or overexpress a Wnt/B-catenin signalling pathway activator, in such a way that said
Wnt/B-catenin signalling pathway is activated, in the manufacture of a pharmaceutical
composition for the treatment of a retinal degeneration disease.
The particulars of said. HSCs, progenitor cells, and MSCs have been previously
mentioned. The particulars of the above mentioned treatments aimed to activate the
Wnt’B-catenin signalling y will be discussed below.
In a particular embodiment, the cell population for use in the treatment of a
retinal ration e according to Treatment A comprises a ity, i.e., more
than two, of HSCs, said cells having their Wnt/B-catenin signalling pathway activated.
In a particular embodiment, said HSCs are selected from L-T-HSC, ST-HSC and
combinations thereof.
In another ular embodiment, the cell population for use in the treatment of
a retinal ration disease according to Treatment A comprises a plurality of
progenitor cells, said cells having their Wnt/B-catenin signalling pathway activated. In a
particular embodiment, said progenitor cells are selected from Early MPP, a Late MPP,
a LRP, a CMP, a GMP, MEP and combinations thereof.
In another particular embodiment, the cell population for use in the ent of
a retinal degeneration disease according to Treatment A comprises a plurality of MSCs,
said cells having their Wnt/B—cate'nin signalling pathway ted.
In a ular embodiment, the cell tion for use in the treatment of a
retinal degeneration disease according to Treatment A comprises at least one HSC and
at least one progenitor cell, said cells having their W'nt/B-catenin signalling pathway
activated. In a particular embodiment, said. HSC cell is a LT-HSC or a ST-HSC; in
another particular embodiment, said progenitor cell is an Early MPP, a Late MPP, a
LRP, a CMP, a GMP or a MEP.
In r partiCular embodiment, the cell population for use in the treatment of
a retinal degeneration disease according to Treatment A ses at least one HSC and
at least one MSC, said cells having their Wnt/B-catenin signalling pathway activated. In
a particular embodiment, said HSC cell is a LT-HSC or a ST-HSC.
In r particular embodiment, the cell population for use in the treatment of
a retinal degeneration e according to Treatment A comprises at least one
progenitor cell and at least one MSC, said cells having their Wnt/fi-catenin signalling
pathway activated. In a particular embodiment, said progenitor cell is an Early MPP, a
Late MPP, a LRP, a CMP, a GMP or a MEP.
In another partiCular embodiment, the cell population for use in the treatment of
a retinal degeneration disease according to Treatment A comprises at least one HSC, at
least one progenitor cell and. at least one MSC, said cells having their WnU’B-eatenin
signalling y activated. In a ular embodiment, said HSC cell is a LT-HSC or
a ST—HSC; in another particular embodiment, said progenitor cell is an Early MPP, a
Late MPP, a LRP, a CMP, a GMP or a MEP.
In a particular ment, a cell population comprising HSCs, precursor cells
and MSCs, obtainable from bone marrow, is identified sometimes herein as “HSPC”,
i.e._, as “hematopoietic stem and. progenitor cells”. Said cell population HSPC may
include HSC, progenitor cells and M80; in different ratios or proportions. Said. HSPC
cell population can be obtained, for example, from bone marrow, or, alternatively, by
mixing HSCs, progenitor cells and MSCs, in the d ratios or proportions, in order
to obtain a HSPC cell population. The skilled person in the art will understand that said
cell population may be enriched in any type of specific cells by tional means, for
example, by separating a specific type of cells by any suitable technique based. on the
use of binding pairs for the ponding surface markers. Thus, in a particular
embodiment. the HSPC cell population may be enriched in HSCs, or in progenitor cells,
or in MSCs. In order that said cell population identified as HSPC is suitable for use in
the treatment of a retinal degeneration disease according to Treatment A, it is necessary
that the cells of said. cell population have their Wnt/B-catenin ling pathway
activated.
For use within the teachings of the present invention, the cell having its Wnt/B-
catenin signalling pathway activated. and being selected. from the group consisting of a
hematopoietic stem cell, a progenitor cell, and a mesenchymal stem cell, for use in the
treatment of a retinal degeneration disease according to the ion, or the cell
population for use in the treatment of a retinal ration disease according to the
invention, may be from the same t, i.e., autologous, in order to minimize the risk
of eventual rejections or red side reactions; heless, the invention also
contemplates the use of allogeneic cells, i.e., cells from other subject of the same
s as that of the recipient subject in which case the use of ic or local
i'mmunosuppressive agents may be recommended, although the retina has low immune
response, and, therefore, compatible cells from a ent human subject could be used
provided that said cells are selected from HSCs, progenitor cells, and MSCs and,
subjected to a treatment or manipulation to have their Wnt/B-catenin signalling pathway
activated as mentioned. above.
The expression E-catenin signalling pathway” refers to a network of
proteins that play a variety of important roles in embryonic development, cell
differentiation, and cell ty generation. Unless ise indicated, it refers to the
cal Wnt pathway and includes a series of events that occur when W'nt proteins
bind to cell-surface receptors of the Frizzled family, causing the receptors to activate
Dishevelled family proteins and. ultimately resulting in a change in the amount of B-
catenin that reaches the nucleus. Dishevelled (DSH) is a key component of a
membrane-associated Wnt receptor complex, which, when activated. by Wnt binding,
inhibits a second complex of proteins that includes axin, glycogen synthase kinase 3
(GSK-3), and the protein adenomatous polyposis coli (APC). The axin/GSK-3/APC
complex ly promotes the proteolytic degradation of the B-catenin intracellular
signalling molecule. Afier this. B—catenin destruction x is inhibited, a pool of
cytoplasmic B-catenin stabilizes, and some B-cateni'n, is able to enter the nucleus and
interact with TCF/LEF family transcription factors to promote specific gene expression.
Several protein kinases and protein phosphatases have been associated with the ability
of the cell surface Wnt—activated Wnt receptor complex to bind axin and emble
the axin/GSK3 complex. Phosphorylation of the cytoplasmic domain of LRP by CKl
and GSK3 can regulate axin binding to LRP. The protein kinase ty of GSK3
appears to be important for both the formation of the membrane—associated
Wnt/FRZ/LRP/DSI-L/Axin complex and the function of the Axin/APC/GSKS/B—catenin
complex. Phosphorylation of B-catenin by GSK3 leads to the ction of B—catenin.
A “W‘nt/ -catenin si nallin oathwa activator”, as used herein, refers to a
molecule capable of activating the Wnt’B-catenin signalling pathway. In general, the
Wut’fi-catenin signalling pathway is activated when the target genes are transcribed; by
illustrative, tion of the Wnt/B-catenin signalling pathway may be confirmed by
analyzing the expression of the target genes, e.g., Axi'n2, by RT-PCR. or by detection of
B-catenin translocation in the nuclei of the cells by, e.g., immunostaining, or by
ing the phosphorylation of Dishevelled or the phosphorylation of the LRP tail, etc.
Wnt/B-catenin signalling pathway activators may act on membrane receptors of Wnt
signalling proteins and on the proteins that comprise the ling cascade. Illustrative,
non-limiting examples of Wnt/B-catenin ling pathway activators include peptides
or proteins as well as chemical nds other than peptides or proteins (i.e., non-
peptide drugs”, such as :
- peptides or proteins, for e, Wnt protein isoforms such as Wntl, Wnt2,
Wnt2b/l3, Wnt3, , W'nt4, Wnt5a, W'ntSb, Wnt6, W'nt7a, W'nt7b, W'nt8a,
Wnt8b, W'nt9a, Wnt9b, Wntha, Wnthb, W'nt'll or W'ntl6; B—cateni-n; a
spondin, such as a R-spondi-n, etc.; or fimctional variants thereof, e.g., peptides
or proteins that have an amino acid sequence that is at least 40%, typically at
least 50%, advantageously at least 60%, preferably at least 70%, more
preferably at least 80%, still more preferably at least 90% identical to the amino
acid sequences of the previously mentioned peptides or proteins and that
maintain the y to te the Wnt/B-cateni'n signalling pathway; or
- non-peptide compounds, for example, 2-(4-acetylphenylazo')-”-(3,3-dimethyl-
3,4-dihydro—2H—isoquinolinylidene)-aeetamide (IQl), (25’)—2-[2—(indan
yloxy)( l l e'nylyl)methyl)-9H—purinylamino]phenyl-propan- l —
ol (081 l 2), deoxychol ic acid (DCA), 2-amino[3 ,4-
lenedioxy)benzylamin0](3-methoxyphenyl')pyrimidine, or an
(hetero)arylpyrimidine disclosed by Gilbert et al., in Bioorganic & Medicinal
Chemistry Letters, Volume 20, Issue 1, 1 January 2010, 366-370.
Examples of Wm protein isoforms, which belong to the Wnt secreted proteins
family and. act as activators of the Wnt/B-eatenin signalling pathway, include the
following or orthologues thereof (S wiss—prot nces):
Homo .sapiens: Wntl: P04628; Wnt2: P09544; Wnt2b/l3: 093097; Wnt3:
PS6703; W'nt3a: P56704; W'nt4: P56705; W'ntSa: P4122]; Wnt5b:
7; Wnt6: Q9Y6F9; W'nt7a: 000755; W-nt7b: P56706; Wnt8a:
Q9H1J5; W-nt9a: 014904; W'nt9b: 014905; W'nt10a: Q9GZT5; Wnt10b:
000744; Wntll: 096014; Wnt'l 6: ;
Mus musculus: W'ntl: P04426; Wnt2: P215521; Wnt2b/‘l3: 0702832;
W'nt3: P'l7553; Wnt3a: P27467; W'nt4: P22724; W'nt5a: P22725; Wnt5b:
P22726; W'nt6: 1; W'nt8a: Q64527; Wnt9a: ; Wnt9b:
0354682; Wntha: P70701; Wnthb: P486l4; Wntll: P48615; Wntl6:
Q9QYSl.l;
as well as a functional isoform, variant or fragment thereof, i.e._, an
isoforrn, t or fragment thereof having the ability to activate the
Wnth-catenin signalling pathway.
Examples of B-catenin include the following or orthologues thereof (Swiss-prot
references):
Homo sapiens: P35222;
M’us museums: Q02248;
as well as a functional isofonn, variant or fragment thereof, i.e._, an
m, variant or fragment thereof having the ability to activate the
Wnt’B-catcnin signalling pathway.
The R-Spondi'ns (RSpo) are 4 secreted agonists of the canonical W‘ntJB-catenin
signalling pathway. Also known as cysteine-rich and single thrombospondin domain
containing proteins (Cristins), R-Spondins share around 40% amino acid identity
(Lowther, W. et a]. .]. Virol. 79210093; Kim, K.-A. ct a]. (2006) Cell Cycle 5:23).
All the R-Spondi'ns contain two nt cysteine-rich fu'rin-likc domains followed by a
thrombospondin (TSP-l) motif and a region rich in basic residues. Only the furin-likc
domains are needed for B-catcnin stabilization (Kim, K.-A. et al. (2006) Cell Cycle
5:23; Kazanskaya, O. et al. (2004) Dev. Cell 7:525). Injection of recombinant R-
Spondin l in mice causes activation of B—catenin and proliferation of intestinal crypt
epithelial cells, and. rates experimental colitis (Kim, K.—A. et al. ) Science
30921256; Zhao, J. et al. (2007) Gastroenterology 132:1331). din 1 (RSPOl)
appears to regulate W‘nt/B-cateni'n by competing with the Wnt nist DKK-l for
binding to the Wnt co-receptor, Kremen. This ition s internalization of
DKK-‘l/LRP-6/Kremcn complexes (Binnerts, M.E. et al. (2007) Proc. Natl. Acad. Sci.
USA 104:147007). Illustrative, mitative, examples of R-Spondins which act as
activators of the Wnt/B-catenin signalling pathway, include the following or orthologues
thereof (Swiss-prot references):
Homo sapi‘ens: R-spond'in-l: Q2MKA7; R-spondin-Z: Q6UXX9; R-spondin-3:
; R-spondin-4: QZIOMS, or a filnctional isoform, variant or fragment
thereof, i.e., an isoform, variant or fragment thereof having the ability to activate
the Wntffi-catenin signalling pathway, for example, an isoform, variant or
fragment thereof that maintain their onal domains.
Illustrative, non-limitative, examples of said. o_)arylpyrimidines include the
compounds of formula V) below.
In a particular ment, the (hetero)arylpyrimidine is an (hetero)aryl-
pyrimidine agonist of the catenin signalling pathway of formula (I), (ll), (III) or
(IV) [Table 1].
Table l
Illustrative examples of (hetero)arylpyrimidines agonists of the W'nt/B-catenin
signalling y
Compound Formula Definitions
of formula
(I) R is N—(3-1H—imidazol
H y] )propane), N -(2-pyridi n
g/ Mel/Neg: yl)ethane)_. N-(2-pyridinyl)ethanc),
JV N 3,5-dimethyl-1H—pyrazol—l-
yl)propyl), N-(Z-(lH-mdol-‘J-
/ yl)cthane), or N-(S)(l H-‘indol
.\ yl)propanol amine
(II) R1 is CHg-l dazole, 4-pyridine,
H 3-(1H—indole), 3—(2—methyl-1H—indol-
/NVNN/A‘Rl 5-01), or 4-(1H—imidazole); and
ké Ni R2 is 4-(pyridinyl), 4-(pyrid'in
R2 yl), 4-(3-n1trophenyl), 2-
(benzo[b]th1ophene) or 2-(naphthyl)
R is H, ethyl, methylenecyclohexyl,
H 2-fluoro(trifluoromethyl)benzyl or
_ N“V_ Nk propynyl; and
l NH 3
, N Nag R“ is 2—(benzo[b]thiophene) or 2-
T/ R30 (naphthyl)
(IV) H R is 3,5-difluorobenzyl, propynyl,
2-acetamide or anitrile; and
R2 is 2-(benzo[b]thiophene) or 2-
(naphthyl)
An “inhibitor of a Wnt/B-cate'nin ling pathway repressor”, as used ,
refers to a molecule capable of activating the Wnt/B-eatenin signalling pathway by
inhibiting or blocking a Wnt/B-catenin ling pathway repressor, i.e., a compound
which represses, blocks or silences the activation of the Wnt/B-catenin signalling
pathway. rative, non-limitative, examples of Wnt/B-catenin signalling pathway
repressors include glycogen synthase kinase 3 (GSK-3), secreted. frizzledV-related protein
1 (SFRPI), and. the like.
Illustrative, non-li-mitative, examples of inhibitors of SFRP'] include 5-
lsulfonyl)-N -(4—'pipcridinyl)-2 -(trif1uoromcthyl')bcnzcnesulfonamide (WAY-
316606).
- Illustrative, 'non—l'imitative, examples of inhibitors of GSK-3 include:lithium
salts (Cg.n lithium chloride), 6-bromoindirub'in-3 -0Xi'me (BIG), 6-
bromoindi'rub'in-3lJacetoxi‘me (BlO—acetoxi'me), 6-{_2—[4-(2,4-dichloro-phe'nyl)-
5-(4-methyl—1H—imidazol-Z-yl)—pyrimidin-2 -ylamino]-ethyl-amino '} -nieotino-
nitrile 9021), N—[(4-methoxyphenyl)methyl]-N'-(5-nitrothiazolyl)urea
(AR-A01 44 18), 3-(2,4-dichlorophenyl)(1-methyl-lH—indolyl)-1H—pyrrole—
2,5-dione (SB-216763), 5-benzylaminooxo-2,3-dihydro-1,2,4-thiadiazole
(TDZD-ZO), 3-[(3-ehlorohydroxyphenyl)amino](2-nitro-phenyl)-1H-
pyrrole—2,5-dione 5286), etc, or functional analogs or derivatives thereof,
i.e., compounds which contain functional groups which render the compound of
st when administered to a subject.
Further examples of GSK-3 inhibitors are known to those skilled in the art.
Examples are described in, for example, WO 99/65897 and W0 03/074072 and
references cited therein. For e, various GSK-3 inhibitor compounds are disclosed
in US 2005(0054663, US 200230156087, WO 02/20495 and W0 99.65897 (pyrimidine
and pyridine based compounds); US 200350008866. US 200l/0044436 and
W001/44246 (bicyclic based compounds); US 2001;003:4051 (pyrazine based,
compounds); and W0 98.?36528 (purine based compounds). Further GSK-3 inhibitor
compounds include those disclosed. in WO 02/22598 (quinolinone based compOunds),
US 2004/0077707 le based compounds); US 2004/0138273 (carbocyclic
compounds); US 2005/0004152 (thiazole compounds); and US 20040034037
oaryl compounds). Further GSK-3 inhibitor compounds include 'macrocyclic
'maleimide selective GS K-3 [3 inhibitors developed by n & Johnson and described
in, for example, Kuo et a1. (2003) J Med Chem 46(‘l9):402l-3l, a particular example
being 10,11_.13,14,16,17,19,2022,23-Decahydro-9_.4:24,29-dimetho-1H id.o (2,3-
n:3',2'-t) pyrrolo (3,4-q)-(1,4,7,10,13,22) tetraoxadiazacyclotetracosine-l,3 (2H)-dione.
Further, substituted aminopyrimidine derivatives CHIR 98014 (6-pyridinediamine, N6-
[2-[[4-(2,4-dichlorophenyl)( l azol- l -yl)pyrimidinyl]amino]cthyl]nitro-)
and CHIR 99021 [4-(2,4-dichloro-phenyl)(4-methyl-l H-imidazolyl)-
pyrimidin-Z-ylarnino]-ethylamino}-nicotinonitrilc) inhibit human GSK-3 potently.
Also, a number of other GSK-3 inhibitors which may be useful in the present invention
are commercially available from Calb'ioche'm(l§), for example: 5-methyl-l H-pyrazol
-phenquuinazolinyl)ami'ne_. 4-benzylmethyl-l.2,4-thiadiazolidi'ne-3,5-dione
(TDZD8), 2—thio(3-iodobenzyl)( l -p.yridyl)—[l ,3,4]—oxadiazolc, 3-hyd'roxy-
propyl)-lH-pyrrol0[2,3-b]pyridin—3-yl]pyrazinyl-pyrrole-2,5-dionc, etc. Included
within the scope of the invention are the functional analogs or derivatives of the above
mentioned compounds.
For a review of compounds capable of activating the Wnt/B-catenin signalling
y see Chen et al, Am J Physiol Gastrointest Liver Physiol. 2010, Barker et al._,
Nat Rev Drug Discov. 2006 and Meijer et al, Trends Pharmacol Sci. 2004.
In a particular embodiment, the compound used for treating a cell selected from
the group ting of a HSC, a progenitor cell, a MSC and any combination thereof,
in such a way that the Wilt-’B—catenin signalling pathway thereof is activated. is selected
from the group consisting of a Wnt isoform, [3-catenin, a R-spond‘in, or functional
variants or fragments thereof, IO], 08]], DCA, 2-a'm'ino[3,4-(‘methylenedioxy)-
amino](3-mcthoxyphcnyl)pyrimidine, an (hetero)arylpyrimidine such as, for
example, an (hetero)arylpyrimidine of formula (I); (II), (III) or (IV) [Table l], a GSK-3
inhibitor, a SFRPI inhibitor, and any combinations thereof. In a ular embodiment,
said Wnt protein m is selected from the group consisting of Wntl, Wnt2,
Wnt2bf13, Wnt3, Wnt3a, Wnt4, WntSa, WntSb, Wnté, Wnt7a, Wnt7b, Wnt8a, WntSb,
Wnt9a, Wnt9b, Wntha, Wnthb, Wntll, Wntl6, and combinations thereof, or
functional ts or fragments f. In another particular embodiment, said. Wntlfi-
catenin signalling pathway activator is B-catenin or a functional variant or nt
thereof. In another particular ment, said W'nt’B-caten'in signalling pathway
activator is a R-spond-in such as R-spondin-l, R-spondi'n-Z, R-spond-in-3, R-spond-in—4,
or a functional isoform, variant or fragment thereof.
In another particular embodiment, the SFRPl inhibitor is WAY-316606. In
another particular embodiment, the GSK-3 inhibitor is selected from the group
consisting of a lithium salt, preferably, lithium chloride, BIO, BIO-acetoxime,
CHIR99021, AR-A0l44l8. SB-216763, TDZD-20, 83415286, and any combination
thereof.
In a preferred ment, the Wnt-“B-catenin signalling y activator is
selected from the group consisting of Wnt3a, B-catenin, R—spondin-l, and. a combination
thereof. In r preferred ment, the inhibitor of the Wnt B-caten-in signalling
pathway repressor is selected from the group consisting of BIO, CHIR9902'], and a
combination thereof.
In a particular embodiment, the cell for use in the treatment of a retinal
degeneration disease according to the invention, alone or in a cell population
comprising a plurality of said cells, the cell being selected. from the group consisting of
a HSC, a progenitor cell and a MSC, is a cell d. with a Wnt/B-catenin signalling
y activator in such a way that said pathway is activated. According to this
embodiment, a cell, or a plurality of cells, selected from the group consisting of a HSC,
a progenitor cell and a MSC, is contacted, cg, cultured or incubated, with a Wnt/B-
catenin signalling pathway activator. The amount of said Wnt/[B-catenin signalling
pathway activator may vary within a range, nevertheless, preferably, the Wnt/D-catenin
signalling pathway activator will be added in a suitable amount, i.e., in an amount
which allows to obtain a specific amount of B-catenin accumulated in the nucleus of the
cells. By illustrative, in a particular embodiment, a range of about "100 to about
ml of Wnt3a may be used to treat said cells under suitable specific culture
conditions. The amount of Wnt’B—catenin signalling pathway activator which allows to
obtain a specific amount of B-catenin accumulated in the cells and translocated in the
s of the cells with which cell fusion-mediated. ramming is observed can be
determined by the skilled. person in the art by conventional assays, for example, by
contacting the cell with a Wnt-‘B-catenin pathway activator, at different concentrations
and during different periods of time before transplantation of the so treated cells into an
animal and then analyzing if cell fusion-mediated reprogramming occurs, for example,
by detecting and/or determining the expression of undifferentiated cells markers, e.g._.
Nanog, Oct4, Nestin, Otx2, Noggin, SSEA-l, etc. In a particular embodiment, the cells
are treated with Wnt3a as Wnt/B-catenin pathway activator, in a suitable amount of
about 100-300 ngjul for 24 h before lantation of the treated cells.
In another particular embodiment, the cell, alone or in cell population
comprising a ity of said cells, for use in the ent of a retinal degeneration
disease according to the invention, selected from the group consisting of a HSC, a
progenitor cell and a MSC, is a cell treated with an inhibitor of a Wnth-catcnin
signalling pathway sor in such a way that said pathway is activated. According to
this embodiment, a cell ed from the group consisting of a HSC, a progenitor cell
and a MSC. is contacted. c.g._. cultured or incubated, with an inhibitor of a WntlB-
catenin ling y repressor. The amount of said inhibitor of a WnUB-catenin
signalling pathway sor may vary within a range; nevertheless, preferably, the
inhibitor of a Wnt/B-catenin signalling pathway repressor will be added in a suitable
amount, i.e.. in an amount which allows to obtain a specific amount of B-catenin
accumulated in the nucleus of the cells. By illustrative, in a particular embodiment, a
range of about 1 to about 3 uM of B10 may be used to treat said cells in a specific
culture condition (see below). The amount of inhibitor of Wnt’B-catenin pathway
sor which allows to obtain a specific amount of B-catenin accumulated in the cells
and translocated in the nucleus of the cells with which cell fusion-mediated
reprogramming is ed can be determined by the skilled. person in the art by means
of an assay as that mentioned in e 1. Briefly, said assay ses contacting the
cell with an inhibitor of a Wnt/[3-catenin pathway 'rep'ressor, at different concentrations
and during different periods of time before transplantation of the so treated cells into an
animal and then analyzing if cell fusion-mediated reprogramming occurs, for example.
by detecting andfor determining the expression of undifferentiated cells markers, c.g.,
Nanog, Oct4, Nestin, Otx2, Noggin, SSEA-l, etc. In a particular embodiment, the cells
are treated with BIO as an inhibitor of a catenin pathway repressor (GSK-3), in a
suitable amount of about 1-3 uM for 24 h before transplantation of the treated cells.
In another particular embodiment, the cell for use in the ent of a retinal
degeneration disease according to the invention, selected. from the group consisting of a
HSC, a progenitor cell and a MSC, which may be present in a cell tion as
mentioned above, is a cell that overexpresses a -catenin pathway activator.
As used , a “cell that overexpresses a Wnt/B-catenin signalling pathway
activator” is a cell, such as a cell selected from the group consisting of a HSC, a
progenitor cell and a MSC, that has been genetically manipulated to overexpress a
catenin signalling pathway activator, wherein said catenin signalling
pathway activator is a peptide or protein. In a particular embodiment, said Wnt/B-
catcnin ling pathway activator is a Wnt protein isoform such as Wntl, WntZ,
Wnt2bf13, Wnt3, Wnt3a, Wnt4, WntSa, WntSb, Wnt6, Wnt7a, WntSa, Wnt8b, Wnt9a,
Wnt9b, Wntha, Wnthb, Wntl 1, Wntlé, or a functional variant or fragment thereof. In
another particular embodiment, said Wnt/B-catenin signalling pathway activator is [3-
catcnin or a onal Variant or fragment thereof. In another particular embodiment,
said Wnt/B-catenin signalling pathway activator is a R-spondin such as R-spondin-l, R-
spondin-Z. R-spondin-3, R-spondin-4. or a functional isoform, t or fragment
thereof. In an ment, the polynucleotide comprising the nucleotide ce
encoding the Wnt/B-catenin signalling pathway activator is comprised. in an expression
cassette, and said polynucleotide is operatively bound to (i.e., under the control of) an
sion control sequence of said. polynucleotide comprising the nucleotide sequence
encoding the Wnt/B-catenin signalling pathway activator. Expression control sequences
are sequences that control and regulate transcription and, where appropriate, translation
of a protein, and include promoter sequences, ces encoding transcriptional
regulators, me binding sequences (RBS) and-’01“ transcription terminator
sequences. In aparticular embodiment, said expression control sequence is functional in
cukaryotic cells, such as mammalian cells, preferably human cells, for example, the
human cytomegalovirus (hCMV) promoter, the combination of the cytomegalovirus
(CM V) early enhancer element and chicken beta-actin promoter (CAG), the cukaryotic
translation initiation factor (elF) promoter, etc.
AdvantageOusly, said. sion cassette further ses a marker or gene
encoding a motive or for a phenotype allowing the selection of the host cell transformed.
with said expression cassette. Illustrative examples of said markers that could be present
in the expression cassette of the invention include antibiotic-resistant genes, toxic
compound-resistant genes, fluorescent marker-expressing genes, and generally all those
genes that allow selecting the genetically transformed cells. The gene construct can be
inserted in a suitable vector. The choice of the vector will depend on the host cell where
it will subsequently be introduced. By way of illustration, the vector in which the
polynucleotide comprising the nucleotide sequence encoding the Wnt/B-catenin
signalling pathway activator is introduced can be a plasmid or a vector which, when
uced in a host cell, either becomes integrated or not in the genome of said. cell.
Said vector can be obtained by conventional methods known by persons skilled in the
art [Sambrook and Russell, “Molecular Cloning, A Laboratory Manual”, 3rd ed., Cold
Spring Harbor Laboratory Press, N.Y., 2001 Vol 1-3]. In a ular embodiment, said
inant vector is a vector that is useful for transforming animal cells, preferably
mammalian cells. Said vector can be used to transform, transfect or infect cells such as
cells selected from the group consisting of HSCs, progenitor cells and MSCs.
Transformed, ectcd or infected cells can be obtained by conventional methods
known by persons skilled in the art [Sambrok and Russell. (2001), cited supra].
The cells for use in the treatment of a retinal degeneration e according to
the invention, selected from the group ting of a HSC, a progenitor cell and a
MSC, preferably isolated cells, may be used to initiate, or seed, cell cultures. The
specific cells may be isolated. in view of their s as it has been previously
mentioned. Isolated cells may be transferred to sterile tissue culture vessels, either
uncoated or coated with extracellular matrix or ligands such as n, collagen
(native, denatured or crosslinked), gelatin, fibroncctin, and other ellular matrix
ns. The cells for use in the treatment of a retinal degeneration disease according to
the invention may be cultured in any suitable culture medium (depending on the nature
of the cells) capable of ning growth of said cells such as, for example, DMEM
(high or low glucose), advanced DMEM, CDB 20'], Eagle s basal medium,
Hamls F10 medium (F10), Hamls F-‘lZ medium (F12), lscove's modified Dulbecco's -
l7 medium, DMEM/FIZ, RPMI 1640, etc. If necessary, the culture medium may be
supplemented with one or more components including, for example, fetal bovine serum
(FBS); equine serum (ES); human serum (HS); beta-mercaptoethanol (BME or 2-ME),
preferably about 0.001% (Viv); one or more growth factors, for example, platelet-
derived. growth factor (PDGF), epidermal growth factor (EGF), fibroblast growth factor
(FGF), ar endothelial growth factor (VEGF), n-like growth factor-1 (IGF-l),
leukocyte inhibitory factor (LIF), stem cell factor (SCF) and e'rythropoictin; cytokines
as interleukin-3 (IL—3), interleukin-6 (IL-6), FMS-like ne kinase 3 (Flt3); amino
acids, including L-valine; and one or more antibiotic and/or antimycotic agents to
l microbial contamination, such as, for example, penicillin G. streptomycin
sulfate, amphotericin B, gentamicin, and. nystatin, either alone or in combination. The
cells may be seeded in Culture vessels at a density to allow cell growth.
Methods for the selection of the most riate culture medium, medium
preparation, and cell culture techniques are well known in the art and are described in a
variety of sources, including Doyle et al., (eds), 1995, Cell & Tissue Culture:
Laboratory Procedures, John Wiley &Sons, Chichester; and H0 and Wang (eds), 1991,
Animal Cell Biorcactors, Buttewvorth-Heincmann, .
As it is shown in Example 1, the cells, or the cell population, for use in the
treatment of a retinal degeneration disease according to the invention, transplanted into
the sub'retinal space of rd] mice at postnatal day '10 (pl 0) fuse with rods and Muller
cells, thus forming hybrids which de—differentiate and. finally re-differentiate in retinal
neurons, for example photoreceptor cells such as rods, etc, ganglion cells, etc. In this
case, the activation of Wnt/[El-catenin signalling pathway in the transplanted cells
appears to be ial to induce de—differentiation of newly formed hybrids that finally
're-differentiatc in newborn retinal neurons. Further, the newborn photoreceptor cells
fully regenerate the retina in the lanted mice, with rescue of functional Vision.
These data demonstrate that cell fusion-mediated regeneration is a very efficient s
in mammalian , and that it can be triggered by activation of Wnt/D-catenin
signalling pathway. Retinitis tosa (RP) is a very severe disease for which no
treatment is currently available. However, retinal regeneration through transplantation
of the cells or cell population for use in the treatment of a l degeneration disease
according to the invention constitutes an approach for the rescue of vision in subjects
ed by RP or even by a variety of retinal degeneration diseases.
The cells or cell tion for use in the treatment of a retinal degeneration
disease according to the invention can be used as a cell therapy for treating a l
degeneration disease since, once transplanted. into a target location in the eye, said. cells
fuse with retinal cells, such as retinal neurons andfor retinal glial cells, thus providing
hybrid cells which entiate into one or more phenotypes. ing to the
invention, the ent of the retinal degeneration disease occurs by reprogramming of
retinal cells mediated by cell fusion of said cell with said retinal cells, e.g., retinal
neurons and’or retinal glial cells. Reprogram'ming, in general, can be ed to the
passage of a cell from the differentiated state (or differentiated cell — i.e., a cell
specialized for a c function, such as a heart, liver, etc, that cannot generate other
types of cells) to an undifferentiated state (or undifferentiated stem cell - i.e., a cell not
specialized for a specific Function that retains the ial to give rise to specialized
cells), both at level of embryonic state or progenitor state; but also reprogramming can
be referred to the passage from one differentiated. state to another differentiated state
(for example, a fibroblast that becomes a neuron withOut going back to a
precursor/embryonic state, or a retinal neuron that becomes r retinal neuron
without going back to a precursor/embryonic state). In this description,
“reprogramming” refers only to the de-differentiation of a somatic cell which is
followed by differentiation of the hybrid cells previously formed as a result of the cell
fusion between a cell (e.g., a HSC, a progenitor cell or a MSC) and a somatic cell (e.g.,
a retinal neuron or a retinal glial cell).
As used , the expression “cell fusion” relates to cell-cell fusion that occurs
spontaneOusly or mediated by exogenous agents. Cell-cell fusion regulates many
developmental processes as well as cell fate and cell differentiation. Somatic cells can
fuse spontaneously with stem cells, and the resulting hybrid clones have a stem cell-like
phenotype. The stem cell features of stem cells are dominant over the somatic cell traits
and allow the reprogramming of the somatic cell nucleus. Thus, cell-cell fusion is a way
to force the fate of a cell, and in the case of fusion with cells. such as HSCs, progenitor
cells or MSCs. this mechanism induces cellular reprogramming, that is,
dedifferentiation of somatic cells. The ors have shown that fusion-mediated
reprogramming of a c cell is greatly enhanced by time-dependent activation of
the Wnt/B-catenin signalling pathway. After Wnt binding to its receptors or inhibition of
GSK—3, as a component of the destruction complex, B-catenin is stabilized and
translocates into the nucleus, where it activates several target genes.
As used herein, the term “retinal neuron” refers to the neurons which form part
ofthe retina. The retina is a light-sensitive tissue lining the inner surface of the eye. It is
a layered. structure with several layers of neurons interconnected by synapses. The only
s that are directly sensitive to light are the photoreceptor cells. These are mainly
of two types: rods and cones. Rods function mainly in dim light and provide black-and-
white Vision. while cones t daytime Vision and the perception of colour. A third,
much rarer type of photoreceptor, the photosensitive ganglion cell, is important for
reflexive ses to bright daylight. Neural signals from the rods and cones undergo
processing by other neurons ofthe retina. The output takes the form of action potentials
in retinal ganglion cells whose axons form the optic nerve. The retinal neurons further
include horizontal cells, bipolar cells, amacrine cells, interplexiform cells, ganglion
cells, among others. In addition to said cells there are glial cells in the retina such as
Muller cells (Muller glia), which are the main glial cell of the retina and. act as
supporting cells. astrocytes and microglial cells (Webvision — The Organization of the
Retina and Visual System, Part I], Chapter entitled “Glial cells of the Retina”, by Helga
Kolb. dated July 3'] , 2012).
In a particular embodiment, the retinal cells comprise retinal neurons such as
rods and the like and retinal glial cells such as Miiller cells, etc., which fuse with the
cells or cell population for use in the treatment of a retinal degeneration disease
ing to the invention, e.g., BIO-treated HSPCs (Example 1). In another particular
embodiment, the retinal s comprise ganglion cells and/or amacrine cells which
fuse with the transplanted HSPCs (Example 2). In another particular ment it is
contemplated the fusion of cells selected from the group ting of HSCs, progenitor
cells, MSCs and any ation thereof. including the the cells for use in the treatment
of a retinal degeneration disease according to the invention, or a population thereof,
e.g., HS PCs, with endogenous proliferating cells (e.g., RSPCs).
The final retinal s which may ed after reprogramming of the fused
retinal neurons may vary, for example, photoreceptor cells, ganglion cells, interneu'rons,
'J‘I etc. In a particular embodiment, fused retinal neurons (e.g., rods) and retinal glial cells
(e.g., Muller cells) are rammed to mainly rods (Example 1), whereas in another
particular embodiment fused. retinal neurons (e.g., ganglion cells and/or amacrine cells)
are reprogrammed to ganglion cells and interneurons (Example 2).
Although the inventors wish not to be bound. by any theory, it is believed. that the
reprogrammed retinal neurons may be of the same type (or different) as that of the
retinal neuron fused to the cell or cell population for use in the treatment of a retinal
degeneration disease according to the invention. e.g., a rod may be reprogrammed to a
rod or to another type of retinal neuron such as, e.g., a ganglion cell, an amacrine cell,
etc; a ganglion cell may be reprogrammed to a ganglion cell or to another type of
retinal neuron such as, e.g., a rod, an amacrine cell, etc; an amacrine cell may be
reprogrammed to an ne cell or to another type of retinal neuron such as, e.g., a
rod, a ganglion cell, etc. Further, a retinal glial cell, such as a Muller cell, after fusion
with a cell or cell population for use in the treatment of a retinal ration e
according to the ion, may be reprogrammed to a retinal neuron such as a rod, or to
another type of retinal neuron such as, e.g., a ganglion cell, an amacrine cell, etc.
Indeed, e I shows fusion of HSPCs with rods and the differentiation of the
hybrid cells only into rods.
In a particular embodiment, the treatment of said retinal ration disease
comprises reprogramming of l cells, such as retinal neurons (e.g., rods, ganglion
cells, ne cells, etc.) and/0r retinal glial cells (e. g._, Muller cells, etc.) mediated by
cell fusion of said cell or cell population for use in the treatment of a retinal
ration disease according to the invention with said retinal cells and
differentiation of the resulting hybrid cells to retinal neurons such as photoreceptor cells
(e.g., rods. etc.), ganglion cells, amacrine cells, etc. In another ular embodiment,
the treatment of said retinal degeneration disease comprises reprogramming of retinal
neurons mediated by cell fusion of said cell or cell population for use in the treatment of
a retinal degeneration disease according to the invention with said retinal neurons and
differentiation of the resulting hybrid cells to the same or different type of retinal
neurons for e photoreceptor cells, such as rods, etc., ganglion cells, amacrine
cells, etc.
In a particular embodiment, the retinal cells se retinal neurons (e.g., rods,
'J‘I ganglion cells, amacrine cells, etc.). In r particular embodiment, the retinal cells
comprise retinal glial cells (e.g., Muller cells, etc.). In another particular ment,
the retinal cells comprise retinal neurons (e.g., rods, ganglion cells, ne cells, etc.)
and retinal glial cells (e.g., Muller cells, etc.).
A “retinal degeneration e”, as defined herein, is a disease associated with
deterioration of the retina caused. by the progressive and eventual death of the cells of
the retinal tissue. The term al degeneration disease” also includes indirect causes
of retinal degeneration, i.e._. retinal degenerative conditions derived from other primary
pathologies, such as cts, diabetes, glaucoma, etc. In a particular embodiment, said
retinal degeneration disease is selected from the group comprising retinitis pignentosa,
age-related. macular degeneration, Stargardt disease, cone-rod dystrophy, ital
nary night blindness, Leber congenital amaurosis, Best's vitelliform macular
dystrophy, anterior ischemic optic neuropathy, choroideremia, age-related macular
degeneration, acular phy, Bictti lline corneoretinal dystrophy,
UsherLs syndrome, etc., as well as retinal degenerative conditions derived. from other
primary pathologies, such as cataracts, diabetes, glaucoma, etc. In a particular
embodiment, said retinal degeneration disease derives from cataracts, diabetes or
glaucoma. In another particular embodiment, said retinal degeneration disease is age-
related macular degeneration that is presented in two forms: “31'” that results from
atrophy t0 the retinal pigment epithelial layer below the , which causes vision loss
through loss of photoreceptors (rods and cones) in the central part of the eye; and “w_et”
that causes vision loss due to abnormal blood. vessel growth (choroidal
neovascularization) in the choriocapillaris, through BruchlE membrane, tely
leading to blood. and protein leakage below the macula, eventually causing irreversible
damage to the photoreceptors and rapid vision loss. In a more ular embodiment,
said retinal degeneration disease is RP, a heterogeneous family of inherited retinal
disorders characterized by progressive degeneration of the eceptors With
subsequent degeneration of RPE, which is characterized by pigment deposits
predominantly in the peripheral retina and by a relative sparing of the central retina. In
most of the cases of RP, there is primary degeneration of photoreceptor rods, with
secondary degeneration of cones.
In the context of the present invention, r.treatment of retinal degeneration
'J‘I M” means the administration of the cells for use in the treatment of a l
degeneration disease according to the ion, or a population of said. cells, or a
pharmaceutical composition sing said cells or a ceutical composition
comprising cells other than the cells for use in the treatment of a l degeneration
disease according to the invention (see Treatment B below) to prevent or treat the onset
of symptoms, complications or biochemical indications of a retinal degeneration
disease, to alleviate its ms or to stop or inhibit its development and progression
such as, for example, the onset of blindness. The treatment can be a prophylactic
treatment to delay the onset of the disease or to prevent the manifestation of its clinical
or subelinical symptoms or a therapeutic treatment to ate or alleviate the
symptoms after the manifestation ofthe disease.
Survival of transplanted cells in a living t may be ined. h the
use of a y of scanning techniques, e.g._. computerized axial tomography (CAT or
CT) scan, magnetic resonance imaging (MRI) or positron emission tomography (PET)
scans. Alternatively, determination of transplant survival may also be done post mortem
by removing the tissue and examining it visually or thrOugh a microscope. Examining
restoration of the ocular function that was damaged or diseased can assess functional
integration of transplanted cells into ocular tissue of a subject. For example,
effectiveness in the treatment of retinal degeneration diseases may be determined by
improvement of Visual acuity and evaluation for abnormalities and grading of
stereoscopic color fundus photographs (Age—Related Eye Disease Study Research
Group, NE15 NIH, AREDS Report No. 8, 2001, Arch. Ophthalmol. 119: 1417-1436).
For the administration to a t, the cells or cell population for use in the
treatment of a retinal degeneration disease ing to the ion may be
formulated in a pharmaceutical composition, preparation or formulation, using
pha-rmaceutically acceptable carriers, which particulars Will be discussed below under
section entitled “Pharmaceutical composition”.
Treatment B
In another aspect, the invention relates to a cell selected from the group
consisting ofa hematopoietic stem cell, a progenitor cell, and a mescnchymal stem cell,
for use in the treatment of a retinal degeneration disease, by reprogramming of retinal
cells, such as retinal neurons and/or retinal glial cells, mediated by cell fusion of said
cell with said. retinal cells, said reprogramming being mediated by activation of the
catenin signalling pathway. In other words, according to this , the
invention provides a cell selected from the group consisting of a hematopoietic stem cell
(HSC), a progenitor cell, and a mesenchymal stem cell (MSC), for use in the ent
of a retinal degeneration disease, by ramming, mediated by the Wnth-catenin
signalling pathway, or" a retinal cell, such as a l neuron and/or a retinal glial cell,
by Fusion of said cell with said retinal cell upon contact of said cell with said retinal cell
in the eye of a subject.
Alternatively, in other words, this aspect of the invention relates to the use of a
cell selected. from the grOup consisting of a hematopoietic stem cell, a progenitor cell, a
mcscnchymal stem cell, in the manufacture of a pharmaceutical ition for the
treatment of a retinal degeneration disease, by reprogramming of retinal cells, such as
retinal neurons and/or retinal glial cells, mediated. by cell fusion of said cell with said
retinal cells, said. reprogramming being mediated by activation of the Wnt/B-catenin
signalling y.
The particulars of the cell ed from the group consisting of a poietic
stem cell, a itor cell, a 'mesenchymal stem cell, and the retinal degeneration
disease to be treated have been previously discussed in connection with above
Treatment A, whose ulars are hereby incorporated.
In a particular embodiment, the retinal cells comprise retinal neurons (e. g., rods,
ganglion cells, amacrine cells, etc). In another particular embodiment, the retinal cells
comprise retinal glial cells (e.g., Muller cells, etc.). In another particular embodiment,
the retinal cells comprise retinal neurons (e.g., rods, ganglion cells, amacrine cells, etc.)
and retinal glial cells (c.g., Muller cells, etc.).
In st to above Treatment A, in Treatment B it is not necessary that the cell
(HSC, progenitor cell or MSC) to be implanted has its Wnt-‘B-e-atenin signalling
pathway activated at the time of the cell is implanted into the eye because said pathway
may be endogenously activated or by administration of a Wnt/B-catenin signalling
pathway activator or an inhibitor of a Wnt/B-catenin signalling pathway repressor, as it
will be discussed below. Thus, according to Treatment B, it is not necessary that the cell
(HSC, itor cell or MSC) is d, prior to its implantation into the eye, with a
Wnt/B-catenin signalling pathway activator or with an inhibitor of a Wnt/B-catenin
signalling pathway repressor or that overexpresses a Wnt/B-catenin signalling pathway
tor, but what is necessary is that retinal regeneration occurs by reprogramming of
retinal cells, such as retinal neurons and/or l glial cells, mediated by cell fusion of
said cell with said. retinal cells, said ramming being mediated. by activation of the
Wnt/B-catenin signalling pathway. In this case, the activation of the W'nt/B-catenin
signalling pathway may be endogenous, i.e., it can be achieved by the subject to which
the cells are to be administered (implanted or transplanted) as a consequence of a
damage, lesion or injury in the retina (what may occur in retinal degeneration diseases)
or by administration of a Wnt/B-catenin signalling pathway activator or an inhibitor of a
Wnt/B-catenin ling pathway repressor. Several assays performed. by the inventors
have shown that after endogenous activation of the Wnt/B-catenin signalling pathway
reprogramming of the hybrid cells formed after damage is observed (Example 2). On
the other hand, recruitment of endogenous bone marrow cells (BMC s) after damage in
the eye and. ectopic tion of atenin ling y is sufficient to
observe reprogramming of the hybrid cells (Example 2). Therefore, in a particular
embodiment, the cell for use in the treatment of a retinal degeneration disease according
to Treatment B (i.e., by reprogramming of retinal cells, such as retinal neurons and/or
l glial cells, mediated by cell Fusion of said cell with said retinal cells, said
reprogramming being ed by activation of the Wnt/B-catenin pathway) is a BMC
(c-kit+, sea-1+) recruited from the bone marrow (BM) into the eye and. the eye is treated.
with a catenin signalling y activator in order to obtain regeneration of the
retinal tissue.
The effects of the activation of the Wnt/B-catenin signalling pathway, as well as
illustrative, non-limitative, examples of Wnt/B-catenin ling pathway activators
and inhibitors of Wnt/B-catenin signalling pathway repressors have been discussed in
connection with above Treatment A, whose particulars are hereby incorporated.
Example 2 shows that upon activation of -catenin signalling pathway,
mouse retinal neurons can be transiently rammed in viva back to a precursor stage
after spontaneous fusion with transplanted cells (e.g., HSPCs, or ESCs). Newly formed
hybrid cells reactivate neuronal precursor markers (e.g., HSPCs and ESCs ramme
retinal neurons back to Nanog and Nestin expression). Further, said hybrid cells can
proliferate, differentiate along a neuro-ectodermal lineage (in the case of hybrid. cells
formed by HSPCs and retinal s), and finally into terminally differentiated l
neurons (e.g., photoreceptor cells), which can regenerate the damaged retinal tissue;
alternatively, hybrid cells formed. by ESCs and retinal neurons can also proliferate and
differentiate, in addition to the neuroectodermal lineage, in endoderm and ectoderm
es what may result in formation of a teratoma. Following retinal damage and
induction of catenin signalling pathway in the eye, usion-mediated
reprogramming also occurs after endogenous mobilisation of bone marrow cells in the
eyes. These data show that in-vivo reprogramming of terminally differentiated. retinal
neurons is a possible mechanism of tissue regeneration.
In a particular embodiment, the cell for use in the treatment of a retinal
degeneration disease according to Treatment B, is a HSC. In another ular
embodiment, said cell is a LT-H SC or a ST-H SC.
In another particular embodiment, the cell for use in the treatment of a retinal
ration disease according to Treatment B, is a itor cell. In another
particular embodiment, said progenitor cell is an Early MPP, a Late MPP, a LRP, a
(3MP, a GM? or a MEP.
In r particular ment, the cell for use in the treatment of a retinal
degeneration disease according to Treatment B, is a MSC.
The cells for use in the treatment of a retinal degeneration disease according to
Treatment B may be forming part of a population of said cells which use in the
treatment of a retinal degeneration disease constitutes an additional aspect of the present
invention.
Thus. the invention further s to a cell population comprising a plurality of
cells, said cells being selected from the group consisting of a hematopoietic stem cell
(H SC), a progenitor cell, a mescnchymal stem cell (MSC) and any combination thereof,
for use in the treatment of a retinal degeneration disease according to Treatment B.
In other words, the invention relates to a cell population sing a plurality
of cells, said cells being selected from the group ting of a HSC, a progenitor cell,
a MSC and any combination thereof, for use in the treatment of a retinal degeneration
disease, by ramming of retinal cells, such as retinal neurons and/or retinal glial
cells, mediated by cell fusion of said cell with said l cells, said reprogramming
being mediated by activation of the Wnt/B-catenin ling pathway. To that end. the
cell population is ted. in the eye of a subject in need of treatment of a retinal
ration disease. Thus, according to this aspect, the invention es a cell
population comprising a plurality of cells, said cells being selected. from the group
consisting of a HSC, a progenitor cell, a MSC and. any combination thereof, for use in
the treatment of a retinal degeneration disease, by reprogramming, mediated by the
Wnt/B-catenin signalling pathway, of a retinal ccll, such as a retinal neuron and/or a
retinal glial cell, by fusion of said cell With said retinal cell upon t of said cell
with said retinal cell in the eye of a subject.
Alternatively drafted. this aspect of the invention relates to the use of a cell
population comprising a plurality of cells, said cells being ed. from the group
consisting of HSCs, progenitor cells, MSCs and any combination thereof, in the
manufacture of a pharmaceutical composition for the treatment of a retinal degeneration
disease, by reprogramming of retinal cells, such as retinal neurons andfor retinal glial
cells, mediated by cell fusion of said cells with said retinal cells, said reprogramming
being mediated by activation of the WntIB-catenin signalling pathway. or, atively,
to the use of a cell population sing a plurality of cells, said cells being selected
from the group consisting of a HSC, a progenitor cell, a MSC and any combination
thereof, in the manufacture of a pharmaceutical composition for the treatment of a
retinal degeneration disease, by ramming of retinal cells, such as retinal neurons
and/0r retinal glial cells, mediated by cell fusion of said. cells with said. retinal cells, said
reprogramming being mediated by activation ofthe Wnt/B-catenin signalling pathway.
The particulars of said. HSCs, progenitor cells, and. MSCs have been previously
mentioned.
In a particular embodiment, the retinal cells comprise retinal neurons (c.g., rods,
ganglion cells, amacrine cells, etc.). In another particular embodiment, the retinal cells
comprise retinal glial cells (e.g., Muller cells, etc.). In another particular embodiment,
the retinal cells se l neurons (e.g._. rods, on cells. amacri'nc cells, etc.)
and retinal glial cells (e.g., Miiller cells. etc.).
In a particular ment, the cell population for use in the treatment of a
retinal degeneration disease according to Treatment B comprises a plurality, ire, more
than two, of HSCs. In a particular ment, said HSCs are selected from LT-HSC,
ST-HSC and combinations thereof.
In another particular embodiment, the cell population for use in the treatment of
a retinal degeneration disease according to Treatment B comprises a plurality of
progenitor cells. In a particular embodiment, said progenitor cells are selected from
Early MPP, a Late MPP, a LRP, a CMP, a GMP, MEP and combinations thereof.
In another particular embodiment, the cell population for use in the treatment of
a retinal degeneration disease according to Treatment B comprises a ity of MSCs.
In a particular ment, the cell population for use in the treatment of a
retinal degeneration disease according to Treatment B comprises at least one HSC and.
at least one progenitor cell. In a particular embodiment, said. HSC cell is a LT-HSC or a
ST-HSC; in another particular embodiment, said progenitor cell is an Early MPP, a Late
MPP, a LRP, a CMP, a GMP or a MEP.
In another particular embodiment, the cell tion for use in the treatment of
a retinal degeneration discasc according to Treatment B comprises at least one HSC and
at least one MSC. In a particular embodiment, said HSC cell is a LT-HSC or a ST—HSC.
In another ular embodiment, the cell population for use in the treatment of
a retinal degeneration disease ing to Treatment B ses at least one
progenitor cell and at least one MSC. In a particular embodiment, said progenitor cell is
an Early MPP, a Late MPP, a LRP. a CMP, a GMP or a MEP.
In another particular embodiment, the cell population for use in the treatment of
a retinal degeneration disease according to Treatment B comprises at least one HSC, at
least one itor cell and at least one MSC. In a particular embodiment, said HSC
cell is a LT-HSC or a ST-HSC; in another particular embodiment, said. progenitor cell is
an Early MPP, a Late MPP, a LRP. a CMP, a GMP or a MEP.
In a particular embodiment, a cell population for use in the treatment of a retinal
degeneration disease according to Treatment B is the cell composition identified as
, Le, a cell population compn'sing HSCs, progenitor cells and MSCs; said. cell
population can be obtained, for example, from bone , or, alternatively, by
mixing HSCs, progenitor cells and MSCs, in the desired ratios or proportions. in order
to obtain a HSPC cell population. Thus, said cell population HSPC may include HSC,
progenitor cells and MSCs in different ratios or tions. The skilled person in the
art will understand that said cell population may be enriched in any type of specific cells
by conventional means, for example, by ting a specific type of cells by any
suitable technique based on the use of binding pairs for the corresponding surface
markers. Thus, in a particular embodiment, the HSPC cell population may be enriched
in HSCs, or in progenitor cells, or even in MSCs.
Compositions
In another aspect, the invention relates to a cell composition, after referred
to as “cell composition of the invention”, wherein at least 50% of the cells of said cell
composition are selected from the group consisting of hematopoietic stem cells (HSCs),
progenitor cells, mesenchymal stem cells (MSCs) and any combination thereof and
wherein said cells have their Wnt/B-catenin signalling pathway activated, or n the
Wnt/B-catenin ling pathway of said cells is activated, or, wherein said cells have
been treated with a Wnt’B-catenin signalling pathway tor, or with an inhibitor of a
Wnt/B-c-atcnin signalling pathway repressor, andfor wherein said cclls overcxprcss a
WntlB-c-atenin signalling pathway activator.
In a particular embodiment, the cell composition of the invention is a
ition n at least 60%, preferably 70%, more preferably 80%, still more
preferably 90%, yet more preferably 95%, and even more preferably 100% of the cells
are HSCs, progenitor cells, and/or MSCs, in any ratio, having their W‘nt/B-catenin
signalling pathway activated. (as a , for example, of having been treated with a
Wnt/B-catenin ling pathway activator, or with an inhibitor of a Wnt/B-catenin
signalling y repressor, or by manipulation to overexpress a Wnt/B-catenin
signalling pathway activator). The cell composition of the invention further comprises a
medium; said medium must be compatible with the cells contained in said composition;
illustrative, non-limitative examples of media which can be present in the cell
composition of the invention include isotonic solutions optionally supplemented with
serum; cell culture media or, alternatively, a solid, semisolid, gelatinous or viscous
support medium.
Pharmaceutical compositions
'J‘I The cells and cell population for use in the treatment of a retinal degeneration
disease according to Treatments A and B of the present invention may be administered
in a pharmaceutical composition, ation, or formulation, by using
pharmaceutically able carriers.
Thus, in an aspect, the invention relates to a pharmaceutical composition,
hereinafter referred. to as “phannaceutical composition of the ion”, selected. from
the group consisting of:
l) a pharmaceutical composition comprising at least a cell selected from
the group consisting of a hematopoietic stem cell (HSC), a progenitor
cell, a mesenchymal stem cell (MSC), and any combination thereof,
wherein the Wnt/B-catenin signalling pathway of said, cells is
ted, and a pharmaceutically acceptable r, and.
2) a pharmaceutical composition comprising at least a cell selected from
the group consisting of a hematopoietic stem cell (HSC), a progenitor
cell, a mcscnchyrnal stem cell (MSC), and any combination thereof,
in ation with a Wnt/B-catenin signalling y activator or
an inhibitor of a B-catenin signalling pathway repressor, and a
pharmaceutically acceptable carrier.
In order that the HSCs, progenitor cells, and/or MSCs have their Wnt/B-cate'nin
signalling pathway activated [pharmaceutical composition of the invention 1)], said
HSCs, progenitor cells and/0r MSCs are d with a Wnt/B-catenin signalling
pathway activator, or with an inhibitor of a Wnt/B-catenin signalling pathway repressor,
and/or are manipulated. in order to press a Wnt/B-catenin signalling pathway
activator.
The pharmaceutical composition of the invention can be used in the treatment of
a retinal degeneration disease.
As used herein, the term “an” includes vehicles, media or ents,
whereby the cells for use in the treatment of a retinal degeneration e according to
Treatments A or B of the invention can be administered. Obviously, said carrier must be
ible with said cells. rative, non-limiting examples of suitable
pharmaceutically acceptable carriers include any logically compatible carrier, for
example, isotonic solutions (e.g., 0.9% NaCl e saline solution, phosphate buffered
saline (PBS) solution, Ringer-lactate solution, etc.) optionally supplemented with
serum, preferably with autologous serum; cell e media (e.g., DMEM, etc); etc.
The pharmaceutical composition of the ion may comprise auxiliary
components as would be familiar to medicinal chemists or biologists, for example, an
antioxidant agent suitable for ocular administration (e.g., EDTA, sodium sulfite, sodium
sulfite, mercaptopropionyl glycine, N-acetyl cysteine, beta- mercaptoethylamine,
glutathione and similar species, ascorbic acid and its salts or sulfite or sodium
'metabisulfite, etc.)_, a buffering agent to maintain the pH at a suitable pH to minimize
irritation of the eye (e.g., for direct intravitreal or i'ntraocular injection, the
pharmaceutical compositions should. be at pH 7.2 to 7.5, alternatively at pH 7.3-7.4), a
ty agent le for administration to the eye (e..g., sodium chloride to make
compositions approximately isotonic with 0.9% saline solution), a viscosity enhancing
agent (e.g., hyd'roxyethylcellulose, hydroxypropylccllulose, methylcellulose,
polyvinylpyrrolidone, etc.), etc. In some embodiments, the pharmaceutical composition
of the invention may n a preservative (c.g., benzalkonium chloride, benzcthonium
de, chlorobutanol, phenylmercuric acetate or nitrate, thimerosal, methyl or
propylp8arabens, etc.) Said pharmaceutically acceptable substances which can be used
in the ceutical composition of the invention are generally known by the persons
skilled in the art and are normally used in the preparation of cell compositions.
Examples of suitable pharmaceutical carriers are described, for example, in
“Remington's Pharmaceutical Sciences”, of E.W. Martin.
The cells for use in the treatment of a retinal degeneration disease according to
Treatments A or B of the ion may be administered. alone (e.g., as substantially
homogeneous populations) or as mixtures with other cells, for example, neurons, neural
stem cells, l stem cells, ocular progenitor cells, retinal or corneal epithelial stem
cells and/or other multipote'nt or pluripotent stem cells. Where the cells for use in the
treatment of a l degeneration disease according to Treatments A or B of the
invention are administered with other cells, they may be administered simultaneously or
sequentially with the other cells (either before or after the other cells). The cells of
different types may be mixed with the cells for use in the treatment of a retinal
degeneration disease according to Treatments A or B of the invention immediately or
shortly prior to administration, or they may be co-cultured together for a period of time
prior to administration.
The cells for use in the treatment of a retinal degeneration disease according to
Treatments A or B of the invention may be administered. with at least one
pharmaceutical agent, such as, for e, growth factors, trophic factors, conditioned
medium, or other active agents, such as anti-inflammatory agents, anti apoptotic agents,
antioxidants, neurotrophic factors or neuroregenerative or neuroprotective drugs as
known in the art, either together in a single pharmaceutical composition, or in separate
pharmaceutical compositions, simultaneously or sequentially with the other agents
(either before or after administration of the other agents); it is expected that the use of
said agents increases the efficiency of the cell regeneration or decreases cell
degeneration.
Examples of said other agents or components that may be administered with the
cells for use in the treatment of a retinal degeneration disease according to Treatments
A or B of the invention include, but are not d to: ('1) other neuroprotective or
neurobcncficial drugs; (2) selected, extracellular matrix components, such as one or
more types of collagen known in the art, r growth factors, platelet-rich , and
drugs (alternatively, the cells may be genetically engineered to express and produce
growth factors); (3) anti- tic agents (c.g., erythropoietin (EPO), EPO 'mimctibody,
thrombopoietin, n-like growth factor (IGF)-I, lGF—ll, hepatocytc growth ,
caspasc inhibitors); (4) anti- inflammatory compounds (c.g., p38 MAP kinase inhibitors,
TOP—beta inhibitors, statins, IL-6 and IL—1 inhibitors, last, Tranilast, Remicade,
Sirolimus, and eroidal anti-inflammatory drugs (NSAIDS) such as, for example,
tepoxalin, tolmetin, and. en; (5) immunosuppressive or immunomodulatory
agents, such as calcineurin inhibitors, mTOR inhibitors, antiproliferatives,
osteroids and s antibodies; (6) antioxidants such as ol, Vitamins C
and E, coenzyme Q- '10, glutathionc, L-cysteine, N- acetylcysteine, etc.; and (7) local
anesthetics, to name a few.
The pharmaceutical composition of the invention may be typically formulated as
liquid or fluid compositions, semisolids (e.g., gels or hydrogels), foams, or porous
solids (e.g., polymeric matrices, composites, calcium phosphate derivatives, and the
like, as appropriate for ophthalmic tissue ering) or particles for cell encapsulation
'J‘I from natural or tic origin to allow a better administration of the cells or a higher
survival and. on. In a particular embodiment, the cells for use in the treatment of a
retinal degeneration disease according to Treatments A or B of the invention may be
administered in semi-solid or solid devices suitable for surgical tation; or may be
administered with a liquid. carrier (e.g., to be injected. into the ent subject). Thus,
said cells may be surgically implanted, injected. or otherwise administered. ly or
indirectly to the site of ocular damage or distress. When cells are administered in semi-
solid or solid devices, surgical implantation into a precise location in the body is
typically a suitable means of administration. Liquid or fluid pharmaceutical
compositions, r, may be administered to a more general location in the eye (e.g.,
intra-ocularly).
The pharmaceutical composition of the invention may be delivered. to the eye of
a subject in need thereof (patient) in one or more of several delivery modes known in
the art. In an embodiment the pharmaceutical composition is implanted or red to
the retina or surrounding area, via periodic intraocular or intravitrea injection, or under
the retina. In addition ideally cells will be delivered only one time at the early onset of
the disease, however ifthere will be a ion of the phenotype it might be possible
additional deliveries during the life of the subject. As it will be understood by a person
skilled in the art, mes the direct administration of the pharmaceutical composition
of the invention to the site wishing to benefit can be advantageous. Therefore, the direct
administration of the pharmaceutical composition of the invention to the desired. organ
or tissue can be achieved. by direct administration (e.g., through injection, etc.) by
means of inserting a suitable device, e.g., a suitable cannula, or by other means
ned. in this description or known in the technique.
Pharmaceutical compositions for injection may be designed for single-use
stration and do not contain preservatives. able solutions may have
isotonicity equivalent to 0.9% sodium chloride solution (osmolality of 290-300
'milliosmoles). This may be attained by on of sodium chloride or excipients such
as buffering agents and antioxidants, as listed above.
The administration of the pharmaceutical composition of the invention to the
subject will be carried out by conventional means, for e, said pharmaceutical
'J‘I composition can be administered to said subject through intravitreal route by using
suitable devices such as syringes, as, etc. In all cases, the pharmaceutical
composition of the ion will be administered using equipment, apparatuses and,
devices suitable for administering cell compositions known by the person skilled in the
art.
Dosage forms and regimes for administering the cells for use in the treatment of
a retinal degeneration disease according to ents A or B of the invention or any of
the other pharmaceutical compositions described herein are developed in accordance
with good medical practice, taking into account the condition of the subject, e.g., nature
and extent of the retinal degenerative condition, age, sex, body weight and general
medical condition, and other factors known to medical practitioners. Thus, the effective
amount of a pharmaceutical composition to be administered to a t will be
determined by these considerations as known in the art.
Nevertheless, in general, the pharmaceutical composition of the invention (or
any of the other pharmaceutical compositions described. ) will contain a
eutically effective amount of the cells for use in the ent of a retinal
degeneration disease according to Treatments A or B of the invention, preferably a
substantially 'nous population of said cells to provide the desired therapeutic
effect. In the sense used in this description, the term “therapeutically effective amount”
relates to the amount of cells for use in the treatment ofa retinal degeneration disease
according to ents A or B of the invention which is capable of producing the
desired therapeutic effect (e.g., regenerate total or lly the retina and/or rescue of
functional vision, and. the like) and. will generally be determined by, among other
factors, the teristics of said cells themselves and. the desired. therapeutic effect.
Generally, the therapeutically effective amount of said cells for use in the treatment of a
retinal degeneration disease according to Treatments A or B of the ion that must
be administered will depend on, among other factors, the characteristics of the subject
himself, the seriousness of the disease, the dosage form, etc. For this purpose, the dose
mentioned in this invention must only be taken into account as a guideline for the
person d in the art, who must adjust this dose depending on the aforementioned
factors. In a particular embodiment, the pharmaceutical composition of the invention is
administered in a dose containing between about 104 and about 1010 cells for use in the
ent of a retinal degeneration e according to Treatments A or B of the
invention per eye, preferably between about 106 and. 108 cells per eye. The dose of said,
cells can be repeated. depending on the status and evolution of the t in temporal
intervals of days, weeks or months that must be established by the specialist in each
case.
In some occasions, it may be desirable or appropriate to pharmacologically
immunosupprcss a subject prior to initiating cell therapy. This may be accomplished
through the use of systemic or local im-munosuppressive agents, or it may be
accomplished by ring the cells in an encapsulated device. These and other means
for reducing or ating an immune response to the transplanted. cells are known in
the art. As an alternative, the cells for use in the treatment of a retinal degeneration
disease according to Treatments A or B of the invention may be genetically modified. to
reduce their immunogenicity.
Kits
In another aspect, the invention relates to a kit, hereinafter referred. to as “kit of
the invention”, ed from the group consisting of:
l) a kit comprising at least a cell selected from the group consisting of a
hematopoietic stem cell (HSC), a progenitor cell. a chymal
stem cell (MSC), and any combination thereof. wherein the Wnt/B-
eatenin signalling y of said. cells is activated, and. instructions
for use of the kit components, and.
2) a kit comprising at least a cell selected. from the group consisting of a
hematopoietic stem cell (HSC), a progenitor cell, a mesenchymal
stem cell (M SC). and any combination thereof, in combination with a
Wnt/B-catenin signalling pathway activator or an inhibitor of a
Wnt/B-catenin ling pathway repressor, and instructions for use
of the kit components.
In order that the HSCs, progenitor cells, and/or MSCs have their Wnt/B-catenin
signalling pathway activated [kit of the invention 1)], said HSCs, progenitor cells and/or
MSCs are treated with a Wnt/B-catenin signalling pathway activator, or with an
inhibitor of a Wnt’B-catenin signalling pathway sor, and/or are manipulated in
'J‘I order to press a Wn tJB-catenin signalling pathway activator.
The kit of the invention can be used in the treatment of a retinal degeneration
disease.
The particulars of the cells for use in the treatment of a retinal degeneration
disease according to Treatments A or B of the invention, pharmaceutical composition of
the invention, and retinal ration disease to be treated. have been previously
mentioned and are incorporated herein.
ing to another aspect of the invention, a method is provided. for ng a
subject having a retinal degeneration disease (i.e._, a patient), which comprises
administering to said. subject in need. of treatment a cell or a cell population for use in
the treatment of a retinal degeneration disease according to the invention, a
pharmaceutical composition of the invention, in an amount effective to treat the retinal
degeneration disease, wherein said treatment of the retinal degeneration disease occurs
by reprogramming of retinal cells, such as retinal neurons and/or retinal glial cells,
mediated by cell fusion of said cells with said retinal cells, said reprogramming being
'm d by activation of the Wn t/B-catenin pathway.
The particulars of the cells for use in the ent of a retinal degeneration
disease according to the invention, pharmaceutical itions of the invention,
retinal degeneration diseases to be d and effective amount to treat said diseases
have been previously mentioned and are incorporated herein.
In a particular embodiment, the retinal cells comprise retinal neurons (e. g., rods,
ganglion cells, amacrine cells, etc.). In another particular embodiment, the retinal cells
comprise retinal glial cells (e.g., Muller cells, etc.). In r particular ment,
the retina] cells comprise retinal neurons (e.g., rods. ganglion cells, amacrine cells, etc.)
and retinal glial cells (e.g., Muller cells, ctc.).
In a particular embodiment, the method for treating a subject having a retinal
degeneration disease comprises the administration of a pharmaceutical composition of
the invention 1), i.e., a pharmaceutical composition comprising at least a cell ed
from the group consisting of a HSC, a progenitor cell, a MSC, and any ation
thereof, wherein said cells have their Wnt/B-catenin signalling pathway activated, and a
pharmaceutically acceptable carrier, in an amount effective to treat the retinal
degeneration disease, wherein said ent of the retinal ration disease occurs
by reprogramming of l cells, such as retinal neurons and/or l glial cells,
mediated. by cell fusion of said cells with said retinal cells, said reprogramming being
mediated. by activation of the catenin pathway.
In order that the HSCs, progenitor cells, and/or MSCs have their Wnt/B-catenin
ling pathway activated [kit of the invention 1)], said HSCs, progenitor cells and/or
MSCs are treated with a Wnt/B-catenin signalling y activator, or with an
inhibitor of a Wnt/B-catenin signalling pathway repressor, and/or are manipulated in
order to overexpress a Wnt/B-catenin signalling y activator.
In r aspect, the invention es a method for treating a subject having a
retinal degeneration disease (Le, a patient), which ses administering to said
t in need of treatment a cell selected from the group consisting of HSCs,
itor cells and MSCs, or a cell population comprising a plurality of cells, said cells
being selected. from the grow consisting of HSCs, progenitor cells, MSCs, and any
combination thereof, or a pharmaceutical composition comprising said cell or cell
population, in an amount effective to treat the retinal degeneration disease, wherein said
treatment of the retinal degeneration disease occurs by reprogramming of retinal cells,
such as retinal neurons and/or retinal glial cells, mediated by cell fusion of said cells
with said. retinal cells, said reprogramming being mediated. by activation of the Wnt/B-
catenin pathway.
In a particular embodiment, the above method. for treating a subject having a
retinal degeneration disease comprises the administration of a pharmaceutical
composition composition comprising at least a cell selected from the group consisting
of a HSC, a progenitor cell, a MSC, and any combination thereof, together with,
optionally, a Wnt/B-catenin signalling pathway activator, or an inhibitor of a Wnt’B-
catenin signalling pathway repressor, and a phatmac-eutically acceptable carrier, in made
from cells other than the cells of the invention, in an amount ive to treat the retinal
degeneration disease, wherein said treatment of the retinal degeneration disease occurs
by reprogramming of retinal cells, such as retinal neurons and/or retinal glial cells,
ed by cell fusion of said cells with said retinal cells, said reprogramming being
mediated by activation of the Wnt/[3-catenin y.
The t ion is r illustrated, but not limited, by, the following
examples.
EXAMPLE 1
Haematopoietic stem cell fusi0n trioIgers retinal revIeneration in a mouse model of
Retinitis Pigmentosa
I. Methods
Cell preparation
Lineage-negative HSPCs were isolated. from total bone marrow of P
mice (mice stably expressing CRE and red fluorescent protein [RFP]; provided by
Jackson Laboratories) using Lineage Cell Depletion kits (Miltenyi Biotech). They were
treated either with l iLM BIO or PBS and with 1 uM tamoxifen for 24 h before
transplantation.
Animals
R26Yrdl mice (mice ng the R26Lox-Stop-Lox-YFP transgene and
homozygous for the ra’I mutation) [S'rinivas er (11., BMC Dev Bin! 1, 4 (2001)].
Transplantation
A range of 105-106 cells were transplanted. in mice previously anesthetized with an
intraperitoneal injection of ketamine: metomidine (80 mg/kg: 1.0 mg/kg, 1.10.), the eye
lid opened carefully, a small incision made below the ora serrata and I up to 5 pl of a
solution containing cell suspension in PBS was injected into the vitreus or in the
subretinal space. The capillary was maintained in the eye for about 3 seconds to avoid
reflux.
Hflrid FACS sorting
For gene expression analysis, 24 h after cell transplantation mouse retinal tissues
were isolated and disaggregated in tryps'in, by mechanical ation. A FACS cell
sorter was used to isolate the red and green ve hybrid cells. Total RNA was
extracted using RNA Isolation Micro kits (Qiagen), according to the manufacturer
protocol. The RNA was reverse-transcribed with SuperScript III (Invitrogen) and. qRT-
PCR reactions using Platinum SYBR green qPCix—UDG (Invitrogen) were run in an
ABI Prism 7000 real-time PCR machine. All experiments were performed in triplicate,
and differences in cDNA input were compensated for by normalisation to expression of
GAPDH. The primers used in the R analysis are shown in Table 2.
Tablez
Mouse 8 ecific rimers for RT-PCR
Gum] SuperArray ence Corporation
[Catalog No. 5 l A-200]
Rhodopsin FW GTAGATGACCGGGTTATAGATGGA
RV GCAGAGAAGGAAGTCACCCGC
RDS Fw CGGGACTGGTTCGAGATTC
RV ATCCACGTTGCTCTTGCTGC
Cm Fw ATCCGCAGAGCGTCCACT
RV CCCATACTCAAGTGCCCCTA
Rx Fw GTTCGGGTCCAGGTATGGTT
Rv GCGAGGAGGGGAGAATCCTG
Chxi0 Fw ATCCGCAGAGCGTCCACT
RV CGGTCACTGGAGGAAACATC
Nes‘tin Fw TGGAAGTGGCTACA
RV TCAGCTTGGGGTCAGG
Noggin Fw CTTGGATGGCTTACACACCA
RV TGTGGTCACAGACCTTCTGC
0H2 Fw AGTCGCCACCTCTACT
RV CCGCATTGGACGTTAGAAAAG
[Fw: Forward; RV: Reverse]
TUNEL assa
Apoptotic nuclei were detected by TdT-mediated dUTP terminal nick-end
labeling kit , fluorescein; Roche Diagnostics, Monza, Italy) according to the
producerl s protocols.
H&E ng
Briefly, tissue sections were stained with Histo'Pert‘eetTM H&E Staining MN“.
(Manufacturer: BBC Biochemical) according to the produceris ols.
Samples treatment
Tissues were fixed by immersion in 4% paraformaldehyde overnight, and then
embedded in OCT compound (T-issue-Tek). Horizontal serial ns of lO-mm
ess were processed for analysis. For fluoresceine immunostaining, the primary
antibodies used were: anti-Nestin (1:300, Abeam), anti-Otx2 (1:200, Abcam), anti-
Noggin (1:200, Abcam), anti-Thy1.1 (1:100, Abcam), yntaxin (1:50, Sigma), antiglutamine
synthetase (Sigma, 1:100) anti-An‘nexin V (1:200, Abcam) and anti-Ki67
(Sigma, 1.100). The ary antibodies used were: anti-mouse IgG and anti-rabbit
lgG antibodies conjugated with Alexa Fluor 488, Alexa Fluor 546 or Alexa Fluor 633
(1 :1000; Molecular Probes, Invitrogen).
Statistical analysis
The numbers of immunereactive or YFP-positive cells Within three different
retinal areas (40X field) were counted in individual sections. A total of 10 serial sections
were examined. for each eye, from at least three different mice. For statistical is,
the data were expressed as means iSEM, as pooled from at least three independent
experiments, each carried out in duplicate.
2. Results
Retinitis Pigmentosa is a devastating blindness disorder that arises from different
mutations in more than 100 known genes [Wright et al. Nat Rev Genet 11, 4,
doi:11rg2717 [pii]10.1038.-’in'g2717 (2010)]. Rd! mice carry a neous recessive
mutation in the P0563 gene that encodes the [3 subunit of cyclic GMP-specific 3|,5I4
cyclic phosphodiesterase. This loss of Function mutation results in accumulation of
cyclic GMP and Ca2 in the rods, which in turn leads to photoreceptor cell death
[Doona-n er” (1!. Invest Ophthalmol Vis Sci 46, 3530-3538, doi:46/10/3530
[pii]'10.l'I67.’iovs.05-0248 (2005)]. Rd] mice are homozygous for this on, and
they represent a severe model for fast progression of this degenerative disease.
HSPCs are multipotent cells that can give rise to all types of blood cells. In
addition, they have been proposed to retain some plasticity with some degree of
regenerative potential for ent tissues, including for the CNS [Alvarez-Dolado, M.
Front Biosci 12, 1-12 (2007)].
Activation of the Wnt/B-cate'nin pathway has been shown to promote
proliferation and dedifferentiation of Miiller glia (Miiller cells) in different mouse
models of retinal degeneration, suggesting a possible contribution of this pathway in the
modulation of CNS plasticity da, F. e: a]. J Neurosci 27, 4210-4219 (2007)].
Indeed, ors recently reported that periodic activation of the Wnt/B-catenin
pathway via Wnt3a or via the GSK-3 inhibitor BIO in nic stem cells (ESCs)
strongly enhances the reprogramming of neural precursor cells after cell fusion [Lluis et
a]. Cell Stem Cell 3. 493-507 (2008)]. Inventors, ore, asked whether fusion of
HSPCs with retinal neurons along with a transient activation of the Wnt/B-catenin
pathway in transplanted HSPCs might be a mechanism for retinal regeneration and
onal Vision rescue in rdI mice.
CREIRFP
Thus. inventors transplanted Lin' HSPCs (isolated from donor mice stably
expressing CRE and red fluorescent n [RFP]) tinally in the eyes of postnatal
day '10 (p10) R26Yrdl mice (carrying the R26Lox-Stop-Lox-YFP transgene and
homozygous for the rd! mutation) and sacrificed. the mice 24 h later. It was expected. to
e RFP and. yellow cent prorein (YPP) double-positive hybrid. cells in case
of cell fusion (Fig. 1a). Indeed, it was observed a very high number of hybrids
(RFP/YFP-positive) in the outer nuclear layer (ONL) of the retina, and. some in the
inner nuclear layer (IN L) (Fig. 2a).
Inventors have previously shown that the GSK-3 inhibitor BIO does not increase
the fusion efficiency of ESCs with neural progenitor cells in vitro [L-luis et a1. (2008)
cited. supra]. Similarly, here it was observed able levels of hybrids in the ONL
when inventors transplanted HSPCs‘IfiRE’MP pro-treated with BIO for 24 h (henceforth
referred to as BlO-HSPCs), to activate the Wnt’B-catenin pathway (Fig. lb and l c).
This ruled out a role for BIO in modulating fusion efficiency in vivo. In contrast, it was
not ed any fusion event after subretinal transplantations in control ype
R26Y mice at pl 0 (Fig. l d and l e), showing that the genetic cell damage triggers fusion
between retinal neurons and HSPCs.
RH rdI
(not REP positive) were then transplanted subretinally in R26Y
mice to fy the retinal cell fusion partners. These HSPCs fused. specifically with
rods in the ONL (rhodopsianPF double-positive cells) (Fig. 2b) and. with Milller cells
(glutamine synthetase/YFP double-positive cells) (Fig. 2c). However, fusion between
these HS PCs and cones was never observed (Fig. 2d).
Neurodegeneration in rd] mice is already apparent at pl 0 as the photoreceptors
(first rods, and later, as a consequence. cones) undergo apoptosis and degeneration; by
p20 these are already almost completely gone. Interestingly, the number of apoptotic
photoreceptors decreased substantially after BIO-HSPCs transplantation, which
suggested that rod-cell death was delayed or stopped already at 24 h after
transplantation (Fig. 20). Furthermore, in the YFP-positive hybrids that derived from
fusion of the BlO-HSPCsCRE’m with retinal neurons (i.e., the BIO-hybrids), there were
low levels of apoptosis (20%, of total YEP-positive cells) and a high eration rate
(16%). In contrast, in the hybrids formed between O-treated HSPCSCRH’RH) and
l neurons (i.e., 'no-BIO-hybrids), there were high levels of cell death (75%) and a
low proliferation rate (2%) (Fig. 2f, 2g and Fig. 3).
To characterise the YFP/RFP hybrids, they were FACS sorted from the
transplanted s and analysed for expression of l sor neuronal and
retinal markers, by qRT-PCR analysis (Fig. 2h). The neuronal precursors Nestin,
Noggin and. Otx2 were clearly activated in the BIO-hybrids, with low activation of the
Crx, Rx and (7th photoreceptor precursor markers. Moreover, rhodopsin and.
pheripherin (rds), which are expressed in terminally differentiated photoreceptors, and
GATA-I, an HSPC marker, were strongly down-regulated in the BIO-hybrids. In
contrast, in the 'no-BIO-hybrids, there was no reactivation of precursor cell markers or
silencing ofli-neage genes (Fig. 2h).
The protein expression was then analysed in sections. Here, the BIO-hybrids had
activated sion of Nestin, Noggin and Otx2; in st, in the no-BIO-hybrids,
there was almost no activation of these markers (Fig. 4). These data thus show the
induction of a dedifferentiation process in the newly generated BIO-hybrids.
In conclusion, BIO-hybrids derived from fusion of the BIO-treated HSPCs with
retinal neurons do not enter into apoptosis, but instead undergo cell proliferation and
erentiation reac-tivating different retinal precursor al markers. In st,
the hybrids d from non-BIO-treated HSPCS do not erate, and nor do they
dedifferentiate; instead, they undergo apoptosis.
Next, to investigate whether these BIO-hybrids can regenerate retinal tissue,
inventors performed a time-course experiment. BlO-HSPCsRFPiCRE and no-BIO-
HSPCsRFECRE were transplanted subretinally at pl 0 in different groups of R26Yrdl mice,
and TUNEL and H&E staining were performed on retinal sections after 5 (p15), 10
(p20) and 15 (p25) days, and after 2 months (p60). Although the photoreceptors were
still clearly present at p15 in l sections from eyes transplanted with both BIO-
HSPCs and no-BIO-HSPCs, as shown by the normal structure of the ONL (Fig. 5a, 5b
and 6a), the viabilities of the retinal neurons were very different. At p15, there was
read apoptosis in the photoreceptor layer in sections from the eyes transplanted
with no-BlO-HSPCs (Fig. 5c and 6a); in contrast, cell death was almost absent at p15 in
the ONL of retinas transplanted. with BIO-HSPCs (Fig. 5d and 6a). Remarkably, at the
subsequent time points (p20 and p25), the photoreceptor layer in BIO-HSPC-
transplanted eyes maintained its normal structure (Fig. 5f. 5h and 6a), while rods and
cones nuclei were absent in the ON L- of no-BIO-HSPC-transplanted eyes. In their place,
few aberrant nuclear layers of cells were seen, which expressed pigmentu'm and which
were positive to the retinal pigment epithelium marker, Rpe65 and to the RFP only (Fig.
5e, 5f, 5g, 6a and. 6b).
Finally, at 2 months after transplantation, the retinas of the BIO-HSPCs-
transplanted rd! mice were still indistinguishable from the wild—type retinas along the
entire tissue (Fig. 5i, Sj, 5k and 5]), with '10 rows of photoreceptor nuclei and normal
outer and inner segment ures. On the other hand, the histology of no-BlO-HSPCs—
transplanted s was comparable to those of the non-transplanted rd] eyes, with
fully degenerated photoreceptor layers (Fig. 5111, 511, 50 and 5p).
Thus. it can be concluded that the lanted BIO-HSPCs fully preserved the
photoreceptor layer in the rd] mouse s at least up to two months after their
transplantation. This would t either a block in the degeneration mechanism or
activation of a regeneration s. In contrast, transplantation of no-BIO-HSPCs did
not rescue the rd] mouse ype, even if the transplanted cells retained a moderate
potential to transdifferentiate into retinal ted epithelium cells.
To investigate differentiation of the hybrids in the long term, R26Y'd' mice were
transplanted at p10 with BIO-HSPCsCRF‘ or no-BIO—HSPCsCRF‘ and analysed again two
months after the transplantation. Here, there was a full layer of YFP-positive cells in the
BIO-HSPC-transplanted rd! mouse retinas (Fig. 7a).
lmmunofluoreseenee staining showed that YFP hybrids were differentiated into
rods, but not into cones, as they were positive to staining for rhodopsin (Fig. 7a) but not
for cone ops-in (Fig. 7b). Furthermore no YFP hybrid cells that were also positive for the
Muller cell marker glutamine synthetase or for the endothelial cell marker CD31 were
found, thus excluding differentiation of the hybrids into Miiller cells or into retinal
vessels (Fig. 7c and. 7d). In contrast, with the no-BIO-HSPC-transplanted cells, almost
no YFP-positive hybrids were found two months after their transplantation because the
hybrids did not e for this length of time (Fig. 8a). Thus, it can be concluded that
the BIO-hybrids differentiate cally in rods, and as a consequence the cones are
able to survive. All in all, the expression of YFP in all of the rods clearly indicates that
newborn hybrids replace the rd} mutated photoreceptors, y regenerating the
retinal tissue.
To further assess hybrid differentiation in rods and to determine whether this
fusion-mediated regeneration process can rescue the rd] mouse on, the
expression of PDEfiB, which is not sed in rd] mice. was analysed. Remarkably
YFP/rhodopsin double-positive rods were also positive for PDE6B expression, as also
confirmed. by Western blotting of total extracts from transplanted. retina (Fig. 7g). These
results te that the BIO—hybrids can generate wild-type rods, and. thereby can
regenerate the retina (Fig. 7e, 7f and 8b); since rd] rods cannot express wild-type
PDE6B, the mutation was complemented by the HSPC genome in the hybrids,
Next, to determine Whether regenerated rods were also electrophysiologically
functional, inventors performed electroretinogram tests on rd! mice 1 month after
transplantation of BIO-HSPCs or no-BlO-HSPCs. Of note, both A and B waves under
scotopic and ic conditions were recorded in 4 mice out of 8 transplanted with
BIO-HSPCs. with a A amplitude in the order of 150 uV on average (not shown)
ting that the regenerated rods underwent cell-membrane hyperpolarisation in
response to a light stimulus, and that they could transmit the electric signals to the
intemeurons, as indicated by the B-wave response. Retinal regeneration under
histological analysis confirmed the functional rescue (not shown). Moreover, the viSual
acuity of a group of treated. rd] mice between 2.0 and 2.5 months of age were analysed.
with the ter test. In the BIO-HSPCs-transplanted rdj mice, the number of head
tracking movements, which es the automatic response of the animals when
detecting a moving target [Abdeljalil et (1!. Vision Res 45, 1439-1446, doi:80042-
6989(05)00005-2 [pi-i]lO.l0'l6.’j.visrcs.2004.l2.015 (2005)] was significantly higher
than that measured in the non-transplanted and no-BIO-HSPCs-transplanted rd] mice
(not shown). This demonstrated. a visual response after stimulus in the PCs-
transplanted rdl mice.
3. Discussion
Some attempts have been undertaken to improve the function of retinal
degeneration using bone-marrow-derivcd stem cells (BMSCs). It has been reported that
Lin" HSPCs injected intravitreally in rd] mouse eyes can prevent retinal vascular
degeneration, a secondary e ype, which then delayed retinal cone
degeneration. However, the transplanted retinas were formed of nearly only cones, and
the electroretinogram responses were severely abnormal and comparable to untreated
animals [Otani et ai. J Clin Invest 114, 765-774, .l 172/.ICI2'1686 (2004)].
Additional investigations relating to the mechanisms of improved retinal function after
BMSC transplantation have been based. on the role of BMSCs in promoting an increase
in enesis, or a decrease in inflammation, or even anti—apoptotic effects, which
might delay retinal degeneration and therefore be beneficial due to slowed progression
of the disease. In addition, ifferentiation of transplanted BMSCs in l-
pigmented lium, which can sustain photoreceptor survival, has been shown in
acute eye injury mouse models [Siqucira er a1. Arq Bras Oflalmol 73, 9,
doi:SOOO4—27492010000500019 [pii] (2010)]. All of these approaches, however, have
remained far from therapeutically efficient as they have not been seen to significantly
improve the regeneration of retinal tissue.
In addition, systemically lanted BMSCs have been reported to fuse with
resident cells in different tissues, such as heart, skeletal muscle, liver and brain a
et (1!. Nature 4l6, 542-545 (2002); Alvarez-Dolado et al. Nature 425, 968-973 (2003);
Piquer—Gil 63‘ a]. J Cereb Blood Flow fi/Ierab 29, 480-485 (2009)]. However, these fusion
events are seen to be very rare, which naturally promotes some skepticism as to their
physiological relevance [Wurrnser & Gage. Nature 416, 485—487 (2002)]. Here,
ors have clearly demonstrated that if Wntr’B-catenin signalling pathway is not
activated, the hybrids undergo apoptosis and therefore cannot be detected. at late stages.
The majority of these transplanted HSPCs do not fuse, and instead die; however, a few
can transd-ifferentiate into retinal—pigmented epithelium cells, which are of
mesenchymal origin. This transdifferentiation can provide some slowing down of the
degeneration, but it cannot resc ue the phenotype.
In contrast, the activation of the Wnt/B-catenin signalling pathway induces the
HSPC genome in the hybrids to activate the PDE6B gene; in this ion the hybrids
themselves were instructed to differentiate into rods, passing through a transient de-
differentiatcd state. l\'o heterokaryons could be detected, although it cannot formally
discarded. that there were some present. However, the rated eceptors eo-
sed PDE6B and YFP, which ted that the genomes of the retinal neurons and
of the transplanted HSPCs were mixed in the same cells. It remains to be ined
whether reduction mitosis or a multipolar mitosis mechanism as previously reported
during liver regeneration can reduce the ploidy of the regenerated photoreceptors, or if
double genome copies are tolerated in the newborn rods, which finally preserve cone
degeneration. Indeed, tetraploid neurons have been identified in mouse and. human brain
[Wurmser & Gage Cited. supra].
Several gene therapy attempts have been undertaken to treat individual Retinitis
Pigmentosa mutations; however, a mutation-independent cell—therapy approach could be
much more efficient and practical then creating dual gene therapies to treat each
single gene mutation. These data e real hope for the treatment of patients with
Retinitis tosa as well as further l degeneration diseases.
EXAMPLE 2
o Tri oers Neur0n Re r0 rammino in the Mouse Retina
This Example was med to e if somatic cell reprogramming can be
induced in s in mammalian. The results obtained show that upon activation of the
Wnt/B-catenin signalling pathway, mouse retinal s can be transiently
reprogrammed in viva back to a precursor stage after spontaneous fusion with
transplanted haematopoietic stem and progenitor cells (HSPCs). Moreover, it has been
shown that retinal damage is essential for cell-hybrid formation in viva. Newly formed
hybrids reactivate neuronal precursor markers, 0614 and. Nanog; furthermore, they can
proliferate. The hybrids soon commit to differentiation along a neuroeetodermal
e, and. finally into ally differentiated neurons, which can regenerate the
damaged retinal tissue. ing retinal damage and ion of Wnt/B-catenin
signalling pathway in the eye, cell-fusion—mediated reprogramming also occurs after
endogenous mobilisation of bone marrow cells in the eyes. These data. show that in-vivn
reprogramming of terminally differentiated retinal neurons is a possible mechanism of
tissue regeneration.
1. Experimental Procedures
Animal care and treamzems
All of the procedures on mice were performed. in accordance with the ARVO
Statement for the Use of Animals in Ophthalmic and Vision Research, and with our
institutional guidelines for animal research. All of the animals were maintained under a
'l 2 li light/dark cycle, with access to food and water ad libitum.
Retinal damage and BrdU treatment
Mice at the age of 3 months were anaesthetised by injection of ketamine:
metomidine (80 mg/kg: 1.0 mg/kg, intraperitoneal (i.p.)). To induce retinal damage, the
s were treated. intravitreally with 2 ul of 20 mM N-methyl-D-aspartate (NMDA)
(total 40 nmol; Sigma) for 24 h [Timmers er at, Mo] Vis 7, 131-137 (2001)]. Control
eyes received 2 l1] PBS. For the BrdU incorporation assays, the mice received
intraperitoneal (i.p.) BrdU administration of 50 mg/kg body weight.
Stem cellpreparation and transplantation
Retinal stem and progenitor cells (RS PCs) were isolated from the ciliary margin
of adult Cre mice as usly described [Sanges et al., Proc Natl Acad Sci U S A I03,
17366-17371 (2006)]. Lineage negative HSPCs (Lin' HSPCs) were ed from the
total BM of Cre, Cre-RFP or R26Y mice using Lineage Cell Depletion kits nyi
Biotech). Human CD34+ HSPCS were purchased from StemCell Technologies. Cells
were pre—treated with 1 uM tamoxifen for 24 h to induce nuclear translocation of Cre
recombinase, and. labelled with Vybrant DiD (5 lul/ml) (Invitrogen) before
transplantation, where necessary.
To obtain ESQ-sac, 5 X106 ESCs were electroporated with the Cre-recombi'nase-
ca-n'yi‘ng vector (CAGG-Cre), using ES nucleofector kits (Amaxa).
The stem cells (SCs) were left non-treated or were pretreated with 100 ‘ng/ml
Wnt3a or 1 ILLM BIO, for 24 h, and. finally 5 x105 cells were injected. intravitreally into
the eyes of the anaesthetised. mice. The mice were sacrificed by cervical dislocation, and
their eyeballs were enucleated. for histological analyses.
Hybrid isolation fbr gene sion and tetraploz’a’y analysis
Twenty-four hours after cell transplantation, the retinal tissue was isolated. from
treated, mice and disaggregated in n by mechanical trituration.
To analyze the tetraploid content of hybrids, cells were pelleted, washed twice
with [X PBS and fixed for 2 h in ice with 70% ethanol. After fixation, cells were
washed twice with ’lx PBS and incubated with 25 rig/ml propidium iodide and 25 .ug/ml
RNAse A -Aldrich) for 30 minutes at room temperature. Samples were analyzed
by flow cytometry in a FACSCanto n Dickinson). Doublet discrimination was
performed, by gating on width versus pulse-area of the PI channel. Samples were
analyzed. with FlowJo software (Tree Star, Inc).
For gene expression analysis, a BD FACSAria 11 g machine (Beeton
Dickinson) was used to isolate the red and green positive hybrids cells. Total RNA was
ted using RNA Isolation Micro kits (Qiagen), according to the manufacturer
protocol. The eluted RNA was reverse-transcribed with cript III (Invitrogen') and
qRT-PCR reactions using Platinum SYBR green qPCix—UDG (Invitrogen) were
performed in an ABI Prism 7000 real -time PCR machine, according to the manufacturer
endations. The species specific oligos used are listed in Table 3. All of the
experiments were med in triplicate, and differences in cDNA input were
,compensatedl hormalising to the expression of GA PDH.
Table 3
Human and mouse specific primers for qRT-PCR
Human specific primers for gRT-PCR
Species/Gene Sequence 5’-3’ SEQ ID NO:
h0cz4 Fw ACCGAGTGAGAGGC 17
Rv CACACTCGGACCACATCCTTC 18
hNanog Fw CCAACATCCTGAACCTCAGCTAC [9
RV GCCTTCTGCGTCACACCATT 20
hN 9.51m Fw CCAGAGGCTTCTC 2']
Rv CAGGGCTGGTGAGCTTGG 22
h0zx2 Fw ACCCCTCCGTGGGCTACCC 23
Rv CAGTGCCACCTCCTCAGGC 24
hNoggz'n Fw AGCACGAGCGCTTACTGAAG 25
RV AAGCTGCGGAGGAAGTTACA 26
hCD34 Fw GTTGTCAAGACTCATGAACCCA 2’7
RV ACTCGGTGCGTCTCT(ITAGG 28
Mouse specific primers for gRT-PCR
Species/Gene Sequence 5’-3’ SEQ ID NO:
m0cr4 Fw CGTGGAGACTTTGCAGCCTG 29
Rv GCTTGGCAAACTGTTCTAGCTCCT 30
mNanog Fw GCGCATTTTAGCACCCCACA 31
RV GTTCTAAGTCCTAGGTTTGC 32
mNes-tin Fw TGGAAGTGGCTACA ‘l 1
RV TCAGCTTGGGGTCAGG ‘l 2
'm00:2 Fw GAGCTCAGTCGCCACCTCTACT 15
RV CCGCATTGGACGTTAGAAAAG 16
mNoggin FW CTTGGATGGCTTACACACCA
RV TGTGGTCACAGACCTTCTGC
mCD34 FW CTGGTACTTCCAGGGATGCT
RV TGGGTAGCTCTCTGCCTGAT 34
[Fw: Forward; Rv: e]
Gatal primers were purchased at SuperArray Bioscience Corporation [Catalog number
PPM24651A-200]
Bone marrow (Bi-MO replacement
BM transplantation was conducted as previously reported with minor
modifications. The BM of 4- to 6-week-old R26Y or Nest'in-Cre recipient mice was
reconstituted with BM cells from the tibias and femurs of RFP/CRE or R26Y transgenic
mice respectively. BM cells (12th7 cells) were ed. intravenously into the recipients
3 hours after irradiation with y-rays (9 Gy). The eyes of the recipients were ted.
with lead shields to prevent radiation-induced. damage (radiation retinopathy). Four
weeks after transplantation, the eral blood of chimeric mice was extracted from
the tail vein, and the reconstituted BM was assessed.
, sectioning and immum)histochemisngv
s were fixed by ion in 4% paraformaldehyde overnight, and then
embedded in OCT nd (Tissue-Tek). Horizontal serial sections of 10 um
thickness were processed for im'munohistochemistry, and Visualisation of Nanog-GFP
and Rosa26-YFP fluorescence was performed by fluorescent microscopy.
For fluoresceine immunostaining, the primary dies used were: anti-Nanog
(1:200, R&D), anti—Oct4 (1:100, AbCam), anti-Nestin (1:300, Abcam), anti-GATA4
(1:500, Abe-am), anti—Otx2 , Abe-am), anti—Noggin (1:200, , anti—Handl
(1:400, Abcam), anti-Tuj-l (1:100, Abcarn), anti-Thy1.1 (1:100, Abcam), anti-syntaxin
(1:50, Sigma), anti-glutamine synthetasc (Sigma, 'l:l00) anti-Anncxin \i ,
Abcam), anti-Ki67 (Sigma, 1.100) and anti-BrdU (1:300, Sigma). The secondary
antibodies used were; anti-mouse IgG and anti-rabbit IgG antibodies conjugated with
Alexa Fluor 488, Alexa Fluor 546 or Alexa Fluor 633 (1:1000; Molecular Probes,
Invitrogen).
Percentages of GFP and YFP positive cells were evaluated counterstaining the
tissue sections with DAPI (Vectashield, Vector tories, Burlingame, CA, USA),
and they were photographed using either an Axioplan microscope (Zeiss) or a Leica
laser confocal microscope system.
In-vitm culture ereprogrammed hjo’bricls
BIO-treated or non-BIO-treated ESCs or HSPCs were ed into the eyes of
NMDA-damaged. Nanog-GFP-puro mice. Twenty-four hours after transplantation, the
retinal tissue was ed. and treated. with trypsin for 30 min at 37"C. The cells were
then reSuspended. as single-cell sions in ES culture media using a fire bore hole
Pasteur, and plated onto gelatine—coated dishes at a concentration of 3 ><105 cells/ 9.6
cm2. To select the reprogrammed clones, puromycin was added to the culture medium
after 72 h. sitive clones were counted and photographed after one month of
culture. The clones were alkaline phosphatase (AP) stained. after 1 month of Culture, as
previously bed [Lluis et al, Cell Stem Cell 3, 493-507 (2008)].
ation mounted retinas and optic nerves, and counting Qfganglion cells
Retinal flat mounts were prepared as previously described. Briefly, the eyes
were hemiscctcd along the era scrrata, and the retinas were separated. from the pigment
epithelium and. mounted with the ganglion cell side up, on Isopore 3mm (Millipore).
Retinas were then fixed in 4% paraformaldehyde for 20 min, washed with phosphate-
buf‘l‘ered saline, and treated for immu'nostaini'ng as described above. Optic nerves were
dissected from the eyes and mounted directly on the slices using Vectashield (Vector
Laboratories, game, CA, USA).
Total cells in the ganglion cell layer were counted as described previously
(Jakobs et at, (2005). J Cell Biol 171313-315) with minor modifications. Flat-mounted
s were counterstained. with DAPI and. survey pictures were taken at 20X on a
confocal microscope (Leiea SP5) focusing on the gel. Covering the whole retina
required about 80 . Cell nuclei were counted using Fiji Software and graphed as
cells/millimeter; A mensional density map of each image was obtained by a
routine written in Matlab and pictures of the Whole-mount retina were assembled from
individual pictures in Photoshop 9.
Statistical analysis
The numbers of immunoreactivc or of Nanog-GFP- and -YFP-positive cells
Within three different retinal areas (40>< field) were counted in individual sections. A
total of ten serial sections were examined for each eye, from at least three different
mice. For statistical analysis, the data were expressed, as means iSEM, as pooled. from
at least three independent ments, each d. out in duplicate. The experiments
were performed, using at least three different mice. Differences were ed. using the
unpaired Student t-test.
2. Results
NMDA-induced injury triggers fusion between retinal neurons and stem cells
Although cell fusion-mediated somatic cell reprogramming can be induced in
culture, it remained to be seen if terminally differentiated cells can be reprogrammed
via cell fusion within tissues of adult vertebrates.
Thus. inventors first determined r SPCs could fuse with retinal neurons in
viva. For this, inventors used transgenic mice carrying YFP flanked by loxP sites under
the control of the ubiquitously expressed Rosa26 promoter as recipients (i.c. with a
LoxP—STOP-LoxP-YFP [R26Y] allele) [Srinivas er al., BMC Dev Biol 1, 4 (2001)].
Different SPCs stably expressing Cre recombinasc and labelled in red were transplanted
in the eyes of recipient mice by intra—Vitreal injection (5 >105 cells.’eye). Specifically,
inventors used Lineage negative (Lin') HSPCs(-"miRl-'P isolated from CRE-RFP double
transgenic donor mice, l ,l I-ldioctadecyl-3,3,3I_.B -tetramethylindodicarbocyanine dye
(DiD)—labelled RSPCscre ed from the ciliary margin of Cre transgenic mouse eyes
s et al., Proc Natl Acad Sci U S A 103, 17366-17371 (2006)], and. belled
ESCsUe generated. by the inventors. Mice were sacrificed at ent times after SPCs
injection. If cell fusion had occurred n the injected. SPCsore and LoxP—STOP-
LoxP-YFP (R26Y) retinal neurons, it could be expected to detect YFP expression in
l sections, due to excision of the STOP codon by Cre (Fig. 9A).
Firstly, inventors tested Whether retinal tissue damage caused by intravitreal
injections of NMDA in R26Y mice could. induce cell fusion. NMDA caused. apoptosis
of neurons in the in] and gel of the retina (Fig. 10A and 103). as shown previously
[Osakada et 42]., J Neurosci 27. 4210-4219 (2007)]; however. NMDA did not enhance
the stochastic expression of the YFP ene in these R26Y mice (Fig. 10C). Then.
inventors induced NMDA damage in the right eye of R26Y mice and left the
contralateral eye undamaged as control; 24 h later HSP(Ism’miP were transplanted into
both eyes. Mice were finally sacrificed 24, 48 or 72 h after transplantation (Fig. 9A).
Already 24 h after transplantation, up to 70% of the injected HSPCsC'elRH) that
were detected in the optical field had fused with retinal cells, thus giving rise to YFP-
positive hybrids (Fig. 9B, 9D and 10D). Interestingly, the transplanted cells integrated
into the retinal tissue and crossed, the gel, even ng the inl (Fig. 9B, NMDA). In
contrast, there were no YFP-positive hybrids in the lateral, non-damaged, eyes;
furthermore, transplanted HSPCsC’m’lRFP remained on the border of the gcl and were not
integrated into the retinal tissue (Fig. 9C and 9D. No NMDA). Similar s were seen
in retinal ns of mice sacrificed. 48 and 72 h after transplantation (Fig. 9D). The
presence of tetraploid. cells was also analysed. by flow eytometry. Nuclei with 4C DNA
content were clearly evident in the hybrids present in the retinas of R26Y mice
lanted with HSPCsmlRW (Fig. 1 0(1).
These data demonstrated that the injury was necessary to induce migration of
transplanted HSPCs into the retinal tissue and their fusion with retinal neurons.
The localization of the hybrids (YFP positive cells) in the retinal tissue
ted that transplanted cells fused with ganglion cells (that localize their nuclei in
the gel) and amacrine cells (that localize across the ml and the inner plaxiform layer
(ipl)) (Fig. 10A); to note, those are the retinal cells specifically damaged after NMDA
ent [Osakada er a]. (2007). cited supra]. Thus, to confirm which of the retinal
cells fused. with the HSPCs, inventors analyzed the expression of different retinal cell
markers in the YFP—positive hybrids 12 h after the transplantation of Lin‘ HSPCsUemW
into NMDA-damaged R26Y eyes. YFP hybrids either ve to the ganglion-cell
marker thy1.1 in the gel (Fig. 9B), or to the amacrine—cell marker syntaxin in the ipl
(Fig. 9F). No co-localisation was seen with the Miller cell marker ine synthetase
(Fig. 9G). 60% of the YFP-positive hybrids were thyl.l-positive, while 22% were
syntaxin positive (Fig. 10F and lOF), indicating that the majority of the s were
formed between ganglion cells and HSPCs, with some fusion with amacrine cells. In the
remaining 18% of the sitive hybrids, the Fusion partners were unclear; indeed,
there might also have been down-regulation of thy'l.l and/or syntaxin in the newly
formed hybrids.
Next inventors performed similar experiments by injecting DiD-labelled ESCscrc
and DiD-RSPCsCrc into undamaged and NMDA-damaged eyes of the R26Y mice. With
both cell types, up to 70% of the injected cells detected in the optical field fused with
retinal neurons (Fig. 11A, 11B, and 10D). Also these cells fuse with ganglion cells and
amaerine cells as demonstrated by the localisation of the YFP signal in the gel and. ipl
and by the eo-localisation of the YFP and. thy1.1 or syntaxin s (Fig. 11A, 11B and
data not shown).
To further m that injected SPCs do indeed fuse with post-mitotic retinal
neurons, the erative potential of retinal cells before the fusion event was ed.
Concurrently inventors injected thymidinc analogue Sl-lbromo-2 -deoxyuridine (BrdU)
intraperitoneally and NMDA into the eyes of R26Y mice; then, after 24 h ESCsCre were
injected and, finally, the mice were sacrificed 24 h after this transplantation. Not BrdU—
positive cells (red arrows) were seen to be also ve for YFP (green arrows), thus
excluding the fusion of ESCs with proliferating cells (Fig. l 1C). The BrdL'-positive
cells found next to the gel (Fig. 11 C, red arrows) were probably lial cells that had
been recruited to the retina following the damage [Davies et al., Moi Vi's‘ 12, 467-477].
Overall, these data demonstrate that HSPCs, ESCs and RSPCs can
spontaneously fuse with retinal neurons in viva upon cell damage.
The Wnt/B-catenin signalling pathway triggers reprogramming of retinal neurons
in viva
Wnt/B-catenin signalling pathway is ted. after NMDA damage resulting in
increased expression of B-catenin, which accumulates into the cells (see Fig. 12A and.
Osakada er al. (2007) cited supra). Thus, inventors tested whether endogenous Wnt/B-
n pathway activation could. mediate reprogramming after cell fusion in viva.
For this, two different mouse models were used as recipient mice; Nestin-CRE
(transgenic mice expressing Crc rccombinasc gene under the control of Nestin promoter
in neural precursors) [Tronche et (11., Nat Genet 23, 99-103 ( I999); Okita et (11., Nature
448, 7 (2007)]and, Nanog—GFP-Puro mic-e (transgenic mice expressing GFP-
puromycine genes under the control of the Nanog promoter in the embryo [Okita et al._.
Nature 448, 313-317 (2007)], which allowed us to investigate reprogramming at the
neuronal precursor and the nic stages, respectively. DiD-labelled HS PCsRM and
HSPCsRFP were injected into the eyes of the Nestin-CRE and Nanog-GFP-puro mice,
tively. NMDA was injected intravitreally into one eye of a group of mice, while
the contralateral eye remained. undamaged as l. lmportantly here, no expression of
Nanog-OPP (Fig. 12C) or Nestin-Cre (data not shown) transgene was detected
following NMDA ent in the ganglion and amacrine cell. After 24 h, HSPCs were
injected into both the eated. and. NMDA-treated. eyes, and, the mice were sacrificed.
after an additional 24 h. In the case of reprogramming of the retinal neurons. in these
mouse models it could be expected to find double red/green positive cells (Fig. '1 3A and
Fig. 128). No green-positive cells were seen after ion of HSPCs into the non-
damaged eyes (Fig. BB, 13C, 13D and l3E, No NMDA). In contrast, about 30% and
% of the total red. cells were also green when HSPCs were injected into the NMDA-
damaged eyes of -CRE and. Nanog-GFP-puro mice, respectively (Fig. 13B, 13C,
13D and. 13E, NMDA; and. 10C), indicating that up to 30% of the hybrids were indeed
reprogrammed. as they had reactivated Nanog and Nestin promoters in the neuron
genome.
To assess the role of activation of the endogenous W'nt/B-eatcnin signalling
pathway in the reprogramming of retinal neurons, in both of these mouse models,
DKK'] was also ed immediately after NMDA injection; DKKI is an inhibitor of
the atenin y [Osakada et al. (2007) cited supra, Fig. '1 2A]. HSPCs were
transplanted after 24 h, and mice were sacrificed 24 h later. DKKI injections almost
completely blocked the reprogramming of neuron—HSPC hybrids (Fig. 133, l3C and
13D, NMDA+DKK1‘), which demonstrated that endogenous and damage-dependent
activation of the Wnt-‘B-catenin pathway triggers reprogramming of retinal neurons after
their fusion with HSPCs.
Next. inventors aimed. to analyse whether reprogramming of retinal neurons was
increased after transplantation of HSPCs in which the Wnt/[3-catenin signalling pathway
had been previously activated by the GSK-3 inhibitor BIO or by Wnt3a treatment
before injection (Fig. 'l2D, ‘12E and lZF). Surprisingly, 24 h after transplantation of
BIO-pretreated or Wnt3a-pretreated. HSPCs in NMDA—damaged. eyes of the Nestin-
CRE and Nanog-GFP mice. there was a striking increase in the number of
reprogrammed (green-positive) s with t to those seen in NMDA-damaged
eyes that received untreated-HSPCs (Fig. 138 and 13E; NMDA+BIO, NMDA+Wnt3a).
Similar results were also observed in mice sacrificed 48 h and 72 h after cell
transplantation (data not shown). Of note, after injection of BIO-treated HSPCs into
non-damaged eyes, both Nanog-GFP-puro (Fig. 12G) and. Nestin-CRE transgenes (data
not shown) were not expressed, confirming that the tissue damage is necessary for
spontaneous cell fusion-mediated. retinal neuron reprogramming.
To evaluate the efficiency of this iii—viva reprogramming, inventors counted the
green-positive rammed. cells relative to the total population of red-HSPCs
detected in the optical field (Fig. 10(3). In the d retinas, up to 65% of both the
BIO-pretreated and the Wnt3a-pretreated HSPCs reprogrammed retinal neurons after
fusion, leading to the formation of double-positive HSPC-ncuron hybrids in both of
these mouse models (Fig. 13C and. 13D).
Given that it was surprising to observe reprogramming at the embryonic stage
after fusion of HSPCs with ally differentiated neurons, it was investigated.
activation of the Nanog-GFP transgene after transplantation of ESCs and RSPCs into
NMDA-injured eyes.
As it could be expected, in the case of the ESC transplantation, reprogramming
of the retinal neurons, which was also dependent on tion of the endogenous
Wnt/B-catenin ling pathway, was also observed. GFP-positive cells were also
strikingly increased when ESCs were pretreated with BIO or with Wnt3a before being
transplanted (Fig. 14A). To confirm reprogramming 0f ESC-retinal neuron hybrids,
inventors cultured GFP-positive hybrids FACS-sorted from NMDA-da‘maged retinas of
Nanog-GFP-puro mice transplanted with BIO-treated or untreated ESCs.
Reprogrammed GFP positive colonies were grown in culture and they were also
resistant to puromycine selection and. positive to the ne phosphatise (AP) staining
(Fig. 143).
In contrast, no ramming events after ion of RSPCs into the NMDA-
injured eyes of the GFP mice was observed, even in the case of BIO pre-
treatment of transplanted RSPCs (Fig. . Interestingly, only a few YFP-positive
cells were observed after lantation of BIO-treated RSPCMC‘Y, in NMDA-damaged
eyes of Nestin-CRE mice (not shown).
Finally, it was also ruled out an effect of BIO in the enhancement of fusion
events in viva. BIO pre-treatment did not enhance the fusion efficiency of the HSPCs,
ESCs or RS PCs injected into the NMDA-damaged eyes of the R26Y 'mice (Fig. 14D).
In conclusion here, it has been shown that activation of the Wntffi-catenin
signalling pathway triggers the reprogramming of retinal neurons back to an
embryonic/neuronal precursor stage, and. that this occurs ing damage-dependent
cell-cell fusion of HSPCs and ESCs, but not of RSPCs.
To better characterize the rammed hybrids, in addition to look at Nestin-
CRE and Nanog-GFP tra'nsge'nes reactivation, the expression profile of precursor and
embryonic genes in vivo was analyzed in the newly formed hybrids. Then it was
injected eated or untreated HS PCsCMRFP in \IMDA-damaged CYCS 0f R26Y mice,
and 24 h later the hybrid. cells from the retinas were sorted by FACS. Marker expression
was analysed by real time PCR. In the BIO-hybrids (hybrids formed by the BIO-treated
HSPCs) Oct4, Nanog, Nestin, Noggin and. Otx2 were up-regulated (Fig. 15A), indeed,
no expression of these genes was detected in the non-transplanted NMDA-injured
retinas, nor in the HSPCs, with the exception of Nanog in the HSPCs (Fig. 16A and
16B). In contrast, Gatal, which is a HSPC specific gene, was down-regulated. in the
BIO-hybrids (Fig. 15A). None of the sors markers were re-expressed (or they
were poorly expressed in the case of Nanog and Nest-in) in non-BlO-hybrids, where
expression of Gatal was comparable to that observed in the HSPCs (Fig. 15A and Fig.
168).
sion of Oct4, Nanog and Nestin proteins in the BIO-hybrids was also
confirmed. by their merged immunostaining signals with the YEP-positive hybrids in
sections (Fig. 15B).
r, to clearly trate that the re-expression of embryonic and
progenitor markers resulted from reprogramming of the neuron genome and not from
the genome of the injected HSPCs, inter-species hybrids were analyzed. For this,
inventors transplanted BIO-treated and belled CD34 human HSPCs into
damaged eyes of Nanog-GFP mice. The reprogramming of the retinal s was
confirmed. in sections after fusion of the human HSPCs (Fig. 16C). Interestingly Oct4,
Nanog, Nestin, Noggin and Otx2 were all expressed (as analysed with mouse-specific
oligonucleotides; see Table 3) from the reprogrammed mouse neuron genome in the
sorted hybrids (Fig. 15C). In addition, in the human genome. expression of Oct4,
Nestin, Otx2 and Noggin was activated, while CD34 was down-regulated (Fig. '1 5D).
l, it can be concluded that HSPC-fusion-mcdiated reprogramming of
retinal neurons controlled by Wnt/B-catenin signalling pathway can occur in viva.
Reprogrammed neurons can proliferate and differentiate in viva
Next the proliferative potential of the reprogrammed neurons was investigated.
Thus, BIO-treated. and ted. HSPCsUe were injected. into the NMDA-damaged. eyes
of a group of R26Y mice and retinal sections were analysed 24 h later.
Surprisingly. 8% of the YFP-positive reprogrammed hybrids (after injection of
BIO-treated m) underwent proliferation (Fig. '15E and 156. Ki67/YFP double
positive); these cells were not committed to an apoptotic fate, as only about 5% of the
hybrids were positive for Annexin-V staining (Fig. 15F and. 15H). On the contrary,
injection of O-treated HSPCsCRF‘ led to the formation of non-proliferative s
(Fig. 15E and lSl; as negative to Ki67 staining) that underwent apoptosis, as up to 30%
of the sitive hybrids were positive for Annexin-V staining (Fig. 15F and '15.],
Anexin-V!YFP double positive). Similar results were obtained 72 h after transplantation
of BIO-treated or non-BIO-treated ESCs (Fig. 16D and. 16E). Overall, these data show
that hybrids formed between HSPCs or ESCs and retinal neurons embark into apoptosis.
but if the Wnt/B-catenin pathway is activated in the transplanted SPCs. the neurons can
be reprogrammed, survive and ter into the cell cycle.
Inventors then analysed the iii-vim entiation potential of the reprogrammed
retinal neurons in the NMDA-damaged. retinas of the R26Y mice injected with BIO-
treated. and non-BIO-treated. HSPCsCfe. The mice were sacrificed. 24, 48 and. 72 h afier
lantation. The percentages of YFP-positive hybrids for each marker were
determined from retinal sections (Fig. 10C). ably, 24 h after the injection of the
eated HS PCs, reprogrammed neurons (as YFP positive) were y re-
expressing Nestin, Noggin and OtXZ, and this expression was maintained at the
subsequent time points analysed (48, 72 h). Conversely, the al terminal
differentiation marker Tuj-l was progressively silenced. In addition Seal and c-kit were
ly down-regulated in these hybrids. Oct4 and Nanog were also highly expressed
at 24 and 48 h, although their expression was decreased by 72 h (Fig. l SB and 15K). In
contrast, a low number of YFP positive hybrids obtained after fusion with non-BIO-
treated HS PCs reactivated Nestin, Noggin and Otx2, and instead they maintained
expression of Tuj-l, Sca-l and c-kit in the majority of the hybrids. Oct4 and Nanog
were also expressed, gh only at 24 h and in very few hybrids at the later (48, 72 h)
time points (Fig. 15L), GATA4, a mesoderrn , and Handl, an endoderm marker,
were never expressed in the hybrids (Fig. 15K and. 15L). In conclusion, the BIO-hybrids
were reprogrammed and tended to differentiate into the neuroectoderm e. In
contrast, the non-BIO hybrids were poorly reprogrammed, and thus they did. not embark
into neuroectoderm differentiation.
Similar differentiation analysis, performed after injection of BIO-treated ESCsCrc
in the damaged R26Y retinas, showed a delay in the neuroectodermal differentiation
potential of the ing hybrids (as Nestin, Noggin and Otx2 were expressed. more at
72 h afier ESC ion while Oct4 and Nanog where highly expressed from 24 to 72
h) and the positive expression of Gata4 and Handl. These s indicate that ESC-
neuron hybrids are more pluripotent and can differentiate in the neuroeetodermal
lineage but also in the mesoderm and endoderm lineages (Figure "l 6F).
Finally, ors investigated r the BIO-hybrids that were committed to
a neural differentiation fate can terminally differentiate into retinal neurons and thus
regenerate the damaged retina. For this, a group of NMDA-damaged eyes of R26Y mice
were injected with eated or non-BlO-treated HSPCsCWRFP and sacrificed 2 weeks
later. Remarkably, YFP/RFP neurons in the gel and in the in] were observed only after
transplantation of BIO-treated HSPCs. These cells were positive to the markers for
thy1.1 and syntaxin, clearly indicating that the hybrids differentiated into ganglion and.
amacrine neurons. On the contrary, no D hybrids were detected. 2 weeks afier
transplantation of untreated. HSPCs, as they undergo cell death at short time. Next, the
histology of the transplanted retina was analyzed. Strikingly, it was ed that the
number of nuclear rows in the gel and in the in] of the retinas transplanted With the BIO-
treated HSPCs was increased substantially with respect to those with the non-BIO-
treated HSPCs and to splanted retinas. Their numbers were comparable to those
in the wild-type retina (Fig. 17A, 17B and. 17C). These data clearly indie-ate that
reprogrammed HSPC-neuron hybrids can differentiate in retinal neurons and regenerate
the damaged retina. Thus, it can be concluded that cell-fusion-mediatcd ramming
can trigger retinal tissue regeneration
Reprogrammed hybrids can regenerate the injured retina
Having seen that the reprogrammed hybrids can proliferate and differentiate
towards neuroectodermal lineage inventors aimed to evaluate long-term differentiation
and their regenerative potential. Then, HSPCscre were pre-treated. with BIO to activate
Wnt signalling and transplanted. into the NMDA-damaged. R26Y eyes. In parallel,
untreated. re ’ere lanted. as control. The mice were sacrificed. 4 weeks later
(Figure 18A).
Analysis of flat-mounted retinas transplanted with BlO-HSPCs showed a high
number of YFP+ hybrids (Figure 183) that were positive for expression of ganglion
(SMl-32) and. amacrine (Chat) neuron markers (Figure 18C). Inventors then also
analysed the optical nerves 24h and one month after transplantation. ably, in
one-month optical nerves we observed YFP+ axons, likely derived, fi’orn tions of
the regenerated ganglion neurons (Figure 18D). In contrast, retinas transplanted. with
untreated HSPCsCrc showed very few YFP+ hybrids (Figure 22A) and no YFP+ axons
were found along the l nerves (Figure 18D, untr.HSPCs). Interestingly, no YFP+
axons were seen in the optical nerves 24 h after transplantation of BIO-HSPCs (Figure
22B), indicating that the newly generated ganglion neurons project their axons some
time after transplantation, likely during the regeneration process (Figure 180).
NMDA treatment induces recruitment of macrophages in the eye (Sasahara et
(11., Am J Pathol I72, 703 (2008)). Indeed, as expected, in retinas harvested 24 h
after transplantation, a tage of the YFP+ hybrids were positive to tc/
macrophage CD45 and Macl s, which suggested phagocytosis of some
transplanted relRH’ by endogenous macrophages carrying the R26Y allele or
phagocytosis of some YFP+ hybrids themselves (Figures 22C and, 22D). Interestingly,
this percentage was already drastically decreased. in retinas harvested 2 weeks after
transplantation es 22B and 22F). This result y indicates that although some
hybrids can be phagocytosed son after transplantation, a percentage of them can e
and regenerate the retinas.
Next, inventors analysed the occurrence of cell nuclei regeneration in al
sections. Interestingly, the number of neuronal nuclei in the ganglion cell layer (Figures
WA and 173, gel), and the number of nuclear rows in the inner nuclear layer (Figures
1 7A and 17C, inl) of retinas transplanted with BIO-HS PCs was comparable to wild-type
retinas and substantially increased with respect to nontransplanted retinas or retinas
transplanted with untreated HSPCs es 17A, 17B and 17C). This clearly tes
retinal regeneration. ors also investigated the r density of the ganglion
neurons in the whole unted. retinas by counting the total number of ganglion
nuclei in the whole retinas harvested one month after transplantation. Remarkably, there
was a significant increase of nuclei number in BIO-HSPCsCl'e-transplanted. retinas, with
respect to the non-transplanted retinas (Figure I7D). r, newly generated
ganglion neurons were not uniformly distributed, as shown by the nuclear density maps,
indicating no-n-homogenous retinal regeneration (Figure 171-3).
These data clearly demonstrate that if Wnt signalling is activated, partial
ration of retinal cells after NMDA-damage can be achieved. after fusion of
transplanted HSPCs.
Endogenous BMC fusion-mediated reprogramming of retinal s occurs in
viva after damage
It has been reported. that endogenous BMCs can be recruited. into the eye after
NMDA damage [Sasahara et (11., Am J Pat/'20! 172-, [693-1703 (2008)]; however, their
role remains unknown. Thus, ors investigated whether endogenous BVICs can
also fuse and reprogrammc retinal neurons after NMDA damage. For this, BMCs from
donor RFP-(IRE mice (transgenic mice expressing RFP and CRE, both under the
control of the ubiquitously expressed B-actin promoter (Long er (1]., (2005). BMC
hnol 5, 20; Srinivas et a1. (2001) cited supra» were tail-vein transplanted in sub-
lethally irradiated. R26Y ent mice, thereby substituting their BM with BMCWRH).
The repopulation of the BM with cells of donor origin was analysed. according to the
expression of RFP in blood cells and by haemocytometric analysis (Fig. 19A). One
month after transplantation, NMDA was injected intra-Vitreally in one eye of each
group of chimeric mice, and then 24 h later the mice were sacrificed e 20A).
Interestingly, it was found that after NMDA damage, 50% of the RFP-positive cells
were also YFP positive. ting fusion of endogenous BMCs recruited in the eyes
(Fig. 203. 20C and 20F, NMDA, and Fig. 10D). In contrast, no RFP/YFP-positive cells
were found in sections of non-NMDA-injectcd eyes (Fig. 20D, 20E and 20F, No
NMDA). These results, clearly demonstrate that cell Fusion occurs between the BMCs
recruited into the eyes and the l neurons.
Inventors then analysed the identity of these hybrid. cells that were obtained after
endogenOus cell . It was ed that 12 h after NMDA damage, the YFP-
positive cells in the retinal sections were also positive for the Seal, Ckit, Thy1.l,
Syntaxin, and GS cell markers, clearly indicating that HSPCs were recruited from the
BM and fuse with ganglion, amacrine and. Miiller cells (Fig. 200, 20H, 201, 20.1 and
20K).
Next inventors investigated if reprogramming can occur after BMC tment
and fusion with retinal neurons; to this aim. BMCstGY were transplanted into a group of
sub-lethally irradiated Nestin-CRE mice to generate chimeric mice. The reactivation of
Nestin-CRE transgene and the consequent YFP expression enabled. us to identify
ramming events after BMC recruitment in the eye. One month later, NMDA and
BIO were injected into only one eye of the chimeric mice, which were sacrificed 24 h
later (Fig. 21A). YFP-positive cells were observed after injection of BIO in the gel and
inl of NMDA damaged. eye, but not in the NMDA-damaged. (non-BIO injected)
untreated. lateral eyes (Fig. 218 and 21C). This y indicates that the retinal
neurons had fused with the recruited BMCs and were reprogrammed because of the
reactivation of the Nesti'n promoter. About 8% of these YFP-positive s were
ve for Ki67 expression, and only 1% were Annexin-V positive, which indicated
that some of the hybrids were dividing and very few were apoptotic (Fig. 2'] D, 198 and
19C). Strikingly, 50% of these YFP-positive hybrids were also positive for Oct4
expression (Fig. 21E, 21F and 21(3), and 70% for Nanog (Fig. 21E, 21H and 211),
confirming that reprogramming of the retinal neurons occ-urred also after mobilisation
ofthe BMCs into the eyes.
In conclusion, endogenous activation of BMC-Fusion-mediated ramming
ofrcti'nal neurons can occur in the eye if the Wnt/B-catenin pathway is activated.
3. Discussion
Here it has been trated that the canonical Wnt’B-catenin signalling
pathway mediates the reprogramming of retinal neurons in vivo. In addition, it has been
shown that spontaneous cell fusion can occur in the mouse retina after injury and that a
proportion of fusion hybrids proliferate if they are reprogrammed by Wnt activity.
Furthermore, it has also been shown that if not reprogrammed, the neuron-SPC hybrids
o apoptosis. Surprisingly, the reprogrammed hybrids can regenerate the d.
retinal tissue. Finally, it has been clearly showed that after activation of the Wnt/B-
catenin signalling y in the eye, BM-derived cells that are recruited into the
injured. retina can fuse and. reprogramme the l neurons upon activation of the
Wnt/B-catenin signalling pathway. Overall, it can be concluded that cell-fusion-
mediated reprogramming can be an nous mechanism ofdamage repair.
Adult SPCs show a high degree of plasticity and pluripotency, and they can
contribute to a wide spectrum of differentiated cells. Transplanted BMCs can fuse and
acquire the identity of liver cells, Purkinje neurons, kidney cells, epithelial cells, and.
more. This plasticity has been ed to either transdifferentiation or cell-cell fusion
mechanisms.
Up to now however, cell fusion events have been considered very rare, and
therefore the cell identity of the rn” hybrids has never been clearly investigated.
Here, inventors have demonstrated that cell-cell fusion occurs and can be visualised. as a
very relevant event y after transplantation of HSPCs into a damaged eye. This is
true also after sation of c-kit/sca-l-positive cells from the BM into damaged
retinas. In previous studies, the s of hybrids derived from BMC fusion have been
largely underestimated; indeed, it has been found here that unless these newly formed
hybrids are reprogrammed, they undergo cell death, and. therefore a long time after the
transplantation they cannot be detected.
HSPCs fuse with high ncy with ganglion and amacrine neurons; the
resulting “newborn” hybrids are novel cell entities, which if a Wnt-signalling stimulus
is ed, can initially be transiently reprogrammed and can proliferate and then
become terminally differentiated neurons. It is remarkable that it was found expression
of Nanog and Oct4, and at the same time, expression of Nestin, Noggin and Otx2
precursor neuronal markers in these hybrids. The expression of Nanog and. Oct4 is a
clear evidence of reprogramming back to the embryonic stage; however, this state is
transient, at least in the case of fusion between HSPCs and retinal neurons. The hybrids
very soon commit to neuroectoderma] lineage, and indeed, 72 h after transplantation,
0ct4 and Nanog were already down-regulated. Finally, in two weeks, the s
become terminally differentiated neurons and regenerate the gel and the inl in the retinal
tissue. Interestingly, it was also observed full functional regeneration of photoreceptors
in a mouse model of Retinitis tosa (RP) after cell-fusion-mediated
reprogramming of retinal neurons upon transplantation of Wnt-‘B-catenin y
activated HSPCs (Example 1).
These observations led. to pate that Oct4 and. Nanog are not only stem cell
genes that are expressed in embryos, but that they have a Functional role also in adult
tissue during cell-fusion-mediated regeneration processes. Expression of these genes in
adults is controversial [Shin et (11., Mo] Cells 29, 533-538 (2010); Kucia er (1]., J Physiol
Pharmacol 57 Suppl 5, 5-18 (2006)]; however, it might well be that their expression has
not been clearly appreciated. in some circumstances, probably due to its very transient
nature.
ESCs also have great plasticity, and here inventors were able to fy
dedifferentiation events in vivo; i.e., reprogrammed s expressing Nanog after the
fusion of retinal neurons with ESC s. ESC-retinal-ncuron hybrids are probably more
pluripotent than HSPC-derived hybrids. They can form clones in culture and express
markers of three different lineages; in addition, they form teratoma in vivo (data not
. In st, in vitro, ors were not able to isolate clones from HSPC-
retinal neuron hybrids, clearly indicating their transient reprogramming and fast
commitment to 'neuroectoderm lineage differentiation. Interestingly, reprogramming of
retinal neurons up to the expression of Nanog was not observed. after fusion of RSPCs,
indicating the lower degree of plasticity of these cells with t to HSPCs.
For a long time, it has been thOught that differentiation is a one-way-direetion
mechanism; the possibility to induce somatic-cell reprogramming has completely
ted this opinion. However, to date, neuron dedifferentiation has been considered
as relatively difficult. Here, it has been demonstrated that neurons can indeed change
their developmental stage in a living organism while resident in their own tissue.
r, when they fuse with HSPCs, they keep the memory of their neuronal identity,
as these “newborn” hybrids finally differentiate into neurons. This is not a trivial
observation, as researchers normally force in vz'zro reprogrammed cells to propagate
with a de-differentiatcd phenotype; indeed, even ESCs, in principle, do not exist in the
embryo. Pluripotent cells, such as the reprogrammed cells, should rapidly undergo a
change of fate in viva, which will depend on the different tissue signals, and they should
commit to progress into a specific differentiation fate. A lineage identity memory that is
not erased during the reprogramming process might be ial, to direct the correct
differentiation path in viva. Interestingly, induced pluripotent SCs (iPSCs) have been
shown to retain epigenetic memory of their somatic cells of origin [P010 67 al, Nat
hnol 28, 848-855 (2010); Kim et at, Nature 467, 285-290 (2010)]. Here, in the
model used herein, the transition from one cell fate to another is not direct, but passes
through the transient re-expression of precursor genes; thereby passing h an
intermediate, less-differentiated, developmental precursor.
Wnt signalling controls the regeneration of tissues in se to damage in
lower otes [Lengfeld et at, Dev Biol 330, 186-199 (2009)]. Regeneration of the
Zebra fish tail fin and. the Xenopus limbs requires activation of catenin
signalling; likewise for tissue regeneration in planarians [De Robertis, Sci Signal 3,
pe2'l (2010)]. Interestingly, in fish and postnatal chicken retina, down-regulation of
Miillcr cell specific markers, such as glutamine synthetase and tion of progenitor
markers, such as Pax6 and Chx10 have been associated. to a regenerative potential of
these cells. However, exogenous activation of Wnt signalling is necessary to induce
Miiller cell de-differcntiation in mouse retina. The W'nt signalling regenerative activity
that is present in lower eukaryotes might therefore have been lost during evolution.
Although all of these studies highlight the important role of the catenin
signalling pathway in the regeneration process, the biological mechanisms that form the
basis of this ration were still largely unknown to date; here, it is shown that at
least in mOuse retina, regeneration can occur through cell—fusion-mediated
reprogramming. On the other hand, it was found, a not homogenous regeneration of the
lanted retinas, indicating that other factors, such nerve growth s for
example, might be used to enhance the process. Also, it cannot be excluded that in
addition to generate new neurons and therefore to ide regenerate the retinal ,
a delayed. neuronal ration might have also been induced.
Moreover, this process can be induced upon recruitment of BMCs into the eye.
Interestingly, a few recruited B.Vle fuse with Muller cells after damage were ed.
Therefore, it might well be that the de-differentiation of Muller cells, reported
previously [Osakada et al., (2007) cited supra] is due to fusion events with recruited
BMCS.
This nous in viva reprogramming can be a ism of damage repair
and, minor damages, like photo-damage or ical-damage, might be repaired
through cell fusion-mediated reprogramming after recruitment of BMCs. It is also
possible that Wnt-mediated reprogramming is a safeguard, mechanism after in viva cell
fusion. The hybrids that are not reprogrammed undergo apoptosis-mediated cell death.
Instead, Wnt-mediated reprogrammed hybrids can survive and can proliferate.
However, although other attempts to fully regenerate damaged mouse retinas
after ectopic activation of Wnt signalling in the eye have failed da et al., (2007)
cited supra] here it has been demonstrated that in addition to the activation of Wnt
signalling, cell-fusion-mediated reprogramming is also essential in the ration
process. Thus, strategies to increase BMC recruitment to the eyes along with the
tion of Wnt signalling might be therapeutically relevant to regenerate damaged.
retinal tissue.
The assays show that expression of RFP and YFP transgenes derived from the
genome of the two ent fusion partners were detected two weeks after cell fusion,
which indicates the contribution of both genomes in the hybrids. Moreover,
proliferation of the reprogrammed hybrids was observed, an indication that they were
mononucleate cells or bonajflde synkarions. Stable heterokaryons have been seen with
Purkinje cell fusion with BM-derived cells, and their numbers were greatly increased
upon inflammation [Johansson et al., Nat Cell Biol l0, 575-583 ]. In addition,
recently, heterokaryons have been also found. in ype retinas [Morillo et al., Proc
Natl Acad Sci U S A 107, 109-114 ]. However, inventors never detected
heterokaryons in the retina of the injected eyes, although its presence cannot be
formally excluded.
On the other hand, it sh0u.ld be taken into account that ental consequences
were seen when increased resistance to apoptosis was observed after fusion of cancer
SCs with somatic cells, such as multidrug resistance of a developing tumour (L-u &
Kang. Cancer Res 6.9, 539 (2009)]. Moreover, cell fusion, and thus polyploid
cells, can also arise during pathological conditions, and often the genetic instability in
these cells can lead to aneuploidy and the development of cancers. Thus, data provided
by the present invention might also be important in the future to follow a different path;
i.e., to study the fusion of cancer SCs with somatic cells during tumour development.
Reprogramming is a gradual and. slow process, with lineage specific genes
silenced, while endogenous genes associated with pluripotency are induced. Overall, the
s is very inefficient, because of the different genetic and epigenetic- barriers
[Sanges & Cosma. Int J Dev Biol 54, 1575-1587 (2010)]. Indeed. pre-iPS (partially
reprogrammed cells) ShOW incomplete epigenetic remodelling and. tent DNA
hypermethylation, among other features. They can be ted into iPS cells through
global inhibition of DNA methylation. Inventors recently showed that deletion of ch3,
which is a repressor of B-caten-in target genes, relieves epigenome modifications during
reprogramming, thereby tating iPS cell derivation in vitro [Lluis et al., (2011) in
press]. This might also take place during in viva cell fusion: the epigenome of SPCs
might be actively remodelled, and some reprogrammers transcribed, which might
change the neuronal epigenome in the hybrids in trans.
In conclusion, it can be ed that cell-fusion-‘mediated ramming
lled by Wnt signalling is a physiological in viva process, which can contribute to
cell regeneration-”repair in normal tissues.
Claims (20)
1. Use of a mesenchymal stem cell (MSC) or a cell tion comprising a hematopoietic stem cell (HSC) and a itor cell, wherein the Wnt/β-catenin 5 signalling pathway of said cells is activated, in the manufacture of a medicament for the treatment of a retinal degeneration disease by direct implantation of said cells into the eye of a subject in need of treatment.
2. Use of a cell or cell population according to claim 1, wherein said cells are cells 10 treated with a Wnt/β-catenin signalling pathway tor, or with an inhibitor of a Wnt/β-catenin signalling pathway sor, and/or are cells that overexpress a Wnt/β-catenin signalling y activator.
3. Use of a cell or cell population according to claim 2, wherein said Wnt/β-catenin 15 pathway activator is ed from the group consisting of a Wnt m, βcatenin , a R-spondin, 2-(4-acetylphenylazo)(3,3-dimethyl-3,4-dihydro-2H- isoquinolinylidene)-acetamide (IQ1), (2S)[2-(indanyloxy)(1,1'- biphenylyl)methyl)-9H-purinylamino]phenyl-propanol (QS11), deoxycholic acid (DCA), 2-amino[3,4-(methylenedioxy)benzylamino](3- 20 methoxyphenyl)pyrimidine, an o)arylpyrimidine of formula (I), (II), (III) or (IV) shown in Table 1, and combinations thereof.
4. Use of a cell or cell population according to claim 2, wherein said inhibitor of a Wnt/β-catenin pathway repressor is ed from the group consisting of a 25 GSK-3 inhibitor, a SFRP1 inhibitor, and combinations f.
5. Use of a cell or cell population according to any one of claims 1 to 4, wherein said retinal degeneration disease is selected from the group consisting of retinitis pigmentosa, age-related macular degeneration, Stargardt disease, cone-rod 30 dystrophy, congenital stationary night blindness, Leber congenital amaurosis, Best's vitelliform macular dystrophy, anterior ischemic optic neuropathy, choroideremia, age-related macular degeneration, foveomacular dystrophy, 2363921v1 Bietti crystalline corneoretinal dystrophy, Usher’s syndrome, and a retinal degenerative condition derived from a primary pathology.
6. Use of a cell or cell tion according to claim 5, wherein said retinal 5 degeneration derives from cataracts, diabetes or glaucoma.
7. Use of a mesenchymal stem cell (MSC) or a cell tion comprising a hematopoietic stem cell (HSC) and a progenitor cell in the manufacture of a medicament for the treatment of a retinal degeneration disease by direct 10 implantation of said cells into the eye of a subject in need of treatment prior to ramming of a retinal cell by fusion of said cells with said retinal cell, said ramming being mediated by activation of the Wnt/β-catenin signalling pathway. 15
8. Use of a cell or a cell population according to claim 7, in combination with a Wnt/β-catenin signalling pathway activator, or with an inhibitor of a Wnt/βcatenin signalling pathway repressor.
9. Use of a cell or a cell population according to claim 8, wherein said Wnt/β- 20 catenin pathway activator is selected from the group consisting of a Wnt isoform, nin, a R-spondin, IQ1, QS11, DCA, 2-amino[3,4- (methylenedioxy)benzylamino](3-methoxyphenyl) pyrimidine, an (hetero)arylpyrimidine of formula (I), (II), (III) or (IV) shown in Table 1, and combinations thereof.
10. Use of a cell or a cell population according to claim 8, wherein said inhibitor of a Wnt/β-catenin pathway repressor is selected from the group consisting of a GSK-3 inhibitor, a SFRP1 inhibitor, and ations thereof. 30
11. Use of a cell or a cell population according to any one of claims 7 to 10, wherein said retinal degeneration disease is selected from the group ting of retinitis pigmentosa, age-related macular degeneration, Stargardt disease, cone-rod dystrophy, congenital nary night blindness, Leber ital amaurosis, 2363921v1 Best's vitelliform macular dystrophy, anterior ic optic neuropathy, choroideremia, age-related macular degeneration, acular phy, Bietti crystalline corneoretinal dystrophy, Usher’s syndrome, and a retinal degenerative condition derived from a y pathology.
12. Use of a cell or a cell population according to claim 11, wherein said retinal degeneration derives from cataracts, diabetes or glaucoma.
13. A cell composition, wherein at least 50% of the cells of said cell composition are 10 hematopoietic stem cells (HSCs) and progenitor cells and wherein the Wnt/βcatenin signalling pathway of said cells is activated.
14. A pharmaceutical composition selected from the group consisting of: 1) a pharmaceutical composition comprising at least a mesenchymal 15 stem cell (MSC) or a hematopoietic stem cell (HSC) and a progenitor cell, wherein the Wnt/β-catenin signalling pathway of said cell is activated, and a pharmaceutically acceptable carrier, and 2) a pharmaceutical ition comprising at least a mesenchymal stem cell (MSC) or a hematopoietic stem cell (HSC) and a itor 20 cell, in combination with a Wnt/β-catenin signalling pathway activator or an inhibitor of a Wnt/β-catenin signalling pathway repressor, and a pharmaceutically acceptable carrier.
15. Use of a ceutical composition according to claim 14 in the manufacture 25 of a ment for the treatment of a retinal degeneration disease by direct implantation of said ition into the eye of a subject in need of treatment.
16. Use of a pharmaceutical composition according to claim 15 wherein said ition is administered by intraocular, intravitreal or subretinal injection.
17. A kit selected from the group consisting of: 1) a kit comprising at least a mesenchymal stem cell (MSC) or a hematopoietic stem cell (HSC) and a itor cell wherein the 2363921v1 Wnt/β-catenin signalling pathway of said cell is activated, and instructions for use of the kit components, and 2) a kit sing at least a mesenchymal stem cell (MSC) or a hematopoietic stem cell (HSC) and a itor cell , in combination 5 with a Wnt/β-catenin ling pathway activator or an inhibitor of a catenin signalling pathway repressor, and ctions for use of the kit components.
18. Use of the kit according to claim 17, in the manufacture of a medicament for the 10 treatment of a retinal degeneration disease.
19. Use of the kit according to claim 18, wherein said retinal degeneration disease is selected from the group consisting of retinitis pigmentosa, age-related macular degeneration, Stargardt disease, cone-rod dystrophy, congenital stationary night 15 blindness, Leber congenital amaurosis, Best's vitelliform macular dystrophy, anterior ic optic neuropathy, choroideremia, age-related macular ration, foveomacular dystrophy, Bietti crystalline corneoretinal phy, Usher’s syndrome, and a retinal degenerative condition derived from a primary pathology.
20. Use of the kit according to claim 18, wherein said retinal degeneration derives from cataracts, diabetes or glaucoma. 2363921v1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11176713A EP2554662A1 (en) | 2011-08-05 | 2011-08-05 | Methods of treatment of retinal degeneration diseases |
EP11176713.3 | 2011-08-05 | ||
PCT/EP2012/065327 WO2013020945A1 (en) | 2011-08-05 | 2012-08-06 | Methods of treatment of retinal degeneration diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ621345A NZ621345A (en) | 2015-09-25 |
NZ621345B2 true NZ621345B2 (en) | 2016-01-06 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20140199277A1 (en) | Methods of Treatment of Retinal Degeneration Diseases | |
Sanges et al. | Wnt/β-catenin signaling triggers neuron reprogramming and regeneration in the mouse retina | |
Sanges et al. | Reprogramming Müller glia via in vivo cell fusion regenerates murine photoreceptors | |
JPWO2018164240A1 (en) | Method for producing retinal pigment epithelial cells | |
CA2628530C (en) | Novel stem cells, nucleotide sequences and proteins therefrom | |
Yamane et al. | Functional role of lacrimal gland fibroblasts in a mouse model of chronic graft-versus-host disease | |
Tsupykov et al. | Long‐term fate of grafted hippocampal neural progenitor cells following ischemic injury | |
US20230272035A1 (en) | Modulators of the immune escape mechanism for universal cell therapy | |
WO2016201133A2 (en) | Hematopoietic cells and methods of using and generating the same | |
Gil et al. | Specific mesoderm subset derived from human pluripotent stem cells ameliorates microvascular pathology in type 2 diabetic mice | |
KR20170093178A (en) | Treatment of ocular conditions using progenitor cells | |
NZ621345B2 (en) | Methods of treatment of retinal degeneration diseases | |
EP3903789A1 (en) | Therapeutic drug for disease accompanied by disorders in retinal system cells or retinal tissue | |
US20200347352A1 (en) | Methods and system of human hemogenic reprograming | |
EP3231434A1 (en) | Method of treatment of parkinsonism | |
Casetti | New roles of STAT5 factors in chronic myeloid leukemia cell maintenance | |
Alsolami | The Role of WNT-beta-Catenin Pathway in the Specification of Primitive and Definitive Hematopoiesis during Differentiation of Pluripotent Stem Cells | |
Bird | Liver regeneration by hepatic progenitor cells | |
Nishikawa et al. | The Role of ROS and Impaired Antioxidant Capacity in Systemic Lupus Erythematosus | |
ALSHARIF | Thymic recovery following chemotherapy damage–the impact of sex hormones and ageing | |
Ferrer et al. | A single wave of monocytes is sufficient to replenish the long-term Langerhans cell network after immune injury | |
Chakrabarti | Development and Maintenance of the Thymic Epithelial Microenvironment | |
Morad | Mesenchymal stem cells: Differentiation, hematopoietic support and possible application in cell and gene therapy for osteoarthritis | |
Alberto et al. | BLT2 Protects Skin from the Damage Caused by Type 2 Diabetes Hyperglycemia by Increasing NO Production Through the nNOS Expression | |
Milan | 5th International Congress on Stem Cells and Tissue Formation |